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Abstract 
A novel protein labelling strategy has been developed based on a chemical reaction known 
as Native Chemical Ligation (NCL). NCL is a highly specific and facile reaction, ligating a 
thioester specifically to an N-terminal cysteine residue and can be used to tag proteins in a 
selective and quantitative manner. This has advantages over traditional labelling methods 
such as use of green fluorescent protein: labelling with a small molecule is less likely to 
interfere with the protein’s native biological activity, and its physicochemical properties can 
be fine-tuned by synthesis. The key challenge is generating the protein bearing an N-
terminal cysteine. The strategy developed in this thesis utilises the Foot-and-Mouth Disease 
Virus 3C protease (3Cpro), a highly selective protease that cleaves at PAKQX with no 
apparent specificity for the P1’ position.  
To demonstrate the application of 3Cpro for NCL-mediated labelling, fluorescein was 
specifically ligated to the N-terminus of the PH domain of Protein Kinase B (PKB), which 
when defective is a key protagonist in a number of cancers. An expression–purification 
strategy was developed to express the protein as a fusion with a GST affinity tag, linked by 
the sequence PAKQC. The GST-PAKQC-PH protein was cleaved using 3Cpro and purified, 
yielding the N-terminal cysteine protein, C-PH, which was subsequently coupled to a 
fluorescein thioester via NCL. The labelled PH domain was successfully used as a probe of 
membrane bound phosphoinositol lipids in a fixed cell imaging assay.  
Suitable thioester tags are generated by converting an activated succinimide ester to a 
mercaptoethanesulfonate thioester using mercaptoethanesulfonate. This reaction was used 
to build up a labelling library of labels ranging from fluorescent dyes for imaging to biotin for 
pull-down studies, all of which were successfully ligated on the C-PH domain. This labelling 
strategy was then taken one step further to allow the specific labelling of the target from 
within a protein mixture. 
NCL is a generic method, requiring only a thioester and a cysteine N-terminus, therefore the 
versatility of this system can be exploited to create an easy to use labelling ‘toolbox’. The 
constructs and chemical tools produced here should enable facile production of a wide 
range of N-terminally labelled recombinant proteins for a vast array of studies 
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Chapter 1 Introduction 
 
This thesis is focused the development of a protein labelling system based on the 
chemical reaction Native Chemical Ligation. The labelling of proteins has long served to 
elucidate valuable information about movements and interactions in vivo1. Knowledge 
of the localisation2, conformation3, activators and effectors4 of a protein can often lead 
to the elucidation of its role within the cell.  
In order to understand the context of this work, this chapter will give an introduction 
to the general area of protein labelling. The label used has, ideally, to possess a 
number of crucial properties5. Firstly it should display facile but site-selective 
attachment, ensuring that only the target protein is labelled. Secondly there should be 
no interference with the protein’s biological activity, for example it should not block 
the active site or a key signalling motif. The tag should also be tolerated by the cellular 
environment so that it is not degraded, as well as not reacting chemically with any 
components of the cell. Finally it has to be possible to monitor it efficiently.  
Two of the most commonly used types of labels, fluorescent and affinity, are examined 
in the context of these requirements5. Also different labelling techniques are 
investigated5; namely the covalent attachments of a chemical group or the engineering 
of a genetic marker as a fusion. 
This literature review will then lead onto the use of an alternative chemical biology 
approach, taking advantage of both chemical and genetic properties. The technique 
will be generic, though in this report the focus will be on labelling for fluorescent 
imaging and protein isolation. 
24 
 
1.1 Fluorescent Labelling of Proteins 
1.1.1 Fluorophores  
Fluorescence is a form of photoluminescence and molecules that exhibit this property are 
known as fluorophores6. This behaviour is illustrated by the Jablonski diagram6, which  
details the electronic states of the fluorophore (Figure 1.1). It involves the ground-state of 
the molecule (S0) absorbing a photon (hν) at a specific excitation wavelength (λ
ex) in a 
process known as excitation to reach an excited state (S1’). The fluorophore then loses a 
small amount of energy due to rotation and interaction with the solvent environment, 
forming a slightly relaxed state (S1). A photon is then emitted at an emission wavelength 
(λem), causing fluorescence and returning the fluorophore to the ground state (S0). λ
em is at a 
longer (less energetic) wavelength then λex due to the loss of energy in the formation of S1 
from S1’
6.  
 
Figure 1.1: Simplified Jablonski diagram showing the fundamental processes in fluorescence
6
. A fluorophore 
in a ground state (S0) absorbs a photon (hν) at an excitation wavelength (λ
ex), reaching an excited electronic 
state (S1’). A small amount of energy then is lost, forming a slightly relaxed excited state (S1). The fluorophore 
then emits a photon at a longer, or less energetic, wavelength (λem). This is detected as fluorescence. 
Fluorescence is often used to study proteins within biological systems5. The variation in λex 
allows different fluorophores to be selectively excited and the detection of the emitted 
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photon at λem allows the visualisation of the molecule by fluorescence. Therefore by using 
these fluorophores as labels, it is possible to quantitatively detect the proteins that they are 
conjugated to5. 
The spectral properties of a fluorophore will affect its suitability for a planned experiment6. 
The excitation and emission wavelengths have to be detectable on an appropriate imaging 
device. It is usual for the excitation to be generated by specific light sources or by use of 
filters7, so it is important to make sure the fluorophore is excitable under these conditions. 
Also if a range of fluorophores are being used it is important that they can be selectively 
excited, so there should be little to no overlap in their excitation spectrum. Another 
property worth bearing in mind is the Stoke shift, the distance between λex and λem. The 
larger this value, the easier it is to separate the exciting light from the emitted fluorescence 
resulting in lower background6.  
There are other important characteristics to look at. The brightness of a fluorophore will 
affect the ease of detection and the quantity required. This is linked the extinction 
coefficient of the molecule and well its quantum yield (the fraction of absorbed photons 
emitted as fluorescence)6. Another factor is photostability, i.e. the decrease in fluorescence 
of a continuously illuminated sample. This is especially problematic in fluorescence 
microscopy, where the sample can be subjected many cycles of fluorescence. The 
propensity of the fluorophore to undergo this photobleaching is dependent on its 
structure8. Finally there are environmental factors such as pH and hydrophobicity that can 
affect some fluorophores9. 
The conjugation of the fluorophore to a target protein also needs to be considered6. This 
needs to occur using a facile and (ideally) inexpensive approach to make the fluorophore a 
viable technological tool. Also this must not have an adverse effect on the fluorophore, as in 
some cases conjugation with a biomolecule can decrease fluorescent properties9. Moreover 
this attachment must not affect the biological activity of the protein5. 
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1.1.2 Chemical fluorophores 
Chemical fluorophores are widely used as protein labels5. These are small organic 
molecules, typically less than 1 kDa, and as such are unlikely to interfere with the proteins 
native function5. There are a large range of these fluorophores, which have undergone both 
chemical and physical optimisation to produce a wide range of properties: excitation and 
emission wavelengths, brightness, efficiency, stability, susceptibility to photobleaching. 
Moreover the extensive permutations of labels (Figure 1.2) allows the selection of one with 
the properties most suited to studying the system in question9.  
 
Figure 1.2: A range of organic fluorophores, with different properties suitable for different experiments
9. 
This shows 28 fluorophores that are commonly used and their key properties. The excitation/absorption 
wavelengths are shown in green, with the emission/fluorescence wavelengths shown in yellow. Key 
excitation wavelengths used by spectroscopic equipment are highlighted at the top. The fluorophores are 
ranked vertically, with the brightest at the top. The solvent conditions required to achieve these properties 
are listed by each fluorophores; aqueous buffer, specific pH or methanol.  
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The drawback of chemical probes is that they cannot specifically target any one protein9. 
Therefore in order to use these as labels, the protein must first be isolated and then 
conjugated to the fluorophore10. There are a number of methods for covalently tagging 
proteins; the two main ones involve an N-hydroxysuccinimide (NHS) ester or maleimide 
derivatives of the labels (Figure 1.3).  
The simplest way to chemically label proteins is using an amine reactive NHS ester10 (Figure 
1.3A). This directly couples the label onto free amino groups on lysine residues (and also on 
to free N-termini), which are typically present in a high amount in the protein. The problem 
with this labelling approach is that it is usually non-specific, generating a number of mixed 
species during the reaction which are difficult to separate11. This multiple labelling can 
affect the analysis of the target protein by disproportionally increasing or decreasing the 
fluorescence detected, therefore distorting the results12. 
 
Figure 1.3: Covalent labelling of proteins using chemical fluorophore derivatives
10
. (A) Amine labelling 
reaction – conjugation of a fluorophore NHS ester to a free amino group found on lysine residues. (B) Thiol 
labelling reaction – conjugation of a fluorophore maleimide to a sulfhydryl group found on cysteine 
residues. 
An alternative is the specific labelling of proteins using maleimides10. These will react with 
the sulfhydryl group on the side chain cysteine residues to form thioethers. In order to make 
this selective there must only be one free cysteine residue in the protein13. This can be 
achieved by either mutating out cysteine in cases when more than one is present or 
mutating in one residue when none are present. The requisite for mutation will vary from 
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protein to protein, resulting in extra cloning steps for each target protein, and will also 
require verification that the biological activity has not been affected. 
There is a limitation associated with both chemical conjugation approaches: the protein 
must first be purified in order to be labelled. This means that the fluorescently tagged 
protein cannot be generated in vivo5. Therefore these labelled proteins are not so useful for 
live cell experiments.  
1.1.3 Green Fluorescent Protein  
An alternative approach to chemical labelling is to use the genetic tag of Green Fluorescent 
Protein, or GFP14. This is a 27 kDa protein which was first isolated from the jellyfish 
Aequorea victoria in 196215. It is now frequently used as a fluorescent protein label, with its 
value being highlighted by the awarding of the 2008 Nobel Prize in Chemistry for work done 
on ‘discovery and development’ of GFP16. 
 
Figure 1.4: The structure of GFP
14
. (A) Three-dimensional structure of the protein in a ball-and-stick model, 
as determined by X-ray crystallography. The β-barrel anti parallel strands are highlighted in green. (B) The 
chromophore of GFP is made up from the cyclised backbone for Ser65-dehydroTyr66-Gly67. The p-
hydroxybenzylidene-imidazolidone fluorophore is highlighted in green.  
(A)
(B)
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The structure of GFP was elucidated by X-ray crystallography17,18 (Figure 1.4). This revealed 
that GFP has a β barrel structure with 11 antiparallel strands (Figure 1.4A) encasing a central 
chromophore in its core (Figure 1.4B). The chromophore, a p-hydroxybenzylidene-
imidazolidone, consists of residues 65-67 (Ser - dehydroTyr - Gly). It is formed inside the 
barrel by cyclisation of the protein backbone and is excited in blue light, resulting in an 
emission of green light19.  
This structural understanding has facilitated the improvement of GFP by a number of 
specific mutations14. This has resulted in the optimisation of fluorescence, increased the 
rate of chromophore formation, facilitated correct folding at 37°C, and enabled a single 
absorption peak which can be excited at 488 nm. These advancements, coupled with the re-
codonisation of GFP to use eukaryotic codons, have resulted in the development of the 
commonly used form of this protein: enhanced GFP (EGFP)19.  
The utility of this protein has been expanded by creating a whole family of fluorescent 
proteins (Figure 1.5)20. Mutations to the chromophore and surrounding residues have 
generated cyan and yellow variants of GFP, C-GFP and Y-GFP respectively19. Furthermore, 
investigations have been carried out into other naturally occurring fluorescent proteins 
based on the GFP model. This has resulted in the development of alternative fluorescent 
proteins, including previously unobtainable red fluorescent ones21.  
 
Figure 1.5: The family of GFP-like proteins, showing the range of emission maxima available
20
. GFP from 
A. victoria and its mutants are shown above the rainbow bar, with B-GFP is indicated by dotted line due to 
decreased photochemical stability.  
The awarding of the Nobel Prize for work on GFP highlights the value of protein labelling in 
general and GFP in particular. A key development that has contributed to the widespread 
use of GFP was cloning of its cDNA and subsequent expression in prokaryotic and eukaryotic 
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cells22. This gene has now been encoded into a number of different plasmids, with the 
insertion of a protein of interest downstream resulting in the expression of this target 
protein as a fusion with GFP14. This means that the protein to be studied is now attached to 
GFP, effectively a green fluorescent label. 
GFP has a number of attributes that make it a label of choice for molecular biologists14. 
Engineering the target protein as a fusion with GFP uses standard expression protocols, 
making it facile to produce22. Protein labelling in this way is controlled and specific with only 
the fusion protein being fluorescent. As the protein label is itself a protein, this fusion 
should be tolerated by the cell and not prove to be cytotoxic14. The protein can be visualised 
by fluorescence easily, due to the optimisation work, by excitation at 488 nm19.  
This fusion protein can be generated within the system being studied, something that is not 
possible with chemical fluorophores. This simplifies the procedure by removing the need for 
purification, specific mutations or a conjugation reaction. Moreover, this allows live cell 
monitoring of the target protein, resulting in a greater understanding of the protein’s native 
function.  
However there are drawbacks with this method. Firstly the size of GFP is 27 kDa, which 
whilst in bio-macromolecular terms this is not very large, it still possesses a significant bulk. 
This can affect not only the native conformation, but also its mobility within the cell, both of 
which can impact on the protein’s function23. For example, when GFP was expressed as a 
fusion with human slow poke K+ channel, it prevented the binding of intracellular Ca2+ which 
controlled the gating of this ion channel 24. There are also limitations in the scope of these 
fluorophores. Although attempts to engineer novel proteins have been made, these cannot 
compare to the variety of chemical fluorophores available19. This is not just in terms of 
range of colours but other factors such as environmental sensitivity, brightness and 
photostability1. 
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1.2 Using Fluorescently Labelled Proteins 
There are vast arrays of different experiments that can be undertaken with fluorescently 
labelled proteins5. The most common applications include imaging studies25, both static and 
dynamic, FRET26 and flow cytometry27. These will be looked at here to see what useful 
information can be elucidated from these experiments and how the labelling method can 
affect the results. 
1.2.1 Fixed Cell Imaging 
The standard way of taking static images to investigate protein localisation is to do fixed cell 
imaging28. This means that the cells are dead but cross-linked to preserve the cellular 
environment. This has the advantage of the cell being easier to handle and manipulate as no 
adverse cellular processes, such as protein degradation, can occur. 
 
Figure 1.6: Fixed cell imaging experiment
28
. (A) The cell to be imaged, for simplicity only the plasma 
membrane and the nucleus are shown in this Figure. (B) The cell is stimulated by culturing in a suitable 
medium. (C) The cell is fixed with PFA and permeablised, in this case by undergoing three freeze/thaw 
cycles. (D) Incubation with the labelled protein to stain the cell. (E) The cell is counterstained with the blue 
nuclear probe DAPI. (F) The mounted cells are imaged using a fluorescent microscope. 
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A typical fixed cell imaging experiment involves inducing a cellular response, fixing the cells 
and then using a fluorescently labelled protein as a reporter for this response28 (Figure 1.6). 
The cells (Figure 1.6A) are cultured in suitable conditions for the experiment, for example 
stimulated by a growth hormone to induce a particular cellular response (Figure 1.6B). They 
are then prepared by fixing them (Figure 1.6C), which can be achieved by using 
paraformaldehyde (PFA) which cross links the amino groups found within the cell28. The 
next step is to insert the fluorescently labelled protein into the cell. This involves 
permeabilising the cell membrane (Figure 1.6C), either by freeze/thaw cycles or a detergent, 
to allow the protein to enter. The labelled protein will then interact with components of the 
cell (Figure 1.6D). Typically the cells are also counterstained with the blue nuclear probe 
DAPI29 to allow easy identification (Figure 1.6E). Finally the cells are mounted on a glass slide 
and visualised (Figure 1.6F). 
The cells are imaged using a fluorescence microscope25. A beam of light is used to excite the 
cells at suitable wavelength for the fluorophore used. The fluorescence emitted is detected 
at the appropriate wavelength. The image can be captured on a CCD camera, which is 
subsequently processed and analysed25.  
This type of imaging is most suited to chemically labelled proteins5. The wide range of 
fluorophores available allow the generation of a fluorescent protein with the ideal spectral 
and stability properties. As this experiment involves inserting labelled protein into the cell, 
the facile generation of this in vitro beforehand is compatible with this methodology. Also 
this imaging technique does not require a singly labelled protein, so it is tolerant to multiple 
labelling often produced by this method.  
1.2.2 Live Cell Imaging  
A more advanced method of cellular imaging involves the use of live cells30. This is a more 
challenging approach as the cells have to be maintained in a healthy state throughout the 
course of the experiment, to allow normal cellular functions to be observed. However if this 
can be done, live cell imaging does allow dynamic images to be taken30. 
The cells are cultured and imaged in a suitable culture chamber which not only allows them 
to be visualised under the microscope but can also the control of a number of vital factors. 
These include temperature, oxygenation, humidity, pH, osmolarity, atmosphere/CO2 
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composition and buffer salts. It is also necessary to be able to access the cells in order to 
alter the conditions in accordance with the experimental needs. Finally the chamber needs 
to be compatible with the microscope used to excite the cells at an appropriate wavelength, 
and then capture the subsequent fluorescence. 
Live cell imaging has enabled the development of new fluorescent imaging experiments31. 
These techniques have facilitated the collection of quantitative, kinetic data on proteins. 
From these data it is now possible to obtain spatial and temporal information for individual 
proteins during complex cellular processes25. 
 
Figure 1.7: Kinetic live cell imaging experiments
25
. (A) Fluorescence recovery after photobleaching (FRAP) 
records the rate of diffusion of a fluorescently labelled protein into an area of the cell that has been 
photobleached; (B) Fluorescence loss in photobleaching (FLIP) monitors the loss of fluorescence in the cell 
following photobleaching of a fluorescently labelled protein only in a specific area. 
One of these techniques is fluorescence recovery after photobleaching (FRAP) (Figure 1.7A), 
which provides information about rates of diffusion25. The fluorescently labelled protein in a 
specific area of the cell is irradiated until it photobleaches. The time taken for the area to 
fluoresce again is then recorded. This is due to the diffusion of unbleached fluorophores 
into the area and can therefore be used to calculate the rate of diffusion of the tagged 
protein32,33. 
(A) FRAP
(B) FLIP
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A similar experiment is Fluorescence Loss In Photobleaching (FLIP) (Figure 1.7B)25. In this 
technique a certain area containing the labelled protein is photobleached, whilst the whole 
cell is imaged. This allows different areas to be monitored for loss of fluorescence, 
elucidating information about the mobility and transport within the cell34,35. 
Advances in commercially available fluorescent microscopes has resulted in the 
development of another technique, Fluorescence Correlation Spectroscopy (FCS)31. This is 
achieved by the measurement of fluorescence intensity fluctuations within a small, defined 
volume over a short period of time, resulting in sensitive data for one or multiple species. 
This approach is used to investigate diffusion, concentration and also protein-protein 
interactions36. 
In order to carry out a live cell imaging experiment it is necessary to insert the labelled 
protein into the cell without perturbing it. One way of achieving this is by microinjection37. 
This does not damage the cell, so this approach can be used for live cell experiments. 
However it is a labour intensive and time consuming approach37. 
The cloning of GFP into a vector for expression in a number of different systems22 has 
created another option for this type of experiment. The cells can be transfected with the 
requisite plasmid and can then express the fluorescent fusion protein in vivo14. This is an 
especially attractive option and makes GFP fusions an ideal choice for live cell imaging30. 
Whilst it is not the focus of this thesis, it is worth acknowledging the tetracysteinebiarsenical 
system5, an alternative chemical based labelling technique used to obtain live cell images. 
This requires the insertion of a short peptide sequence into the target protein containing 
the motif CCXXCC.  This binds via a very strong, yet non-covalent interaction to membrane 
permeable, biarsenical dyes such as he green FlAsH and the red ReAsH fluorophores.  Whilst 
this does allow for lower steric bulk, it does give a higher background fluorescence and 
poorer contrast than fluorescent proteins5.   
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1.2.3 FRET studies 
Investigations of fluorescently labelled proteins can elucidate more information than just 
protein localisation and movement. They can also be used to look at protein-protein 
interactions and ligand binding. This is achieved by using Förster Resonance Energy Transfer 
or FRET26. 
FRET is a technique that can be used to quantify the distance between two fluorophores38. It 
is based on a distance-dependent quantum-mechanical effect, where the excitation of one, 
the donor, is transferred by resonance to the other, the acceptor, without the emission of a 
photon. This can only occur if the emission spectrum of the donor overlaps with the 
absorption spectrum of the acceptor (Figure 1.8). The other requirement is that the two 
groups are in quite close proximity to each other, typically 10-100 Å38. 
 
Figure 1.8: Spectral representation of a FRET pair
38
. The spectra of the donor (green) and the acceptor (red) 
fluorophore is shown, with the excitation spectra are shown in a dashed line and the emission spectra in a 
bold line. The overlap between the emission spectrum of the donor (green, bold) and the excitation 
spectrum of the acceptor (red, dashed) is clearly demonstrated. 
This is a very useful technique for looking at protein interactions39. If the protein is 
conjugated to a donor fluorophore and its ligand, be it anything from a small molecule or 
another protein40, is modified to include an acceptor fluorophore then the distance 
between them can be measured by FRET. The fluorescence of the donor will be quenched 
when binding occurs, but as this interaction falls away the fluorescence will increase. 
Therefore the strength of this binding can then be probed by altering the conditions and 
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components of the assay. Following this by FRET allows the quantitative and continuous 
monitoring of the reaction, resulting in the accurate determination of kinetic constants40.  
FRET binding studies have been carried out with GFP fusion proteins, utilising the overlap 
between the emission of the green GFP and the excitation of the yellow YFP26. However 
better results are observed using organic fluorophores1. One reason for this is that the large 
steric bulk of the fusion proteins can interfere with the binding. Also a tighter spectral 
overlap can be obtained by choosing an appropriate pair of chemical labels. However FRET 
does require single molecular labelling of the protein, so if GFP-like proteins are not used 
then the organic fluorophore must be attached using the more laborious site selective 
maleimide labelling method41.  
1.2.4 Flow Cytometry 
Fluorescently tagged proteins can also be used in flow cytometry experiments. This is a 
method for counting, examining or sorting a stream of particles, typically cells27. The sample 
flows through a beam of light and the scatter from this is detected. The amount of forward 
scatter, at 180° to the beam, is approximately proportional to the size of the particles; whilst 
the side scatter, at 90° to the bead, gives information about the complexity of the particle. 
This information can then be analysed in a 2D scatter plot to show information for the 
whole population27.  
This technique is often used to investigate cells on a single cell level42. The fluorescence 
emitted by cells passing through the beam can be detected to give information about the 
amount of fluorescence present and therefore the levels of the protein it is attached to. It is 
also possible to measure a number of wavelengths simultaneously allowing a number of 
different factors to be tested42.  
This fluorescence flow cytometry can also be used to sort cells, known as fluorescence 
activated cell sorting (FACS)43. Cells are passed through the beam in a steady stream of 
liquid and then separated off into droplets, with each one containing no more than a single 
cell. The fluorescence of the cells is analysed and the droplets charged in accordance with 
their fluorescence. An electrostatic deflection system then separates these differently 
charged droplets into separate containers where the cells are collected.  
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GFP fusion proteins are frequently used for flow cytometry experiments27. The fusion 
protein is expressed within the cells being investigated, as with live cell imaging. This allows 
the facile generation of the labelled protein in vivo for either studying or separating off cells 
with a specific feature. However it is also possible to use chemically labelled proteins, for 
example as probes for specific cell surface molecules42.   
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1.3 Affinity Labels 
Protein labels are not just restricted to fluorescent groups, with another key group being 
affinity tags44. There are numerous different kinds of affinity groups, which range from 
proteins to small chemical groups. They can serve as a purification tool, as well as giving 
useful information about protein-protein interactions.  
1.3.1 Examples of affinity labels 
One common affinity label is the Schistosoma japonicum glutathione-S-transferase protein, 
GST45. The native function of this protein is to conjugate reduced glutathione onto 
unwanted compounds within the body46. These then become soluble, facilitating their 
excretion from the body. In order to carry this out, GST has a strong affinity to glutathione.  
GST is attached to the protein of interest as a fusion protein47. This is achieved by using a 
plasmid that contains a multiple cloning site with a range of restriction sites downstream of 
the gene encoding for GST45. The protein of interest can then be inserted, allowing it to be 
expressed as a fusion with GST. This label has the advantage of not only serving as an 
affinity tag, but also to facilitate protein solubility44. However, as a fusion protein, it is large 
and can interfere with the protein’s native biological activity44. It is also known to clip, or 
self-cleave, from the fusion protein48. 
A smaller, genetic affinity label is the polyhistidine-tag, known as a His-tag44. This widely 
used label consists of (minimally) six histidine residues, utilising the strong affinity of this 
sequence for the metal ion Ni2+ 49. In a similar approach to GST, the His-tag is expressed as a 
fusion with the protein of interest. The six histidine sequence can be placed at the N- or C-
terminus of the protein, dependent on the requirements of the target. Its smaller size also 
means it is less likely to interfere with the protein itself44. 
An alternative affinity method involves the use of the chemical label biotin44. Biotin is a 
naturally occurring vitamin co-factor, involved in carbon dioxide transfer50. It also has an 
extremely strong affinity to the protein avidin and its derivatives51. In fact this is one of the 
strongest non-covalent bonds known, making it an ideal affinity label. 
Unlike the genetic tags of GST and polyhistidine, biotin is typically attached to a protein of 
interest using a chemical route10. These are the same of those for the organic fluorophores 
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(Section 1.1.2), namely via NHS esters and maleimides, meaning that the biotinylation is 
carried out in vitro. However the small nature of the group makes it unlikely to interfere 
with protein activity and the strength of the bond with avidin makes it the most effective 
affinity method51. 
1.3.2 Uses of affinity labels 
 
Figure 1.9: A typical affinity chromatography experiment
44
. (A) A target protein that is attached to an affinity 
label can be removed from a protein mixture via immobilisation on beads or a column that is conjugated to 
a suitable ligand. (B) The target protein can be released from the complex by cleavage from the affinity label 
by an appropriate protease. (C) Alternatively the affinity label-target protein fusion can be eluted using a 
free form of the ligand, or the affinity label. 
Affinity labels are used to separate the target protein from a protein mixture via affinity 
chromatography44(Figure 1.9). This is achieved by immobilising the protein on beads or a 
column that is conjugated to an appropriate group. In the case of GST, His-tag or biotin this 
will be glutathione45, nickel 49 and or avidin51 respectively. The protein can then be released 
by protease cleavage from the affinity label44. Alternatively, the affinity label protein 
complex can be eluted using a high concentration of the appropriate compound, namely 
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glutathione, imidazole or biotin44. The choice of method is dependent on experimental 
requirements and whether the affinity tag needs to be removed or can be tolerated. 
One use of affinity tags is for protein purification44. When a recombinant protein is 
expressed, be it in a prokaryotic system like E. coli or a mammalian cell line, it needs to be 
separated from the native proteins in the system. This can be easily and effectively done 
using affinity chromatography. If the protein is engineered as a fusion, for example with GST 
or a His-tag, then this can be utilised for purification. Subsequently a solution of the target 
protein can be obtained either by cleavage or elution as detailed above. 
Affinity labels can also be used for pull-down studies44. For this experiment the target 
protein is incubated in a protein mixture. When it is removed from the mixture by its affinity 
tag, any other proteins that it interacts with will also be removed with it. This protein 
complex can then be analysed to identify these potential binding partners. Biotin is an ideal 
affinity label for this, given its small and unobtrusive nature as well as its extremely high 
affinity for avidin51. 
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1.4 Other Protein Labelling Techniques 
Two of the principal ways of labelling proteins, either by chemically tagging or by genetic 
engineering, have been explored (Section 1.1 and Section 1.3). However there are other 
methods available. Whilst these approaches are not the focus of this thesis, they are briefly 
described here to put the other methods in context. 
1.4.1 Immunofluorescence 
A common method for protein labelling is via the use of antibodies5. An antibody is an 
immunoglobulin protein that is produced by the immune system to recognise a specific 
molecule, or antigen52. This property means that the antibody will bind selectively to its 
antigen. If the antibody is raised against a specific protein, then it can be used as a protein 
label. This is done by injecting the protein of interest into a mammal, for example a 
mouse53. Isolated lymphocytes producing the specific antibody can then be cultured to keep 
producing it. This antibody can now be used to specifically label the protein originally used 
as the antigen5 .  
 
Figure 1.10: Protein labelling by immunofluorescence
5
. The antibody binds directly and specifically to the 
target protein that is its antigen. The antibody is then visualised directly by conjugation to a fluorophore, or 
indirectly by labelling of a secondary antibody that is conjugated to a fluorophore. 
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Immunofluorescence is the use of fluorescently conjugated antibodies to visualise proteins 
(Figure 1.10)5. This can be done in one of two ways. In a direct labelling experiment the 
antibody is fluorescently labelled by standard chemical methods (Section 1.1.2), and the 
incubated with the target protein resulting in the specific binding of the fluorescent 
antibody. Alternatively a secondary labelled antibody can be used that binds to the primary 
non-labelled one. If the primary antibody is generated in a mouse, then the secondary one 
will be an anti-mouse antibody. This increases the versatility of the experiment because 
secondary antibodies conjugated to a variety of different fluorophores are readily available 
from commercial sources. 
Antibodies can also be used as an affinity label (Section 1.3.2), by taking advantage of their 
specificity for their antigens54. The antibody can be immobilised on a column and used in 
pull-down studies for a target protein. This can be further exploited by using a peptide as 
the antigen instead of the whole protein55, allowing a family of proteins with the same motif 
to be extracted. Alternatively the antibody can by fixed onto a surface. This approach is 
used, for example, in ELISA experiments where the surface-bound antibody captures a 
protein and then visualised by a fluorescent antibody probe to quantify it54.  
A drawback of this system lies in the cross-reactivity of the antibodies. This can result in 
protein oligomerisation which can affect the function and localisation5. Another factor to 
consider is the generation antibodies, which is an expensive and time-consuming process as 
it involves the use of mammals53. There is also a decision that needs to be made between 
the direct and indirect labelled approaches, with the indirect method being more sensitive 
whereas the direct approach is quicker and more economical54. 
1.4.2 Fusion protein labelling 
A recent development has been the chemical labelling of fusion protein domains1. This 
involves the expressing a specific domain as a fusion to the target protein, and then taking 
advantage of its native function to conjugate it to a suitably derivatised label of choice. This 
has the advantage of combining the versatility of chemical labelling with the specificity and 
in vivo nature of a genetic tag. 
One example of this the SNAP-tag™ based on a DNA repair enzyme56. The native function of 
this protein is to covalently attach an alkyl group on the base guanine. A benzylguanine 
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derivatised label will associate with this protein and then covalently attach to a key cysteine 
residue (Cys145). By expressing the target protein as a fusion with the SNAP-tag™, site 
specific protein labelling can be achieved both in vitro and in vivo56 (Figure 1.11).  
 
Figure 1.11: Labelling proteins via a Snap-Tag
56
. The Cys145 residue of the SNAP-tag reacts with synthetic 
benzylguanine substrates resulting the covalently attached benzyl derivative of the label. 
Nonetheless these methods do not negate the problem of the bulky fusion group, which can 
potentially inhibit the expression, movement and function of the target protein1. Also, in 
order to carry this out in vivo, very specialised labels must be used1. Not only do these need 
to have the requisite functional group for the coupling but they must also be cell permeable 
and survive as free species in the appropriate cellular compartment for long enough to allow 
the reaction to occur. This is not always possible, so certain fusion domain tagging systems 
can only be used for labelling proteins in vitro or for those present on the cell surface. 
1.4.3 Quantum Dots 
 
Quantum dots (QDs) are a recent addition to the protein labelling toolbox (Figure 1.12)5. 
They are inorganic nanocrystals, typically containing a CdSe or CdTe core and a ZnS shell. By 
varying the size, QDs can be designed to fluoresce at range of sharp and discrete 
wavelengths. For example larger QDs display red shifted spectral properties. The advantage 
of using these for protein labelling is the increased brightness and photostability that they 
display. It has been estimated that quantum dots are twenty times brighter and a hundred 
times more stable than traditional fluorescent reporters57.  
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Figure 1.12: Schematic of a typical quantum dot (QD)
57
. The inorganic semiconductor cadmium core, 
encapsulated in a Zn based shell, conveys the fluorescent properties onto the QD. The coating makes the QD 
aqueous soluble and allows functionalisation, in this case with an antibody.  
In order to use QDs for protein labelling, it is first necessary to give them a suitable 
coating57. This is achieved using thiol or silane groups that can be subsequently 
functionalised. This not only makes them water soluble, but also prevents quenching by 
water. In addition to this, coating the QDs allows conjugation to biomolecules like 
antibodies or streptavidin5. This allows them to be targeted to specific proteins within the 
cell. QDs have been used to label fixed, permeabilised cells and, by delivery using micelles, 
for live cell imaging57. 
There are, however, problems associated with the use of quantum dots. The first is size, 
with a fully bioconjugated QDs being about 10 nm in size5. This is even larger than GFP 
(4 nm) and therefore has the potential to perturb the native structure and function of the 
system being targeted. Also free Cd is cytotoxic, so extreme care has to be taken in the 
synthesis of the QDs to prevent any leakage57. This is especially important for live cell 
imaging.  
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1.5 Native Chemical Ligation 
1.5.1 NCL reaction 
Native Chemical Ligation (NCL) is a site-selective reaction first proposed by Weiland et al in 
195358(Figure 1.13). It involved the covalent attachment of a thioester group selectively to 
N-terminal cysteine residue of a protein. This reaction occurs in an aqueous buffer and at 
neutral pH59. Typically the reaction will go to completion at room temperature within 
5 hrs59. NCL has become a general synthetic pathway for Chemical Biologists carrying out 
convergent peptide and protein total synthesis59. 
 
Figure 1.13: The mechanism of Native Chemical Ligation
59
. (A) Initial reversible transthioesterification 
reaction between the thiol of the cysteine residue and the thioester molecule; (B) Irreversible S→N acyl shift 
forming a peptide bond. 
The mechanism for NCL is a two step reaction (Figure 1.13). The initial step (Figure 1.13A) 
involves reversible transthioesterification between the thioester and sulfhydryl group of 
cysteine to generate a ligated thioester intermediate. This subsequently undergoes a 
spontaneous, intramolecular S→N acyl rearrangement (Figure 1.13B) to generate the final 
product, which now contains a natural peptide bond at the ligated junction. It is this 
intramolecular rearrangement that gives this reaction its specificity. It is also irreversible 
under typical reaction conditions, providing the driving force behind the reaction 60.  
This system can be catalysed by the addition of a thiol61. This aids the reaction by reducing 
disulfide bond formation. It also regenerates thioesters that reversibly bind with internal 
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cysteine molecules, preserving the specificity of the reaction62. Typical thiols used are the 
aromatic thiophenol and the alkyl mercaptoethanesulfonate61.  
1.5.2 Generating an N-terminal Cysteine  
The only requirement for the protein of interest to undergo NCL is that it has an N-terminal 
cysteine residue. However these occur only rarely in wild-type proteins63. Therefore in order 
to carry out this reaction it is often necessary to engineer the protein to have a cysteine at 
this position. 
A recently developed method for addressing this challenge is the IMPACT™ system designed 
by Chong et al and developed by New England Biolabs64. IMPACT stands for Intein Mediated 
Purification with an Affinity Chitin Tag and takes advantage of the inducible self-cleavage 
activity of engineered protein splicing elements (inteins). Protein splicing is a post-
translational process in which an intervening polypeptide (intein) is auto-catalytically 
excised from a precursor protein, and the flanking N- and C-terminal regions (N- and 
C-exteins) are ligated via a peptide bond65.  
Once the mechanism had been elucidated, it was manipulated via mutagenesis to allow 
intein cleavage resulting in an N-terminal cysteine66. This involves the induction and 
autocatalytic, self-cleavage of the N-terminal intein, caused by a shift in either temperature 
or pH, without the need for a C-terminal intein. Additional modifications were made to the 
system to allow purification of the recombinant protein via the insertion of a chitin binding 
domain upstream of the intein to complete the IMPACT system (Figure 1.14)64. This resulted 
in a process that not only permits production of a protein with an N-terminal cysteine, but 
also allows the protein to be purified and then separated from the intein-affinity tag without 
the use of proteases.  
47 
 
 
Figure 1.14: A schematic of the IMPACT system used to generate N-terminal cysteine proteins
66
. A) The 
target gene is inserted into the cloning vector downstream of the promoter–CBD (chitin binding domain)–
Intein and expressed. B) The fusion protein is washed through a chitin column. C) Cleavage is induced by 
altering the pH and/or temperature to pH7 and 25°C. (D) The N-terminal cysteine target protein is eluted. 
However there are problems associated with this method. Firstly in vivo cleavage can occur 
during expression, reducing the final yield. Also the successful cleavage of the protein from 
the intein can be impeded by the expression conditions needed to produce soluble protein, 
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the structure of the native protein, and the specific sequence of amino acids found at the N-
terminus of the protein67. Due to the dependency of splicing on the properties of the 
protein in question, this cannot be described as a generic method for expressing N-terminal 
cysteinyl proteins. 
An alternative approach is to use proteases. A protease is an enzyme that hydrolyses a 
peptide bond, classified by the Enzyme Commission of the International Union of 
Biochemistry as EC 3.4. There are a number of naturally occurring proteases with different 
biological functions resulting in enzymes with a range of specificities and recognition 
sequences 68. The peptide bond that the protease hydrolyses is called the scissile bond. The 
residues upstream are labelled P1, P2, P3 … and downstream P1’, P2’ … with the cleavage 
point denoted by ‘’, i.e. P3-P2-P1P1’-P2’-P3’.  
Proteases are commonly used in the purification of recombinant proteins. The expressed 
protein is usually attached to an affinity tag. This allows it to be separated from the debris of 
the cell in which it was expressed, normally by the use of a suitable affinity column (Section 
1.3.2). If a protease cleavage sequence is inserted between the tag and the protein then 
that specific protease can be used to cleave off the target protein. 
 
Figure 1.15: Using proteases to generate proteins suitable for NCL. Mutation of the P1’ amino acid to a 
cysteine residue (red) will result in cleavage of the protein to produce a cysteine N-terminus 
Modifications to this technique and use of an appropriate protease can facilitate purification 
of a recombinant protein with an N-terminal cysteine (Figure 1.15). This can be achieved if 
the amino acid in the P1’ position of the cleavage site is mutated to a cysteine residue. The 
P3-P2-P1-C-P2’-P3’
Protease 
cleavage
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49 
 
proteases Factor Xa69, Thrombin70 and TEV71 have successfully generated N-terminal 
cysteinyl proteins suitable for NCL in this manner.  
There are several factors that need to be taken into account when generating protein for 
NCL using proteases. Firstly the protease has to tolerate a cysteine residue at the P1’ 
position71. Moreover the mutation of cleavage sequence must not result in a significant loss 
of proteolytic activity, as the protease must still be able to cleave the sequence at a 
reasonable rate. Also some proteases, such as Factor Xa and Thrombin, have been reported 
to carry out off site cleavage, generating unwanted truncated protein side products72. 
Finally, unlike with the intein approach, an extra purification step is required to remove the 
protease from the target protein after cleavage44. 
It is possible to carry out the ligation without an N-terminal cysteine residue by using an 
auxillary at this position that mimics its structure73.  One way of achieving this is with thiol 
derivatised benzyl group on the N-terminus, though for this to be effective a glycine is 
normally preferred at the coupling site.  Alternatively β-mercaptoamino acids can be used 
and subsequently desulfurised, yet this will require the protection of any internal cysteine 
present. However as this thesis is focusing on a biological methodology for generating 
N-terminal cysteines, this chemical strategy will not be discussed further. 
1.5.3 Thioester Synthesis 
A suitable thioester can easily be synthesised using standard organic chemistry 
techniques71. However it is important that it is compatible with reaction conditions, i.e. it is 
soluble in aqueous medium at neutral pH. This can be achieved by incubating an NHS 
activated ester with a charged thiol, for example mercaptoethanesulfonate, in sodium 
borate buffer for two hours (Figure 1.16)74. This is a facile method, suitable for generating 
thioester groups on small organic molecules and will be used in this thesis. 
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Figure 1.16: Reaction scheme for the synthesis of a water soluble thioester, suitable for NCL
74
. An NHS-
activated ester reacts with the thiol mercaptoethanesulfonate to give a thioester moiety. 
Alternative approaches are possible and indeed preferable for peptides and proteins. 
Peptide thioesters can be generated using a method based on standard solid phase peptide 
synthesis (SPPS)75. The peptide is built up on a sulfamylbutyryl resin, activated with TMS and 
then cleaved by ethyl mercaptopropionate and sodium thiophenoxide to yield the thioester. 
Protein thioesters can be generated using the IMPACT system (Section 1.5.2)66. In this 
version of the system, the intein is fused onto the C-terminus of the protein and cleaved 
with DTT to give the C-terminal thioester protein. 
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1.6 Uses of NCL 
1.6.1 Biological potential of this reaction 
This strategy has a number of characteristics that make it a useful biochemical technique. 
Firstly the conditions of the reaction are compatible for working with biological systems76. 
NCL occurs at physiological pH and in aqueous solution, which are ideal for working with 
proteins, as these are non-denaturing conditions.  
Secondly this is a non-enzymatic, highly chemoselective reaction77. It will only occur at the 
N-terminal cysteine, not at any other residues within the protein, and internal cysteines are 
tolerated. This is because the initial transthioesterification is reversible but only the 
N-terminal cysteine is able to undergo the S→N acyl shift. Consequently there is no need for 
the use of protecting groups76. Furthermore, there is no racemisation at the point of 
ligation78.  
There is another key advantage of this system, which is the scope for variation79. The 
thioester can have any physiochemical property that can be fine-tuned synthesised. This 
means that anything from a chemical label to a large biomolecule can be ligated onto the 
target protein, facilitating a range of different studies. Moreover the same N-terminal 
cysteine protein can be used for all these studies. This can eliminate discrepancies across 
the experiments due variations in the recombinant protein.  
1.6.2 Expressed protein ligation 
The most common use for NCL is to engineer semi-synthetic proteins, a process known as 
Expressed Protein Ligation (EPL)77. This involves generating fragments of the protein by 
either recombinant expression or chemical synthesis and then using NCL to covalently 
attach it together. All that is necessary is to ensure that there is an N-terminal cysteine 
(Section 1.5.2) and a C-terminal thioester (Section 1.5.3) on the relevant fragments. The use 
of EPL has allowed access to protein that could not be generating using standard biological 
or chemical approaches. 
EPL can be used to explore the effects of post-translational modifications (PTM) on 
proteins80. The selective incorporation PTMS such phosphorylation81, glycoylation82 or 
ubiquitinylation83 has resulted in the elucidation of novel structural and functional 
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information. An elegant example of this is the assembly of multiple isoforms of the protein 
GlyCAM1 (Figure 1.17). Each domain was expressed separately in both a glycosylated and 
non-glycosylated state, allowing the assembly of multiple isoforms of the target protein that 
can then be studied. The effect of glycosylation on the ability of this protein to bind to L-
selectin can now be determined.  
 
Figure 1.17:The isoforms of the glycosylated GlyCAM1, a mucin-like glycoprotein that is a ligand for the 
leukocyte adhesion molecule L-selectin
 82
.  These were assembled modularly from two glycosylated or 
non-glycosylated mucin like domains via EPL. 
Another valuable use of EPL is the incorporation of non-canonical amino acids into 
proteins84. This is achieved by chemically building the peptide to easily incorporate specific 
groups, from unnatural amino acids to biophysical markers, and then ligating this onto a 
recombinant protein. The usefulness of this is highlighted by the semi-synthesis of the HIV-1 
protease85. This was generated by EPL, with the introduction of a 13C-labelled Asp25, a key 
catalytic residue. NMR studies in the presence of an inhibitor highlighted new insights into 
the mechanism of this enzyme, allowing the design of improved HIV inhibitors. 
1.6.3 Protein labelling 
The use of this reaction for protein labelling would combine some of the benefits of the 
genetic and chemical approaches: facile and selective protein labelling with a large scope of 
tags available. The reaction can only occur at a cysteine N-terminus, which can be 
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genetically engineered onto the target protein. Also the only requirement for the label is the 
presence a thioester group, so it can have any desired and engineerable physiochemical 
properties. Therefore the reaction can be selective and generic, ideal for protein labelling. 
Chemical labels such as fluorescein and biotin thioester derivatives have been used in 
NCL71,74, though this has been mainly limited to validating the presence of an N-terminal 
cysteine residue on the target protein rather than to study the labelled protein. A system 
has also been developed to label the C-terminus of proteins using NCL.  This involves the 
generation of a C-terminal thioester using inteins (Section 1.5.3), followed by ligation to a 
chemically modified cysteine residue60.   However it is more common for NCL to be used for 
generating complicated, previously unobtainable proteins through expressed protein 
ligation (Section 1.6.2). As such it remains a tool of the chemical biologists, and is not known 
to the majority of biochemists who routinely carry out protein labelling.  
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1.7 FMDV 3C protease 
This thesis will look at the development of an alternative method for generating N-terminal 
cysteinyl proteins. The most effective methods to date are the use of inteins66 or the TEV 
protease71 (Section 1.5.2). The use of inteins is dependent on the makeup of the protein for 
successful N-terminal cysteine generation and even TEV required that the target protein 
does not randomly contain its cleavage sequence. Another stringent protease method 
would give a wider choice of approaches, to allow the most suitable one to be selected for 
the specific system being studied. Also this could lead to the development of a dual, 
orthogonal NCL system in conjunction with existing methods. The protease that will be 
investigated with the aim of producing a cysteine N-terminal protein is the 3C protease of 
the foot-and-mouth disease virus (FMDV). 
1.7.1 Virus life cycle 
Foot-and-mouth disease is a highly infectious disease of cloven-hoofed animals. The viral 
agent, FMDV, is the prototype member of the Aphthovirus genua of the family 
Picornaviridae. It consists of a single stranded, +-sense RNA genome of approximately 
8500 bases, covalently bound to 3B protein and surrounded by four structural proteins to 
form an icosahedral capsid composed of 60 copies of the four structural proteins (Figure 
1.18)86  
 
Figure 1.18: The make-up of the foot-and-mouth disease virus
86
. (A) The genome of FMDV and the proteins 
it encodes. (B) The viral capsid, detailing how the structural proteins are arranged on it 
55 
 
The capsid binds to parts of the αv subgroup of integrin receptors on the cell surface via an 
RGD tripeptide sequence87. Once inside the cell the virus is uncoated and the RNA released 
into the cytoplasm. The 3B protein is cleaved and translation can occur. The genome 
contains a single long open reading frame, with the encoded polypeptide being processed to 
the mature viral proteins by three proteases, Lpro, 2A and 3Cpro 86.  
Lpro auto-catalytically excises itself from the polypeptide and is responsible for shutting 
down the host’s protein synthesis by cleaving eIF4G, the protein initiation factor88. 2A also 
undergoes autocatalytic excision. The remaining processing of the polypeptide chain is 
performed by the vital enzyme 3Cpro 86. 
The functions of the other non-structural proteins are not entirely understood. 2B and 2C 
proteins are thought to be involved in the virus-induced cytopathic effects. 3A and 3B are 
vital RNA replication factors that are associated with cellular membranes, while 3D is the 
viral-encoded RNA polymerase 89. 
1.7.2 3C protease 
 
Figure 1.19: The crystal structure of FMDV 3C
pro
, with the active site residues His48, Asp84 and Cys163 
indicated 
90
. 
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The FMDV 3Cpro is a cysteine protease with a chymotrypsin-like fold. This consists of two 
β-barrel domains, each consisting of four-stranded anti-parallel β-sheets, packed together 
to form a shallow peptide binding cleft (Figure 1.19)90. Both FMDV 3Cpro and chymotrypsin 
contain a catalytic triad of residues at the enzyme active site, which is responsible for 
hydrolysing the peptide bond. Though unlike chymotrypsin, this viral enzyme has a Cys-His-
Asp catalytic triad as opposed to Ser-His-Asp. Based on its similarity to the serine proteases, 
it is likely that the FMDV 3Cpro utilises a similar mechanism91. In the case of chymotrypsin, 
the His57 activates the Ser195 side chain for nucleophilic attack on the scissile bond by 
abstracting a proton. The Asp102 serves to stabilise the resulting positive charge on the 
His57 residue92 (Figure 1.20). It appears that Cys163 of FMDV 3Cpro acts as the nucleophile in 
place of the serine.  
 
Figure 1.20: Hydrolysis of a peptide (blue) by chymotrypsin (black)
92
. The role of the catalytic triad of ser-his-
asp, found in the active site, is shown here. Ser195, after activation by His57, is the nucleophile in this 
reaction whilst Asp102 acts as a stabiliser. It is believed that 3C
pro
 acts by a similar mechanism, by with a Cys 
as the active site nucleophile. 
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Experimental studies have been carried out to determine the cleavage sequence of this 
protease91. The native viral polyprotein junctions in FMDV have been synthesised, and the 
hydrolysis has been monitored using RP-HPLC. This was followed by in depth FRET analysis 
of these sequences using alanine scanning and specific point mutations93. The results of 
these investigations have shown that the optimum peptide sequence for cleavage by 3Cpro is 
PAKQ, with no apparent specificity for the P1’ position.  
1.7.3 Tolerance of cysteine in P1’ position peptide study 
3Cpro, by merit of its specific cleavage sequence, has a number of the properties that make it 
a desirable protease for the production of an N-terminal cysteine residue91. Firstly, it has an 
unusual and highly specific cleavage sequence, so should not cleave at off-target sites. 
Secondly, previous work has been done to optimise the sequence. Finally, initial results 
suggest that the cleavage sequence is not dependent upon the P1’ position. 
Work was carried out to determine the effect of a cysteine residue at the P1’position94. The 
cleavage rates were obtained for both the optimum cleavage sequence APAKQ↓LLDFDLLK 
(Peptide 1) and the sequence with a P1’ cysteine residue APAKQ↓CLDFDLLK (Peptide 2). 
FRET substrates of these peptides synthesised by SPPS containing the donor/acceptor pair 
EDANS and DABCYL95. When the peptide substrate is cleaved by the protease the distance 
between the two groups increases beyond the range of the FRET interaction, resulting in an 
increase in fluorescence from the EDANS donor group. By measuring the initial rate of 
reaction for each peptide over a range of concentrations, kcat/KM can be determined
94. This 
is the specificity constant that can be used to compare the 3Cpro activity for each peptide. 
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Figure 1.21: Analysis the activity of 3C
pro
 on a P1’ cysteine cleavage sequence by FRET
96
. (A) Peptide 1 
(optimal cleavage sequence), with kcat/KM = 566.2 (M
-1
s
-1
); (B) Peptide 2 (cysteine P1’ peptide) with kcat/KM = 
78.2 (M
-1
s
-1
). 
Comparison of these kcat/KM values shows the effect of a cysteine a P1’ position on the 3C
pro 
cleavage sequence (Figure 1.21). The kcat/KM for peptide 2 (78.2 M
-1s-1), which is less than 
one order of magnitude lower than for the optimum sequence of peptide 1 (566.2 M-1s-1). 
This shows that there is only a minor loss in activity when the cysteine is substituted for the 
P1’ leucine96.  
This peptide model system has demonstrated that 3Cpro can tolerate a cysteine residue the 
P1’ position with an acceptable loss in catalytic activity94. Work carried out on the TEV 
protease to assess its tolerance of mutations in its cleavage sequence showed a similar 
decrease in activity with a P1’ cysteine97, and this protease has been successfully used to 
generate protein suitable for NCL71. Therefore this result is encouraging that it could be 
possible to use 3Cpro to generate N-terminal cysteine proteases. 
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1.8 A model target protein: PKB-PH domain 
A model target protein to be tagged using NCL in this proof-of-principle project required a 
number of properties: it should ideally be of biological interest, it must be easily 
over-expressed in a recombinant system, the N-terminus must be available for modification, 
and so cannot be involved in the protein’s biological activity, and it cannot contain a PAKQ 
motif. A recombinant protein that meets these requirements is the PH domain of Protein 
Kinase B (PKB) 
1.8.1  PKB 
PKB, also referred to as Akt, is a serine/threonine kinase that exists in three mammalian 
isoforms, α, β and γ. It is part of the AGC (cAMP dependent, cGMP dependent, and Protein 
Kinase C) family of protein kinases, all of which have similar functions and exhibit a high 
degree of kinase domain homology. PKB is a key component in a number of signalling 
cascades 
PKB consists of three domains, highly conserved over the three isoforms. PH domains bind 
proteins to specific phosphatidylinositol poly-phosphates (PIPn) found on the inner surfaces 
of intracellular membranes. The kinase domain is the catalytic part of the protein, 
responsible for phosphorylating its targets. The hydrophobic motif acts as a docking site and 
allosteric regulator of the enzyme98. 
Phosphatidylinositols consist of a diacyl glycerol (DAG), having two long lipophilic saturated 
or unsaturated fatty acid esters, linked by a phosphodiester to a cyclohexane hexitol, myo-
inositol, head group99. The ability of the free hydroxyl groups of the head group to undergo 
reversible phosphorylation is responsible for the recruitment of PKB, and other PH-domain 
bearing proteins, to membranes. When phosphatidylinositol 3-kinase (PI3-K) phosphorylates 
PI(4,5)P2 on the 3-OH of the inositol ring, PI(3,4,5)P3 is generated, resulting in the binding of 
the PKB PH domain.  
This binding induces a conformational change which opens up the protein for activation by 
specific kinases100 (Figure 1.22). Present at the plasma membrane, itself recognising 
PI(3,4,5)P3 through a PH domain, is protein dependant kinase 1 (PDK1). PDK1 
phosphorylates PKB at Thr308 in the activation segment T-loop of the kinase domain101. This 
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results in partial activation of the protein, with phosphorylation of Ser 473 by the kinase 
mTORC2 in the hydrophobic motif (HM) required for complete catalytic activity102. The 
activated PKB leaves the membrane, ready to continue the signalling cascade103. 
 
Figure 1.22: Activation of PKB
103
. Inactivated PKB (dark green) is recruited to PIP3 on the plasma membrane 
(blue) via its PH domain. Once there it is phosphorylated (orange) by PDK1 (red) on Thr308 and mTOR2 
(purple) on Ser473. The activated PKB (light green) now leaves the membrane to phosphorylate 
downstream effectors in its signalling cascade. 
PKB is involved in a number of signalling pathways, including apoptosis, expression and 
cellular proliferation98. Therefore alterations of PKB can result in cancer. This is why 
extensive work has been carried out in order to try and fully understand activation and 
signalling pathways of this enzyme. The labelling of the PKB-PH domain has proved useful in 
providing some of this information104-106 
1.8.2 PKB -PH Domain 
The PH, or pleckstrin homology, domain has been identified in numerous proteins that bind 
to PIPn groups. There are four types of PH domains, categorised occurring to their affinity for 
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the different PIPn groups. The PH domain from PKB falls into Group 3, with a high and equal 
affinity for PI(3,4,5)P3 and PI(3,4)P2
107. 
Analysis of a number of PH domains from different proteins has shown minimal primary 
sequence homology, but a highly conserved 3D structure108. The PKB PH domain structure 
has been elucidated by NMR, X-ray crystallography and experimental studies109. This shows 
the typical PH domain fold, consisting of a collapsed β-barrel with an α-helix running across 
the base. There is a positively charged pocket on the top of the β-barrel structure that 
interacts with the PIPn group. 
 
Figure 1.23: Structural models of the PKB PH domain
109
. (A) Schematic drawing with the β-sheets in yellow 
and the α-helix in red. The coils and turns in the connecting strands are shown in green and blue 
respectively (B) Electrostatic surface in the same view with the positive potential in blue and the negative 
potential in red. The positively charged pocket of basic residues for PIPn binding is indicated. 
1.8.3 Current protein labelling experiments 
There have been a number of studies carried out using the labelled PH domain from 
PKB105, 110. This is because of its binding specificity for certain PIPn groups. These 
investigations have resulted in the mapping of these groups on the protein membrane, 
which has enabled a number of signal cascades in different physiological and disease-like 
states to be followed. 
Fixed cell imaging studies have been carried out with immunofluorescent staining105. This 
has resulted in the monitoring of the insulin-dependent signalling pathway that involves PKB 
(A) (B)
Positively charged pocket
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and well as the identification of inhibitors to the components of the pathway. The labelled 
PH domain was used to successfully discriminate between the up-regulated and down-
regulated states of the pathway by visualising the PI(3,4,5)P3 and PI(3,4)P2 present. However 
the immunolabelling was carried out by an anti-GST antibody on a GST-PH fusion, which will 
add considerable bulk to the protein, especially with respect to the small size of the 
phosphoinositol head group.  
In vivo mapping has also been carried out with the PH domain110. The engineering of GFP-PH 
fusion proteins has allowed the monitoring and visualisation of the different PIPn groups on 
a single cell level, resulting in the mapping of the phosphatidylinositol signalling pathways. 
However the fusions were found to interfere with cellular functions and the images 
produced have low resolution. 
The generation of the N-terminal cysteinyl PH domain by NCL would allow the specific 
labelling of this protein with a suitable organic fluorescent dye. The successful labelling of 
this protein can be determined by its ability to map PI(3,4,5)P3 and PI(3,4)P2 in cells. This 
approach could also serve to combat some of the limitations of current techniques. 
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1.9 Project Objectives 
The aim of this project is to develop a new, generic and facile system for introducing small, 
molecular labels to proteins. This will be based around the chemical reaction Native 
Chemical Ligation59, taking advantage of the specificity of the protease 3Cpro 91. In order to 
do this, the system will: 
• Be validated. In Chapter 2 the labelling will be validated by a proof of principle 
investigation using the PH domain as a model system. 
• Be compared to existing approaches. Chapter 3 will compare this new method of 
generating N-terminal cysteinyl proteins with some existing protease based 
methods. 
• Have a compatible labelling library. Chapter 4 will focus on the development of a 
thioester-based labelling library to allow this system to be exploited for a range of 
applications, to be illustrated by the use of fluorescent labels. 
• Be developed as a protein mixture labelling tool.  In Chapter 5 the utility of this 
system will be expanded to carry out selective labelling of one protein from within a 
mixture, ideal for biotin pull-down studies. 
The biological and chemical requirements for this new strategy, along with accompanying 
protocols, will be used to create an easy to use labelling ‘toolbox’. This will be developed in 
such a manner so that molecular biology scientists, with no background in chemistry, can 
make use of this valuable technique for a vast array of protein labelling studies.  
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Chapter 2 Proof of Principle 
 
This chapter details the establishment of the 3Cpro/NCL labelling system in proteins. 
Having successfully used the protease to generate peptides suitable for NCL94, the next 
step was to transfer this technology into a protein system. In order to do this, two key 
questions need to be addressed: 
• Can the FMDV 3Cpro cleave a fusion protein to yield a cysteinyl N-terminus 
suitable for NCL? 
• Can the labelling be carried out with acceptable efficiency and selectivity, 
without affecting the protein’s biological activity? 
This chapter will describe the work carried out to express a model protein in a 
specifically engineered vector and purify this protein using 3Cpro. It will then examine 
the ability of this system to undergo NCL and finally show the use of this labelled 
protein as a probe in a cellular experiment. 
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2.1 Peptide Labelling using 3Cpro/NCL 
Initial peptide experiments were carried out in the MRes thesis of this work to determine 
feasibility of the 3Cpro/NCL labelling strategy. FRET studies had shown that the protease is 
able to tolerate a cysteine residue at the P1’ position (Section 1.7.3). Therefore a peptide 
containing the 3Cpro cleavage site followed by a cysteine, APAKQCLDFDLLK, was incubated 
with the protease at 37°C overnight. Analysis by RP-HPLC and MALDI-TOF showed that the 
enzyme cleaved the peptide stoichiometrically and specifically, yielding two products 
CLDFDLLK and APAKQ (Figure 2.2).  
The label chosen for ligation on to the cysteine N-terminal peptide fragments was 
fluorescein, a fluorescent organic molecule with an excitation wavelength at 490 nm and 
emission at 515 nm. Carboxyfluorescein can be modified with a charged thiol to form a 
water-soluble fluorescent thioester. When the NHS activated ester of carboxyfluorescein 1 
is treated with sodium 2-mercaptoethanesulfonate (MESNa) 2, it yields the water soluble, 
fluorescein mercaptoethanesulfonate thioester 374(Figure 2.1). 3 is known to react with the 
N-terminal cysteine of a protein under standard conditions for NCL74. 
 
Figure 2.1: Reaction scheme for synthesis of a fluorescein thioester 3 from carboxyfluorescein NHS ester 1 
using MESNa 2. The reactants were incubated in 0.1 M sodium borate buffer, pH 8.3, for 2 hrs at room 
temperature. 
The cleaved peptide fragment CLDFDLLK is now able to undergo NCL with the thioester. This 
was demonstrated by reacting the peptide with a four-fold excess of 3 under standard NCL 
conditions, 0.1 M phosphate buffer, pH 7.4, at room temperature for 5 hrs. RP-HPLC and 
MALDI-TOF analysis showed that an N-terminally fluorescein tagged peptide had been 
produced in quantitative yield (Figure 2.2). 
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Figure 2.2: HPLC and MALDI-TOF analysis of peptide labelling via 3Cpro/NCL. HPLC elution profiles of: (A) 
Starting peptide APAKQCLDFDLLK, incorporating the 3Cpro cleavage sequence. (B) After incubation with 
3Cpro at 37°C for 16 h, showing cleavage into two fragments APAKQ and CLDFDLLK. (C) Fragment CLDFDLLK 
following NCL reaction with the fluorescein thioester 3, at room temperature, for 5 h to introduce the label 
at the N-terminus of the peptide. The traces were obtained on a C-18 reverse phase column over a 
water/acetronitrile solvent gradient at a wavelength of 223 nm and in each case the fragment was 
identified by MALDI-TOF. 
The experiments described above show that 3Cpro can efficiently cleave a peptide containing 
a P1’ cysteine to produce a fragment with a cysteine N-terminus. This resultant peptide can 
subsequently be ligated with a thioester to generate a labelled peptide. These results 
provided encouragement to transfer this 3Cpro/NCL labelling approach into a protein system. 
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2.2 Protein Labelling Strategy 
A two-step strategy was developed to provide an effective and generic protein labelling 
system using 3Cpro and NCL (Figure 2.3)111. This involved the expression of an affinity tag 
fused to a model protein, linked by the motif PAKQC which can be cleaved by 3Cpro 91. 
Finally, the resulting N-terminal cysteinyl protein can be labelled with an appropriate 
thioester tag via NCL74. 
The affinity tag of choice in this system is GST, allowing the GST-PAKQC fusion protein to be 
purified onto glutathione coated beads45. 3Cpro has a His-tag91 which is an orthogonal 
affinity tag that will not bind to these beads but instead to nickel coated ones. Therefore the 
glutathione immobilised fusion protein can be incubated in a solution of 3Cpro, which can 
subsequently be removed from the system following cleavage using nickel beads. The 
purified cysteine N-terminal protein will now be ready to undergo NCL.  
 
Figure 2.3: Strategy for N-terminal labelling of proteins
111
: (A) proteolysis of a GST-PAKQC-fusion protein by 
3C
pro
; (B) labelling of the protein via native chemical ligation. The label is indicated in green and can, in 
principle, be of any chemical type. 
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2.3 Developing protein expression protocol 
The model target protein that will be used to test this 3Cpro/NCL labelling strategy is the 
PH domain of PKB; see Section 1.8 for further details. PKB is a key signalling enzyme 
involved in a number of pathways including apoptosis, expression and cellular 
proliferation98. Its PH domain targets it to the plasma membrane via recognition of the lipids 
PI(3,4,5)P3 and PI(3,4)P2
107. This protein has been routinely expressed in E. coli105 and 
structural studies have shown that its N-terminus is not involved in the in its function so it is 
available for modification109. There are also existing studies with the labelled PH domain 
that will serve as a good basis for comparison104-106. 
2.3.1 pGEX_3C_PH Plasmid 
 A method has been developed for the expression of the PKB PH domain involving the 
Glutathione-S-transferase (GST) Gene Fusion System using the vector pGEX-4T-194. This is a 
versatile system for the expression, purification and detection of fusion proteins produced 
in E. coli45.  The plasmid contains a multiple cloning site with a range of restriction sites 
downstream of the gene encoding for GST, allowing the target protein to be expressed as a 
fusion (Section 1.3.1).  This not only serves to facilitate protein solubility, but presents a 
purification method via affinity chromatography using immobilised glutathione beads. The 
fusion protein can then be eluted under mild, non-denaturing conditions using reduced 
glutathione and cleaved as desired 98. 
Protein expression in this system is initiated by Ptac, the tac promoter, under the control of 
laq Iq – lac operon repressor gene, which binds to the promoter and inhibits translation. The 
native function of this gene in E. coli is to prevent expression of the β-galactosidase enzyme 
in the absence of lactose52. In this pGEX system laq Iq can be inactivated by the lactose 
metabolite mimic IPTG. This allows for control of protein expression which can be switched 
on when desired by the addition of the correct concentration of the inducer IPTG45.   
Also present in the plasmid is Ampr, the ampicillin resistance gene that serves as a selection 
marker. This will confer ampicillin resistance onto the host bacteria, therefore only bacteria 
containing this plasmid can grow in an ampicillin environment112. By growing up bacteria on 
an agar plate containing 0.1 mg/mL ampicillin, these colonies can be identified and selected. 
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Also growing up the bacteria in the presence of ampicillin should prevent anything else 
growing and using up the nutrients, thereby maximising the potential protein yield.   
A suitable plasmid, pGEX_3C, was engineered to express the designed fusion protein. The 
sequence encoding for the amino acids PAKQC (TTC GCC AAG CAG TGT) was inserted into 
the multiple cloning site of the commercial pGEX-4T-1 plasmid after the GST-tag. The insert, 
flanked with the appropriate nucleotides, and the plasmid were digested by BamH I and 
EcoR I restriction sites, and ligated together. This was verified by DNA sequencing94. A target 
protein sequence can now be inserted downstream of this cleavage site.  
 
Figure 2.4: Plasmid map of pGEX_3C_PH, used to express the GST-PAKQC_PH domain fusion protein
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has been engineered from a pGEX-4T-1 plasmid which contains Ptac – the tac promoter induced by IPTG; 
GST – the gene encoding for glutathione-S-transferase protein; Amp
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 – ampicillin resistance gene; laq I
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operon repressor gene; a multiple cloning site – the PAKQC motif is inserted between BamH I and EcoR I 
restriction sites and the gene encoding for the PH domain protein between EcoR I and Sal I restriction sites. 
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PKB-PH domain (pGEX-PH). Therefore the gene encoding for the protein was amplified from 
this construct by PCR, flanked with EcoR I and Sal I restriction sites. Both the PH domain and 
the pGEX_3C were subsequently digested with these enzymes and ligated to give the 
pGEX_3C_PH plasmid (Figure 2.4), which was verified by DNA sequencing94. This construct 
will express GST-PAKQC-PH (a GST tag followed by PAKQC followed by the PH domain), and 
it was used in all the subsequent experiments in this thesis to express this fusion protein. 
2.3.2 Expressing GST-PAKQC-PH  
The traditional method of protein overexpression involves culturing a plasmid containing 
bacterial colony in LB medium to mid-log phase. This is where the potential for protein 
expression is at a maximum and before competition for nutrients and overcrowding cause 
the bacteria to enter stationary phase. This stage is indicated by an optical density of the 
bacterial medium of 0.6 at 600nm (OD600 = 0.6). At this point IPTG is added, a chemical 
mimic of a lactose metabolite that induces protein expression45. In the case of a GST-PH 
fusion protein, this process must occur at 18°C, with 100µM IPTG, for 16 hrs to allow a 
sufficient yield of soluble protein105. GST_PAKQC_PH has been successfully expressed from 
the plasmid pGEX_3C_PH in BL21 (DE3) E. coli using these conditions94. However the yield 
was low, with less than 1 mg of fusion protein being produced from 3 L of media. 
Recently, Studier developed an auto-induction medium, 40mM Na2HPO4, 20mM KH2PO4, 
90mM NaCl, 2% w/v tryptone, 0.5% w/v yeast extract, pH 7.2 with the 0.6% v/v glycerol, 
0.05% w/v glucose, 0.2% w/v lactose113. This initiates protein expression once the bacteria 
are in the correct growth phase without the need to add any additional reagents, reported 
to increase the protein yield. This works by using the correct mix of glucose and lactose and 
glycerol as food sources. Bacteria preferentially consume glucose, which supports growth 
and inhibits lactose entry. Once this food source has been used up, the bacteria switch to 
glycerol which continues to support growth as well as allowing lactose to enter the cell, thus 
inducing protein expression. By using these three food sources in the correct ratio it is 
possible to initiate protein expression at an optimal cell density.  
This autoinduction expression can be done in standard BL21 (DE3) E. coli cells113. The cells 
were transformed with the pGEX_3C_PH plasmid by heat shock. 20 % glycerol stocks of the 
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pGEX_3C_PH BL21 (DE3) cells were created and used to express the fusion protein in all 
subsequent experiments in this thesis. 
The published protocol113 states that one colony, incubated in one litre of auto-induction 
media, can be left shaking at 37°C for 30 hrs and the protein harvested. However previous 
experiments94 have indicated that GST-PH should be expressed at 18°C. To optimise the 
conditions for expression, a series of experiments was carried out at a range of 
temperatures from 18°C to 37°C and for a range of times from 24 hrs to 48 hrs. The results 
showed that incubation at 30°C for 16 hrs, followed by 18°C for 24 hrs were the ideal 
conditions to express the GST-PAKQC-PH fusion protein.  
The GST tag was used to purify the fusion protein. After protein expression, the cells were 
harvested by centrifugation, frozen at -20°C overnight and resuspended in GST Lysis Buffer, 
25 mL per 1 L bacterial culture medium. The cells were then lysed by incubation with 
lysozyme and sonication. DNase was used to digest the DNA present in the lysate. The 
protein was then immobilised on glutathione Sepharose beads via GST. The lysate, 
containing the other proteins expressed by E. coli, was washed away with GST Wash Buffer. 
The immobilised GST-PAKQC-PH can now either be eluted in 20mM reduced glutathione, pH 
8.0, or cleaved on-bead with 3Cpro to liberate the PH domain (Figure 2.5). It should be noted 
that there is a residual level of GST from the breakdown of the fusion protein48. 
 
Figure 2.5: GST-PAKQC-PH expression with autoinduction media and with IPTG, compared by SDS-PAGE 
analysis. Lane 1 – 10µL of cell lysate obtained by lysozyme and sonication after expression in 1 L LB medium 
and induction with IPTG; Lane 2 – 2 µL of the lysate from lane 1 loaded onto 0.3 mL glutathione Sepharose 
beads; Lane 3 – 10 µL of cell lysate obtained by lysozyme and sonication after expression in 1 L 
autoinduction media; Lane 4 – 2 µL of the lysate from lane 3 loaded onto 0.3 mL glutathione Sepharose 
beads; The 12% gels were run at 180 mV for 30 mins and visualised by Coomassie staining.  
1 2 3 4
GST-PAKQC-PH 
Traditional IPTG 
Protein Expression 
Antoinduction
Protein Expression 
GST
73 
 
Using auto-induction medium removes the need to monitor the cell density and add the 
expensive IPTG, resulting in an easier and cheaper method. Moreover it significantly 
increases the protein yield by allowing the protein expression to occur when the cells have 
reached a higher cell density, but one that is still able to sustain protein expression113. 1 mg 
of GST-PAKQC-PH was purified from 3 L of medium using the traditional method. This was 
increased five-fold to 5 mg/3 L using the auto-induction medium. All protein used in 
subsequent experiments was generated via this technique. 
2.3.3 Expressing 3Cpro 
The protocol for expressing 3Cpro developed in Stephen Curry’s laboratory in Imperial 
College91, who kindly donated the plasmid for this work. The protein is expressed as a fusion 
of the FMDV 3B and 3Cpro genes with a C-terminal His-tag. This facilitates the correct folding 
of 3Cpro, which then self-cleaves from the 3B protein and can be purified via Ni-beads. The 
protein also contains two mutations, C95K and C142S, to aide solubility.   
Recombinant 3Cpro was expressed in BL21(DE3) cells at 37°C for 30 hrs in the auto-induction 
medium as detailed above. The cells were harvested by centrifugation, frozen and 
resuspended in 3Cpro Lysis Buffer. The cells were lysed by sonication and the protease was 
immobilised via its His-tag, onto nickel beads and purified from the lysate by washing with 
two washings of 5 mM imidazole (Figure 2.6).  
 
Figure 2.6: Expression of 3C
pro
, shown by SDS-PAGE analysis. Lane 1 – cells after overnight expression in 
autoinduction media; Lane 2 - cells after 24hr expression in autoinduction media; Lane 3 – cell lysate 
obtained by sonication after 24hr expression; Lane 4 – flow-through of cell lysate after loading on nickel 
beads; Lane 5 –wash 1 of the beads with 5mM imidazole; Lane 6 –wash 2 of the beads with 5 mM imidazole; 
Lane 7 – eluted fraction, with 100mM imidazole, containing 3C
pro
. The 12% gel was run at 180 mV for 30 
mins and visualised by Coomassie staining. 
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After elution with 100 mM imidazole and dialysis into the 3C storage buffer the protease is 
ready for use. 1 L of medium produced 8 mgs of 3Cpro. It was found that the protease is still 
active after long-term storage at -80°C; however it would only survive one freeze-thaw 
cycle. Furthermore, although the enzyme can be stored at 4°C, activity is lost after 
approximately one week under these conditions. Therefore it is important to aliquot 3Cpro 
into useful volumes before storage. The standard aliquot size used in this thesis was 25 µL of 
200 µM 3Cpro. This means that a 1 L protein expression of 3Cpro is sufficient to process about 
65 x 5 mg of GST-PAKQC-PH produced in each 3 L protein expression; see Section 2.4.1 for 
cleavage conditions of 3Cpro on GST-PAKQC-PH. 
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2.4 Obtaining the N-terminal Cysteine PH Domain 
2.4.1 Determining optimal cleavage conditions 
In order to determine the optimum conditions for 3Cpro cleavage of the GST-PAKQC-PH 
fusion protein, a time course was carried out at a range of concentrations. The fusion 
protein was eluted from glutathione beads in 20 mM reduced glutathione, pH 8.0, and the 
concentration determined by a Bradford assay114. Three experiments were set up with each 
tube containing 50 μL of 50 μM protein in 3Cpro Reaction Buffer and the following 
enzyme:protein ratios – 1:20, 25 µL of 5 µM 3Cpro (Figure 2.7A); 1:40, 25 µL of 2.5 µM 3Cpro 
(Figure 2.7B); and 1:80, 25 µL of 1.25 µM 3Cpro (Figure 2.7C). 10 µL samples were taken after 
2 hrs, 4 hrs, 6 hrs, 8 hrs and 16 hrs and immediately boiled at 95°C in LDS loading buffer to 
stop the proteolysis. The results were analysed by SDS-PAGE. 
 
Figure 2.7: 3C
pro
 cleavage conditions for GST-PAKQC-PH, determined by SDS-PAGE analysis of a time course 
experiment. 3C
pro
 was incubated with GST-PAKQC-PH protein at the following enzyme:protein 
concentrations: A) 1:20, B) 1:40, C) 1:80. A 10µL sample was taken over a range of times - Lane 1 – 0 hrs; 
Lane 2 – 2 hrs; Lane 3 – 4 hrs; Lane 4 – 6 hrs; Lane 5 – 8 hrs; Lane 6 – 16 hrs. The 12% gel was run at 180 mV 
for 30 mins and visualised by Coomassie staining.  
The gel analysis shows that whilst a concentration ratio of 1:20 left overnight is necessary 
for complete cleavage (Figure 2.7A), adequate cleavage is obtained overnight at 1:40 (Figure 
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2.7B). Therefore in all future experiments 3Cpro was incubated with approximately 25 
equivalents of GST-PAKQC-PH at 37°C for 16 hrs to achieve cleavage. Successful results are 
also obtained with 25 equivalents of GST-PAKQC-PH at 25°C for 64 hr. 
2.4.2 Purification of N-terminal cysteine PH Domain 
The PH domain with a cysteine on the N-terminus, C-PH, was liberated from GST by on-bead 
cleavage using 3Cpro.  A typical 3 L auto-induction expression of GST-PAKQC-PH will produce 
about 5 mgs, 125 nmols of the fusion protein. Therefore one 25 µL aliquot of 200 µM 3Cpro 
will provide the requisite 1:25 molar ratio of protease to protein. The glutathione bead 
immobilised fusion protein was resuspended in an equal volume of 3Cpro Reaction Buffer 
and incubated with protease at 37°C, overnight (Figure 2.8 Lane 1). The advantage of 
carrying out this step whilst the protein is on the beads is that the GST tag, and any residual 
GST, will remain there after cleavage. Thus the C-PH/3Cpro mixture can be successfully 
removed by centrifugation of the beads and decanting the resultant supernatant (Figure 2.8 
Lane 2). 
 
Figure 2.8: Purification of C-PH, shown by SDS-PAGE gel analysis. Lane 1 – Glutathione bead immobilised 
GST-PAKQC-PH in 3C lysis buffer after overnight cleavage at 37°C with 3C
pro
 in a 1:25 molar ratio; Lane 2 – 
the supernatant of the cleavage mixture after removal of the glutathione beads; Lane 3 – Collected fraction 
of C-PH after Ni Sepharose removal the His-tagged 3C
pro
. The 12% gel was run at 180 mV for 30 mins and 
visualised by Coomassie staining.  
The second purification step involves the removal of 3Cpro via its His-tag. The supernatant 
containing the C-PH/3Cpro mixture was incubated with 50 µL Ni-beads for each 3Cpro aliquot, 
in Ni Binding Buffer for 1 hr, resulting in 3Cpro binding to the beads. This batch loading 
method is recommended for proteins present at low concentration115. The enriched C-PH 
was washed from the beads and then dialysed into a 0.1 M phosphate buffer, pH 7.4, ready 
for NCL (Figure 2.8 Lane 3)  
2
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2.5 NCL on C-PH 
If C-PH does indeed have an available N-terminal cysteine then it will be able to undergo 
NCL. This will be ascertained by reacting it with a thioester.  This will be carboxyfluorescein 
mercaptoethanesulfonate thioester 3, generated from carboxyfluorescein-NHS ester 1 and 
the thiol sodium mercaptoethanesulfonate (MESNa) 2 (see Section 2.1). This is water 
soluble, making it suitable for NCL74. A fluorescein derivative was chosen as the fluorophore 
for these proof-of-principle experiments because it was readily available, affordable and 
sufficient for fixed-cell imaging (Section 2.6). 
 
Figure 2.9: NCL reaction between fluorescein 3 and C-PH. The thioester and protein are incubated in 0.1 M 
phosphate buffer, pH 7.2, with a thiol catalyst 2, at room temperature for 5 hrs
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1 mg of C-PH in 100 µL phosphate buffer was incubated with a four-fold excess 3 under the 
standard NCL conditions59; in 0.1 M phosphate buffer, pH 7.4for 5 hours, at room 
temperature. A forty-fold excess of the thiol 2 was used as a catalyst (Figure 2.9). This 
reaction was analysed by RP-HPLC on a C-18 column with a gradient of water/acetonitrile 
and detected by UV absorbance at 223 nm. However the shift in retention time between 
starting material (13.0 mins) and product (13.2 mins) was not large enough to monitor this 
reaction reliably. Whilst it is possible to detect the product by UV absorbance at 485 nm of 
the fluorescein, this only shows the presence of the product and with no information about 
the starting material it is not possible to determine the extent of the reaction.  
MALDI-TOF analysis, after sample desalting with C-18 tips, showed more distinct differences 
and was used to monitor subsequent NCL experiments. In order to determine the optimal 
conditions for this reaction, a time course was carried out. Samples were extracted from the 
NCL mixture after 2 hrs and 5 hrs, desalted using C-18 desalting pipette tips, and analysed by 
MALDI-TOF (Figure 2.10) 
 
Figure 2.10: MALDI-TOF traces following the NCL reaction of C-PH and the fluorescein thioester 3. Aliquots 
were taken, desalted and analysed after A) 0 mins; B) 2 hrs; C) 5 hrs. Each peak represents the mass of the 
protein species in the reaction. 
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The traces show the C-PH domain (expected mass 14,099, found 14,094) (Figure 2.10A) 
undergoing NCL to produce a single product peak after 5hrs (Figure 2.10C) with mass 
corresponding to PH domain plus carboxyfluorescein label (expected mass 14,457, found 
14,473). After 2 hrs the reaction is incomplete (Figure 2.10B) showing a peak corresponding 
to the mass of the PH domain plus thiol catalyst (expected mass 14,218, found 14,197) as 
well as the product peak.  
MALDI-TOF analysis on molecules of this size provides good molecular weight estimates, but 
has an intrinsic error of about ± 0.3%112 for proteins. Therefore for a 14 kDa protein this 
corresponds to an error of ±42. This accounts the small differences between the expected 
masses and those found. However, the technique can easily distinguish between the original 
protein and one with a single label attached, which would correspond to an increase in mass 
of 358. Therefore these results show that the NCL reaction between C-PH and the 
fluorescein thioester goes to completion with 5 hrs. Moreover only one unit of label is 
attached to the protein, confirming that this is a controlled site specific reaction. 
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2.6 Retention of Biological Activity 
The traditional approach for labelling proteins chemically is via modification of any free 
amino groups from lysine side chains exposed on the proteins surface (Section 1.1.2). The 
standard protocol for this involves incubating 10 mg of protein with 1 mg of an activated 
succinimide ester of the fluorophore in 1 mL 0.1 M sodium bicarbonate buffer, pH 8.3, for 
1 hr at room temperature10 and was used to produce an AlexaFluor 488 tagged PH domain.  
The AlexaFluor 488-PH domain was supplied by Erika Rosivatz. 
 
Figure 2.11: Non-specific labelling of the PH domain with AlexaFluor 488 NHS ester
74
. The reactants are 
incubated in 0.1 M sodium bicarbonate buffer, pH 8.3, at room temperature for 1 hrs.  
The drawback of such non-specific labelling is that it generates a number of mixed species 
during the reaction. The only elements of control over the labelling are by varying the 
concentration of the label or by adding 1.5M hydroxylamine, pH 8.5 to stop the reaction10. 
This can be optimised by varying the conditions, though this process will waste a significant 
amount of dye.  And even though the amount of label incorporated into the total protein 
mixture can be calculated, it is difficult to separate unlabeled, single and multiply-labelled 
proteins56.  
In comparison the NCL method to produce labelled the fluorescein-C-PH domain (Section 
2.5) used the same relative amounts of protein and label. Though with this approach all the 
protein has been labelled and, moreover, only with a single label resulting in confidence in 
the identity of the resultant labelled protein species. However it is necessary to verify that 
the biological activity of the protein has not been adversely affected by this tagging method.   
A current method of investigating the biological activity of PKB in membrane binding is by 
using fixed cell imaging105, see Section 1.2.1 for further details. This involves growing cells in 
the presence or absence of growth factors and/or downstream effectors, fixing them to 
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glass slides and incubating them with labelled PH domain. The protein is then visualised 
under a fluorescent microscope.  This experiment is typically carried out with the AlexaFluor 
488-PH domain, which is known to be biologically active. Therefore in order to determine 
the activity of the NCL labelled fluorescein-C-PH domain it was directly compared with the 
non-specifically labelled AlexaFluor 488-PH domain in a fixed cell imaging experiment. 
The PKB PH domain binds to the lipids PI(3,4,5)P3 and PI(3,4)P2 that are found on the inner 
leaflet of the cell membrane, organelles, vesicles and in the nucleus109. In this experiment 
NIH 3T3 mouse fibroblast cells were grown on poly-L-lysine cover slips and starved overnight 
in serum free medium. They were then stimulated with insulin to produce PI(3,4,5)P3, which 
is subsequently metabolised into PI(3,4)P2
105. As a control, PI(3,4,5)P3 production was 
inhibited with the synthetic molecule LY294002 (LY)116. The cells were then washed and 
fixed with PFA, which not only kills the cells but cross-links lysine residues, thus preserving 
the cell in the state it was in immediately before fixing. Following PBS washes, three 
freeze/thaw cycles were used to permeablise the cells. This is a mild technique, unlike the 
use of detergents, so holes are created in the plasma membrane without disrupting the lipid 
distribution within it. The cytosol leaks out of these cells, creating ‘ghost cells’ with 
organelles, cytoskeleton and membrane lipids still intact28. This means that PI(3,4,5)P3 and 
PI(3,4)P2 are still present within the membranes. 
The cells were now ready to be labelled. The first step involves blocking the charges within 
the cells with BSA to prevent any non-specific interactions. Subsequently the cells were 
incubated with either the AlexaFluor 488-PH or the fluorescein-C-PH for 1 hrs. Finally the 
cells were counterstained with the blue nuclear probe DAPI.  
In order to image the coverslips containing the cells, they were thoroughly washed and then 
mounted on glass slides. The stained fibroblast cells were imaged using a Nikon TE2000 
inverted fluorescence microscope and visualised in the DAPI and FITC channels. Images 
were digitally acquired with a CCD camera for each fluorophore separately, and processed 
using IPLab software and ImageJ. 
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Figure 2.12: Fixed cell imaging of labelled PH-domain (green) binding to PIP3 in fibroblast cells, 
counter-stained with DAPI to show the nucleus (blue). (A) AlexaFluor labelled PH domain in (i) insulin 
stimulated cells; (ii) LY inhibited cells. (B) NCL fluorescein labelled C-PH domain in (i) insulin stimulated cells; 
(ii) LY inhibited cells. 
The AlexaFluor-PH domain visualisation of PI(3,4,5)P3 and PI(3,4)P2 is shown in Figure 2.12A. 
In the cells that were stimulated with insulin (Figure 2.12Ai) the green colouration of the 
AlexaFluor PH domain shows the characteristic localisation of the PI(3,4,5)P3 and PI(3,4)P2, 
with the nucleus stained blue using DAPI. Inhibiting the cells (Figure 2.12Aii) knocks down 
the PH domain binding, with the green colouration only present at a background level, 
(A) (i) (ii)
(B) (ii)(i)
83 
 
leaving just the nucleus visible. This is the expected PH domain binding behaviour under 
these stimulation conditions and the differential staining confirms that the binding is 
specific. Images were also taken from the NCL fluorescein C-PH domain (Figure 2.12B) 
incubated with cells under stimulated (Figure 2.12Bi) and inhibited (Figure 2.12Bii) 
conditions, showing the same binding patterns. 
As is apparent, the results obtained with the NCL-labelled material are comparable in all 
respects to those obtained with non-specifically AlexaFluor-labelled PH domain. These 
results validate this NCL labelling method by proving that the product of this procedure is 
not only fluorescently tagged but moreover, retains its native biological function as a 
specific probe for the lipids PI(3,4,5)P3 and PI(3,4)P2.  
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2.7 Conclusion 
This chapter has detailed the development of this 3Cpro/NCL labelling strategy. This has 
resulted in working protocols for the generation of an N-terminal cysteine protein via the 
site-specific cleavage of a GST-PAKQC-fusion protein with 3Cpro. The model protein system, 
the PH domain, has exemplified the use of NCL for site-specific labelling without affecting 
the native biological activity of the protein. Therefore this work has validated the 3Cpro/NCL 
labelling approach.  
The pGEX_3C plasmid94 was successfully used to engineer a recombinant protein that can be 
processed by 3Cpro. The gene encoding the PH domain was ligated into the pGEX_3C plasmid 
immediately downstream from the PAKQC motif. The GST-PAKQC-PH domain fusion protein 
was successfully expressed by this plasmid and cleaved using 3Cpro.  These results show that 
this strategy can be used to obtain an N-terminal cysteine PH domain, and by extension it 
may be possible to use this approach generically to generate N-terminal cysteine proteins. 
The amount of 3Cpro required to cleave GST-PAKQC-PH was 1:25 enzyme:substrate, at 37°C 
for 16 hrs, or at 25°C for 64 hrs. Therefore 3Cpro can be used as an effective protease for 
processing this recombinant protein. Chapter 3 explores both the efficiency and selectivity 
of 3Cpro compared to other proteases commonly used in molecular biology. 
The suitability of C-PH to undergo NCL, and therefore the presence of a cysteine on the 
N-terminus of the PH domain, has been verified. MALDI-TOF analysis of the reaction 
between C-PH and a fluorescein thioester, under standard NCL conditions74 has shown that 
the recombinant protein expressed from the pGEX_3C plasmid and purified using 3Cpro is 
suitable for NCL. Moreover the protein has been labelled selectively with only a single 
fluorescent tag. The NCL fluorescein labelled C-PH was used successfully as a probe for 
PI(3,4,5)P3 and PI(3,4)P2 in a fixed cell imaging experiment
105. This work has shown that the 
product of the 3Cpro/NCL labelling strategy is a labelled functional protein. 
NCL is a generic method, requiring only a thioester and a cysteine N-terminus, therefore the 
versatility of this system can be exploited to create an easy to use labelling ‘toolbox’. This 
will be explored later in the thesis. Chapter 4 details the development of different 
fluorescent labels for imaging in multiple colours1. Beyond imaging, Chapter 5 looks at the 
affinity tag biotin for pull-down studies51 .  
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Whilst on one hand this range of thioester tags can be expanded, additionally any protein 
that is expressed in the pGEX_3C plasmid and purified using 3Cpro may be suitable for NCL, 
potentially making this an adaptable and useful system. The constructs and chemical tools 
produced here should enable facile production of a wide range of N-terminally labelled 
recombinant proteins for a vast array of studies. 
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2.8 Materials and Methods 
2.8.1 Reagents and Equipment 
Components of the autoinduction and LB media, sugars and antibiotics were purchased 
from Sigma Aldrich. Buffer components were also bought from Sigma Aldrich. The 
pGEX-4T-1 plasmid was purchased from GE Healthcare, whilst the BL21 (DE3) competent 
cells were purchased from Stratagene. GST and Ni Purification kits were purchased from GE 
Healthcare. SDS-PAGE equipment, gels, and reagents Eppendorf® PerfectPure C-18 tips were 
purchased from VWR. NHS-carboxyfluorescein and MESNa were bought from Sigma Aldrich. 
AlexaFluor 488 and DAPI were bought from Invitrogen’s Molecular Probes. NIH 3T3 
fibroblasts cells were purchased from the American type culture collection, coverslips from 
VWR, DAPI from molecular probes and all other reagents for the fixed-cell imaging from 
Sigma Aldrich. 
HPLC was carried out on a Gilson system with 322 Pump, a 234 Autoinjector and 151 UV/vis 
detector. Purification via HPLC was carried out on a Gilson semi-preparative RP-HPLC system 
equipped with 306 pumps and a Gilson 151 UV/vis detector. Both systems were fitted with 
an ACE 5 C18 column (250x4.6 mm) and a SecurityGuard cartridge system (C18, 4 x 3.0 mm). 
The purity was determined from the peak integration of the analytical trace. For peaks 
integrating more than 98% the purity is stated as > 98%. Masses were determined by 
MALDI-TOF using the Micromass MALDI-TOF. High resolution MS (HRMS) was found by ESI-
TOF-MS. Melting point determination was carried out on Standford Reaserch Systems 
Optimelt. DNA sequencing was carried out by the genomic service Cogenics.  
Fluorescence in cells was imaged in the DAPI and FITC channels, using a Nikon TE2000 
inverted fluorescence microscope, captured on a Hamamatsu camera and processed using 
IPLab software and ImageJ. 
2.8.2 N-Terminal Cysteine Generation 
GST-PAKQC-PH Protein Expression105,113  
BL21 (DE3) E. coli cells were transformed by incubating 50 µL of cells on ice with 1 µL, 50 ng 
of the plasmid pGEX_3C_PH at 4°C for 30 mins. Subsequently the cells were heat shocked at 
42°C for 45 seconds, 4°C for 2 mins and grown in 1 mL LB medium117. Transformed cells 
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containing the plasmid were therefore selected for on ampicillin LB agar plates. 20% glycerol 
stocks of the pGEX_3C_PH BL21 (DE3) cells were created.  
Three litres of auto-induction LB medium (40 mM Na2HPO4, 20 mM KH2PO4, 90 mM NaCl, 
2% w/v tryptone, 0.5% w/v yeast extract, pH 7.2) containing 100 μg/mL ampicillin, 0.6% v/v 
glycerol, 0.05% w/v glucose, 0.2% w/v lactose were made up. This was inoculated with a 
colony of BL21(DE3) containing the pGEX_3C_PH plasmid and incubated at 30°C for 16 hrs at 
225 rpm, followed by a further incubation at 18°C for 16 hrs at 225 rpm. 
The cells were spun down (3200 rcf, 4°C, 20 mins), frozen at -20°C overnight and 
resuspended in GST Lysis Buffer (50 mM Tris-Base, 2 mM EDTA, 10 mM benzamidine, 1 mM 
DTT, 1 % v/v Triton X-100), 25 mL per 1 L protein expression. The cells were then lysed by 
incubation with 10 mg/mL lysosyme at 4°C for 2 hrs followed by sonication for 3 x 30 secs. 
DNase, 0.1 mg/mL at 4°C for 30 mins, was used to digest the DNA present in the lysate. The 
lysaste was centrifuged (18000 rcf, 4°C, 30 mins) and the protein in the supernatant fraction 
was retained.  
The protein fraction was loaded onto 1 mL Glutathione Sepharose™ 4B beads with 0.5 M 
NaCl. After mixing at 4°C for 1 hrs, the beads were spun down (3200 rcf, 4°C, 2 mins) and the 
supernatant decanted. The beads were washed in 3 x GST Wash Buffer (0.1 M Phosphate 
Buffer, 0.1 M NaCl, pH 7.4). 
GST_PAKQC_PH is eluted from the beads, if required, using GST Elution Buffer (50mM 
Tris-Cl, pH 8, 20mM reduced glutathione). The buffer is added to an equivalent volume of 
beads and mixed at room temperature for 30 mins. This was spun down (3200 rcf, 4°C, 
2 mins) and the supernatant decanted. This procedure is repeated twice and the eluted 
fractions pooled. A 3 L prep typically gave a yield of 5 mgs protein.  
3C Protein Expression91,113 
BL21 (DE3) E. coli cells were transformed by incubating 50 µL of cells on ice with 1 µL, 50 ng 
of the 3Cpro plasmid at 4°C for 30 mins. Subsequently the cells were heat shocked at 42°C for 
45 seconds, 4°C for 2 mins and grown in 1 mL LB medium. Transformed cells containing the 
plasmid were therefore selected for on kanamycin LB agar plates. 20% glycerol stocks of the 
3Cpro BL21 (DE3) cells were created.  
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1L of auto-induction LB medium containing 25 μg/mL kanamycin, 0.6% v/v glycerol, 0.05% 
w/v glucose, 0.2% w/v lactose was made up. This was inoculated with a colony of BL21(DE3) 
containing the 3Cpro plasmid and incubated at 37°C for 30 hrs at 225 rpm. 
The culture was centrifuged (3200 rcf, 4°C, 20mins) and cell pellet frozen overnight. The 
cells were resuspended in 50 mL 3C Lysis Buffer (50 mM HEPES pH 7.0, 500 mM NaCl, 1  mM 
β–mercaptoethanol, 0.01 % w/v sodium azide) and sonicated for 3 x 30 secs, on ice. The 
lysate was centrifuged (18000 rcf, 4°C, 30 mins) and the protein in the supernatant fraction 
retained.  
The protein fraction was loaded onto Ni Sepharose™ 6 Fast Flow beads in suspension. After 
mixing at 4°C for 1 hr, the beads were spun down (3200 rcf, 4°C, 2 mins) and the 
supernatant decanted. The beads were washed in 2 x 10 mL 3C Lysis Buffer and 2 x 10 mL 
5 mM imidazole in 3C Lysis Buffer. The protein was eluted using 2 x 10 mL 100  mM 
imidazole in 3C Lysis Buffer, dialysed into 3C Storage Buffer (50 mM HEPES pH 7.0, 500 mM 
NaCl, 1 mM β-mercaptoethanol, 0.01 % w/v sodium azide, 10% v/v glycerol). A 1 L prep 
typically gave a yield of 8 mg protein. 
3C Cleavage Time Course111 
Three experiments were set up with each tube containing 50 μL, 2.5 nmols of 50 μM 
GST-PAKQC-PH in 3C Reaction Buffer (100 mM Sodium Phosphate Buffer pH 7.4, 1 mM 
EDTA, 1 mM TCEP, 5% v/v Glycerol). 25 µL 3Cpro; corresponding to 0.13 nmols, 0.06 nmols, 
or 0.03 nmols, was added to give enzyme:protein ratios of 1:20, 1:40 and 1:80. 10 µL 
samples were taken after 2 hrs, 4 hrs, 6 hrs, 8 hrs and 16 hrs and immediately boiled at 95°C 
in LDS loading buffer to stop the proteolysis. The results were analysed by SDS-PAGE and 
visualised by Coomassie staining. 
N-Terminal Cysteine Protein Purification111 
An aliquot of 500 μL GST-PAKQC-PH protein loaded glutathione beads were resuspended in 
500 μL of 3C Cleavage Buffer. 10 μL 300 μM 3Cpro was added and incubated at 37°C for 
16 hrs. The reaction mixture was then centrifuged (3200 rcf, 4°C, 2 mins) and the protein 
supernatant retained. The beads were washed with 3 x 500 µL 3Cpro Cleavage Buffer, 
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centrifuged (3200 rcf, 4°C, 2 mins) and the wash fractions combined with the protein 
supernatant. 
The combined fractions were concentrated to 500 µL, diluted to 2 mL in Ni binding buffer 
and loaded onto 50 µL Ni Sepharose™ 6 Fast Flow beads. After mixing at room temperature 
for 1 hrs, the beads were recovered using a polypropylene gravity flow column and the flow-
through collected. The beads were washed in 3 x 100 µL Ni binding buffer (20 mM 
Phosphate Buffer pH 7.4, 500 mM NaCl, 20 mM imidazole) and the flow-through collected. 
The combined flow-through fractions were pooled, washed and dialysed into phosphate 
buffer (0.1 M, pH 7.4), yielding 1 mg C-PH as determined by Bradford Assay. 
2.8.3 Labelling via Native Chemical Ligation 
Carboxyfluorescein-MES Thioester 3
74
  
10 mg, 20 µmol N-hydroxysuccinimidyl-5(6)-Carboxyfluorescein 1 was combined with 
30 mg, 220 µmol sodium 2-mercaptoethanesulfonate 2 in 5 mL sodium borate buffer 
(0.1 M, pH 8.3). The reaction was stirred at room temperature for 2 hrs in an aluminium foil 
wrapped flask. The orange solution was purified by reverse phase HPLC and lyophilised into 
0.2 mg aliquots. 6 mg, 12 µmol of an orange solid (60%) 3 was obtained. Rt = 11.1 mins 
(2-100 MeCN in H2O over 20 mins), purity 96%; 
1H NMR (400 MHz, MeOD-d4) δ = 8.32 (s, 
1H, ArH), 7.86 (s, 1H, ArH), 7.45 (d, 1H, ArH), 6.60 (m, 4H, ArH), 6.47 (m, 2H, ArH), 4.26 (t, 
2H, O3SCH2), 3.48 (t, 2H, COSCH2); Absorption spectra λ
ex 493, λem 513; Melting point not 
obtained, decomposes at 258°C; HRMS (ESI) 499.017 (requires 499.016).  
Native Chemical Ligation Time Course111 
0.15 mg, 300 nmol 3 and 0.2 mg, 1.2 µmol 2 was added to 1 mg, 70 nmol C-PH in 100 µL 
phosphate buffer (0.1M, pH 7.4). This was incubated at room temperature for 5 hrs. 
Samples of 10µL were taken after 5 mins, 2 hrs and 5 hrs were desalted with Eppendorf® 
PerfectPure C-18 tips and analysed by MALDI-TOF. 
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2.8.4 Fixed Cell Imaging 
Coverslip preparation105 
Acid wash the glass coverslips in 1M HCl at 60°C for 4 hrs. Wash the coverslips 3 x dH2O and 
3 x ddH2O. Then coat them in 1 mg/mL poly-L-lysine, rocking for 30 mins at room 
temperature. Wash in 3 x dH2O, 3 x ddH2O and 3 x EtOH. Separate the individual coverslips 
and blot dry on filter paper. Finally bake at 37°C for 2 hrs. 
Cell preparation105 
NIH 3T3 fibroblasts (mouse fibroblasts) were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% (v/v) newborn calf serum in an atmosphere of 5% (v/v) CO2  at 37 
°C. Cells were seeded on the coverslips and starved over night. They were either stimulated 
with 500 µL, 1 µg/mL of insulin or inhibited with 500 µL, 50 µM LY294002 (LY).   
Fixing and staining105 
The cells were fixed in 4% (w/v) paraformaldehyde (PFA) for 10 mins and washed in 3 x 500 
µL phosphate-buffered saline (PBS). The fixed cells were then permeabilised by 
3 x freeze/thaw cycles at -78°C/37°C. Non-specific protein interactions were blocked with 
500 µL 3% (w/v) bovine serum albumin (BSA)/PBS (fatty acid free) for 1 hr at room 
temperature, followed by 3 x 500µL PBS washes. Cells were then incubated with the 100 µL 
1 µg/mL AlexaFluor 488-PH domain or fluorescein-PH domain for 1 hrs, followed by 
3 x 500 µL PBS washes. Nuclear counterstaining was carried out using 100 µL 1 µg/mL DAPI 
for 10 mins. Coverslips were thoroughly washed in 10 x PBS and 1 x dH2O.   
Imaging105  
The coverslips were mounted on glass slides using Mowiol supplemented with 0.6% (w/v) 
1,4-diazabicyclo-[2.2.2]octane (DABCO), sealed and dried overnight. The cells were imaged 
using a Nikon TE2000 inverted fluorescence microscope. The fluorescence was imaged on 
the microscope using a 100x Fluor oil lens, in the DAPI and FITC channels with excitation 
wavelengths of 340–380, 465–495 respectively. Images were digitally acquired with a CCD 
camera (Hamamatsu) for each fluorophore separately and processed using IPLab software 
and ImageJ.  
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Chapter 3 Comparison with alternative proteases 
 
The concept of using proteases to generate N-terminal cysteinyl proteins for NCL is a 
relatively new one, but there have already been a few successful attempts to use this 
approach, see Section 1.5.2). Each of these studies has used a different protease 
enzyme and different target sequences, and there has been little attempt as yet to 
directly compare these different approaches. The characteristics required of a protease 
that need to be determined are:- 
• Is the activity of the protease high enough to produce a good yield within a working 
time scale? 
• Is the specificity of the protease stringent enough so that secondary cleavage does 
not occur? 
This chapter examines two alternative proteases that might be useful for NCL, thrombin 
and TEV, and compares these with the 3Cpro enzyme. Both thrombin and TEV are often 
utilised in molecular biology procedures for recombinant protein production and it will 
be interesting to see how 3Cpro stands up against and alongside these established 
proteases. 
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3.1 Proteases in molecular biology 
Proteases are often used in molecular biology as a tool to purify recombinant proteins44. 
Typically the target protein is expressed as fusion with an affinity tag, ranging from a string 
of amino acids such as a His-tag to a whole protein like GST (Section 1.3.2). The affinity tag is 
used to purify the fusion protein from all the other unwanted ones, and then a protease is 
used in order to cleave off the affinity tag at a specific sequence to result in the generation 
of the required target protein44. 
Two key requisites of a protease that is usable for this purpose are activity and specificity72. 
The protease must be able to cleave the fusion protein in a reasonable time frame; typically 
this should take no longer than an overnight incubation to achieve complete digestion. It is 
also vital that the protease is not promiscuous, and cleaves only at its target site. A lack of 
selectivity will result in secondary site cleavage(s), causing nicked or truncated products72. 
In order to produce proteins suitable for NCL, it is vital that the protease can cleave the 
fusion protein in such a way to generate a cysteine at the N-terminus of the target protein 
(Section 1.5.2)71. For this to occur the protease must be able to tolerate a cysteine residue in 
the P1’ position of its cleavage site. Therefore whilst it is important that the protease is 
selective for a certain sequence, this specificity should primarily be upstream of the scissile 
bond to allow this modification on the P1’ side. 
There are other, general requirements that the protease must have44. The cleavage 
conditions must be compatible with the system, in terms of buffer component, pH, 
temperature etc. Also it must be possible to remove the enzyme from the system after 
proteolysis, so ideally there must be a suitable affinity purification method for it. 
If a protease can display these characteristics then it will be a very useful tool to engineer 
proteins for NCL. However, it is possible that different fusion proteins will behave in a 
diverse manner, so it is important to also carry out initial screening experiments with any 
new protease / fusion protein combination to verify their compatibility. 
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3.2 Thrombin protease 
3.2.1 Function and specificity 
Thrombin is a key enzyme involved in the blood coagulation cascade52. It is a typsin-like 
serine protease, a name derived from the formation of an Ser-His-Asp catalytic triad in the 
active site that features a serine hydroxyl as the activated nucleophile118 (Figure 3.1). 
Predominantly found as the zymogen (inactive precursor) prothrombin, it is cleaved by 
activated factor Xa in response to blood vessel damage. Once activated, it cleaves Arg-Gly 
bonds in fibrinogen to form fibrin which then polymerises to form the blood clot52.  
 
Figure 3.1: Structure of human α-thrombin, shown in covalent complex with the inhibitor peptide PPACK
119
. 
Thrombin A-chain (red) and B-chain (grey), with PPACK (green) and an Na
+
 ion (yellow), which is required for 
activity. The Ser-His-Asp catalytic triad is highlighted. 
3.2.2 Uses of thrombin in molecular biology 
Thrombin is a well-characterised enzyme, which has led to its use as a molecular biology 
tool. The enzyme is active over a pH range of 5-10, with an ideal pH of 8.3120. Using a ratio of 
1:500 enzyme:protein, the protease can fully cleave a fusion protein within 20 mins at room 
temperature121. This high proteolysis rate, combined with the identification of a specific, 
optimum cleavage sequence LVPR↓GS, has resulted in the successful incorporation of 
thrombin into a number of recombinant protein synthesis strategies69. Processing of a 
purified affinity tagged fusion by thrombin liberates the target protein. There are numerous 
Asp
His
Ser
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examples of the use of thrombin in this manner, ranging from expressing the anti-apoptotic 
protein Bcl-2 to test on isolated mitochondria122 to pure extracellular factor from 
Streptococcus suis type 2 for generating monoclonal antibodies123. Subsequently the 
enzyme can then be removed on a benzamidine column, as benzamidine is a ligand for 
trypsin-like serine proteases44. 
3.2.3 Use for NCL 
Work has been done with thrombin to facilitate its use in generating protein suitable for 
NCL70. The preferred cleavage site for thrombin, LVPR↓GS, was mutated to LVPR↓CS to give a 
cysteine residue in the P1’ position. This was successfully incorporated into two protein 
domains, Csk and Abl, which were subsequently processed by thrombin to result in cysteinyl 
N-termini70. These were both able to undergo NCL with a C-terminal thioester protein. 
Therefore it is possible to use thrombin to engineer proteins with a cysteine N-terminus 
suitable for NCL. 
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3.3 Comparing FMDV 3Cpro and Thrombin proteases 
3.3.1 FMDV 3Cpro and Thrombin cleavable proteins 
The comparison of the proteolytic activity of 3Cpro and thrombin requires proteins that can 
be cleaved by these two enzymes. It is vital to ensure that the target protein does not affect 
the accessibility of the cleavage site, thus allowing a direct comparison. In order to do this 
both proteases were used to digest the linker region between GST and the PKB PH domain.  
The pGEX_3C plasmid that can be used to express a target protein as a fusion with GST 
linked by a 3Cpro cleavage site (Section 2.3.1) was engineered from the commercial plasmid 
pGEX-4T-145. This contains a thrombin cleavage site at the start of the multiple cloning site. 
This means that any protein cloned into this plasmid will be expressed as a fusion with GST 
but moreover can be cleaved from GST after purification using the protease thrombin. 
 
Figure 3.2: Multiple cloning sites of the plasmids pGEX-4T-1 and pGEX_3C. The thrombin cleavage site is 
highlighted in purple, whilst 3C
pro
 cleavage site is highlighted in red. The key restriction sites BamH I, EcoR I 
and Sal I, used for manipulating the plasmid, and the stop codon is also indicated. 
When the pGEX_3C plasmid was engineered (Figure 3.2), the PAKQC sequence was inserted 
between the BamH I and EcoR I sites, thus preserving the thrombin cleavage site. This was 
subsequently used to generate the fusion protein GST-PAKQC-PH (Section 2.3). Whilst this 
protein can be cleaved by 3Cpro, it should also be possible to cleave it with thrombin45. 
Therefore this fusion protein can be used directly to compare the efficiency of these two 
proteases.  
It should be noted, though, that in this case the thrombin cleavage site does not have a P1’ 
Cys, which would be necessary in order to generate proteins suitable for NCL. If present, this 
pGEX-4T-1 Multiple Cloning Site
pGEX_3C Multiple Cloning Site
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would decrease the cleavage efficiency. However this fusion protein can still be used to give 
a general idea of the rate of activity of both thrombin and 3Cpro.  
3.3.2 Thrombin cleavage 
The efficiency of thrombin at cleaving the GST-PAKQC-PH fusion protein was investigated. 
Literature values suggest that a molar ratio of 1:500 protease:fusion protein, for 20 mins at 
25°C is required121. This was used as a starting point to determine the amount required in 
this system, and was found to give partial proteolysis. 
The conditions required for complete thrombin cleavage of GST-PAKQC-PH were 
determined by a time course experiment. The fusion protein was prepared using 
autoinduction medium and purified onto glutathione beads, as detailed in Section 2.3.2. The 
protein was then eluted from glutathione beads in 20 mM reduced glutathione, pH 8.0, and 
the concentration determined by a Bradford assay114. Lyophilised thrombin was purchased 
from Sigma and made up to 100 U/mL, which corresponds to 32 µg/mL.  
500 µg GST-PAKQC-PH in Thrombin Cleavage Buffer was incubated with 4 units thrombin at 
37°C. 10 µl samples were taken after 15 mins, 30 mins, 60 mins and 90 mins, and 
immediately boiled at 95°C in LDS loading buffer to stop the proteolysis. The results were 
analysed by SDS-PAGE (Figure 3.3). 
 
Figure 3.3: Thrombin cleavage conditions. SDS-PAGE analysis, showing the time course experiment to 
determine the optimal cleavage conditions for Thrombin on GST-PAKQC-PH. These were incubated in a 
1:500 enzyme:protein ratio, at 37°C and a 10 µL sample analysed after: Lane 1 – 0 mins; Lane 2 – 15 mins; 
Lane 3 – 30 mins; Lane 4 – 60 mins; Lane 5 – 90 mins. The 12% gel was run at 180 mV for 30 mins and 
visualised by Coomassie staining. 
These results show that 1.4 µg thrombin is sufficient to cleave 500 µg protein at 37°C within 
one hour. This corresponds to a 1:500 protease:fusion protein molar ratio. Whilst taking into 
account the variation in fusion proteins and subsequent accessibility of the thrombin 
1 2 3 4 5
GST
GST-PH
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cleavage site, this value is very similar to the literature value. Therefore this time course 
experiment shows the GST-PAKQC-PH can be cleaved by thrombin at the expected rate. This 
exemplifies the usefulness of thrombin as a molecular biology tool as a relatively low 
amount can process the fusion protein within a short time scale.  
3.3.3 Direct comparison of thrombin and 3Cpro  
The effectiveness of both thrombin and 3Cpro were directly compared on the same fusion 
protein. Cleavage was carried out on bead and using the conditions identified from the 
thrombin time course (Section 3.3.2) and 3Cpro time course (Section 2.4.1) respectively. The 
glutathione bead immobilised protein was incubated with either a 1:500 molar ratio of 
thrombin at 37°C for 1 hr or a 1:25 molar ratio of 3Cpro at 37°C for 16 hrs. After the set 
incubation time, the beads were spun down and a sample of the beads and the supernatant 
were analysed by SDS-PAGE (Figure 3.4). 
 
Figure 3.4: Cleavage comparison thrombin and 3C
pro
 on GST-PAKQC-PH, analysed by SDS-PAGE. Lane 1 – 1 µL 
GST-PAKQC-PH fusion protein bound to glutathione beads; Lane 2 – 1 µL protein bound on glutathione 
beads after 1 hr cleavage with Thrombin at 37°C in a 1:500 molar ratio; Lane 3 – 15 µL the supernatant of the 
cleavage mixture after removal of the glutathione beads; Lane 4 – 1 µL protein bound on glutathione beads 
after 16 hr cleavage with 3C
pro
 at 37°C in a 1:25 molar ratio; Lane 5 – 15 µL the supernatant of the cleavage 
mixture after removal of the glutathione beads. The 12% gel was run at 180 mV for 30 mins and visualised 
by Coomassie staining. 
The GST-PAKQC-PH fusion protein, which contains with both the thrombin and 3Cpro 
cleavage sites, be successfully processed by both proteases (Figure 3.4). Analysis of the 
thrombin experiment shows that the fusion protein (Lane 1) was completely cleaved 
on-bead (Lane 2) to release the PH domain into the supernatant (Lane 3). With the standard 
3Cpro cleavage conditions, the fusion protein is also cleaved fully by 3Cpro (Lane 4) to release 
PH
3Cpro
GST
PH
GST
1 2 3 4
Thrombin 
Cleavage
3Cpro
Cleavage
5
GST-PH
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the PH domain (Lane 5). The presence of 3Cpro but not thrombin in the supernatant is a 
reflection of the increased relative concentration of this protease. 
3.3.4 Which protease is most suitable for NCL?  
These results show that both enzymes can be used to process the GST-PAKQC-PH fusion 
protein. Moreover the cleavage can be carried out on glutathione beads, resulting in the 
release of the PH domain into the supernatant for simplified purification. This shows that 
3Cpro can produce the same results as the established thrombin protease that this pGEX 
system was designed to use. 
Thrombin and 3Cpro can both carry out this proteolysis within a workable time frame. These 
results do show that thrombin is the more efficient protease. Not only does it successfully 
process the fusion protein more quickly, 1 hr as opposed to 16 hrs, thrombin can carry this 
out at a 1:500 molar ratio which represents a 20-fold lower concentration than the 1:25 
molar ration required for 3Cpro. However whilst the one hour thrombin cleavage is 
preferable, the overnight 3Cpro cleavage is sufficient as shown by the successful 
incorporated of this step into a protein expression protocol (Chapter 2)111. 
Modifications would need to be made to this system to result in the thrombin cleaved 
PH domain being suitable for NCL. The current pGEX_3C_PH plasmid contains a thrombin 
cleavage site corresponding to the amino acids LVPR↓GS, which will yield an N-terminal 
glycine. In order to generate the requisite cysteine in this position, the optimum cleavage 
site will need to be mutated to LVPR↓CS, which can be achieved by a standard PCR point 
mutation, altering the DNA sequence from TTC (Ser) to TGT (Cys) with appropriate primers. 
This will result in thrombin generating proteins with a cysteinyl N-terminus, albeit at a less 
efficient rate70. 
However, there is a well-known specificity problem associated with the use of thrombin in 
molecular biology72.  Thrombin has been shown to hydrolyse a number of peptide bonds 
within proteins in addition to the LVPR↓GS motif. A study looking into of thrombin 
proteolysis of 30 hormones found eleven cleavage sites, none of which were the optimum 
thrombin cleavage site LVPRGS124. Moreover, there are a number of cases reporting 
truncated recombinant proteins when thrombin has been used to process fusion proteins125-
127. 
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The reason for the promiscuity of thrombin when processing recombinant fusion proteins 
can be seen by looking at its cleavage site specificity. Proteolysis by thrombin will occur in 
the following situations124:  
• P4-P3-Pro-Arg-P1‘-P2‘, where P3 and P4 are hydrophobic amino acid and PI’, P2’ are 
non acidic amino acids  
• P2-Arg-P1’, where P2 or P1’ are Gly. 
Therefore even though the optimum cleavage for thrombin is LVPRGS, there are numerous 
situations when the conditions above are satisfied and additional cleavage by thrombin can 
occur. 3Cpro, on the other-hand, was found to have high stringency in a cleavage sequence 
study91. These results suggest that 3Cpro is less likely to cause non-specific digestion of fusion 
proteins, though this can only be confirmed by extensive use of 3Cpro on a range of proteins. 
So which protease, thrombin or 3Cpro, is preferable for the generation of recombinant 
proteins suitable for Native Chemical Ligation? Both enzymes can be used in this GST fusion 
protein system to generate the recombinant PH domain (Figure 3.4). It is also possible to 
use either of them to generate a cysteinyl N-terminus, though this will require an extra 
mutagenesis step in the case of thrombin70. The real advantage of thrombin, aside from its 
commercial availability, is its efficiency. Thrombin can process the GST-PH fusion protein in 
just 1 hr with a low concentration (Figure 3.3). Conversely, thrombin is known to carry out 
off-site cleavage whilst processing recombinant fusion proteins, due to a degree of flexibility 
in its substrate specificity124.  
In comparison 3Cpro needs to be incubated at a 20-fold higher concentration, for 16 hrs to 
cleave the fusion protein (Section 2.4.1). However on the more important question of 
selectivity, 3C is known to have higher sequence specificity91 than thrombin124. Whilst 
thrombin is more efficient, 3Cpro is sufficient to process fusion proteins; whereas 3Cpro is 
significantly more selective than thrombin. It is possible that the “best” protease of the pair 
would depend on the particular system being used, or that either protease would be 
suitable. But if cleavage specificity was as an issue then 3Cpro would be better than thrombin 
for generating proteins suitable for NCL. 
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3.4  TEV protease  
3.4.1 Function and specificity 
The 27 kDa catalytic domain of the Nuclear Inclusion a (NIa) protein encoded by the tobacco 
etch virus is commonly known as the TEV protease128. The crystal structure of the protease 
was elucidated in 2002129 (Figure 3.5). TEV shows a chymotrypsin-like two domain 
antiparallel β-barrel fold, typical of these types of viral proteases. Though unlike 
chymotrypsin, a cysteine thiol is the active site nucleophile instead of a serine hydroxyl, thus 
making TEV a cysteine protease with a Cys-His-Asp catalytic triad130. 
 
Figure 3.5: Structure of the TEV protease
129
. This shows the chymotrypsin-like two-domain antiparallel 
β-barrel fold (red and green). The highlighted Cys-His-Asp catalytic triad and the N-terminal His tag are 
depicted as ball-and-stick models (carbon, violet; nitrogen, blue; oxygen, red; and sulfur, yellow). The 
cleaved peptide product is shown (blue).  
The natural function of TEV is to process the polyprotein of the tobacco etch virus131. It 
carries out proteolytic cleavage at ten distinct sites to generate the mature viral proteins. 
Site directed mutagenesis coupled with protease activity studies have been done on these 
natural cleavage sites, which determined the optimal cleavage sequence for TEV as being 
ENLYFQ↓G97,132. Whilst tobacco etch virus is not related to foot-and-mouth disease virus, the 
Asp His
Cys
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role of TEV is completely analogous to 3Cpro and they show structural homology although 
the exact recognition sequences are different. 
3.4.2 TEV protease in molecular biology 
There is a need in molecular biology for more stringent proteases to process recombinant 
proteins. This is why there has been a movement over the last decade towards viral 
proteases, as they display significantly higher specificity when compared to traditional 
proteases like thrombin133. TEV is the most widely used viral protease in molecular biology, 
helped by the extensive research taken to characterise its structure, specificity and 
activity134.  
Due to its high specificity, TEV has become a protease of choice for processing recombinant 
protein. From purifying recombinant proteins with fusion tags135 to generating native 
proteins in vivo136, there are many examples of the usefulness of this protease. Its 
proteolytic activity, whilst not as high as thrombin, is still at an acceptable level. Overnight 
cleavage can be obtained with a molar ratio of protease to target protein is reported to be 
between 1:20137 and 1:50138, depending on the nature of the target protein and the 
temperature used. The protease has a His-tag to allow purification after the required 
processing has been completed. 
However this high specificity and low activity does make TEV an expensive option. It can be 
obtained in its most active and soluble form (AcTEV) from Invitrogen but at a high cost when 
compared to other proteases. Advances have been made to overcome initial solubility 
problems with expressing recombinant TEV139 so, if the plasmid was readily available, 
soluble TEV could be expressed in individual laboratories.  
While cost and availability could make it less attractive than thrombin, there is no doubt 
that the stringency of TEV makes it a preferable option. There are no reported cases of 
secondary cleavage sites where TEV has been used in the purification of recombinant 
proteins140. In fact a recent fluorescent anisotropy study shows that whilst TEV has a lower 
proteolysis rate it is less promiscuous than thrombin141.  
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3.4.3 Use of TEV for NCL 
Work has been carried out to see if the TEV protease could be used to generate proteins 
suitable for NCL. It was determined that TEV could tolerate residues with short aliphatic side 
chains (G, S, A, M, C) at the P1’ glycine position129, albeit with a loss in activity with respect 
to P1’ glycine 97.  Therefore it is possible to use TEV to generate proteins with an N-terminal 
cysteine, suitable for NCL 
 
Figure 3.6: Use of TEV protease for NCL
142
. Successful expression of (A) C-37-H6 HIV entry inhibitor peptide 
and (B) truncated interleukin-2 9(6-133) with N-terminal cysteines using TEV protease cleavage of fusion 
proteins.  
Processing proteins in this way for NCL reactions has proved successful (see Figure 3.6). The 
TEV/NCL strategy has applied to techniques such as protein labelling with fluorescein and 
biotin71, as well as post-translational modifications by generating glycosylated proteins142. In 
both these cases a fusion protein containing the sequence ENLYFQ↓C was successfully 
cleaved by the protease to generate a protein that was able to undergo NCL. Therefore TEV 
can be used to generate protein with N-terminal cysteines, expanding the utility of this viral 
protease to Native Chemical Ligation.  
(A) (A)
TEV
protease
TEV
protease
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3.5 Engineering a construct for a TEV cleavable protein 
3.5.1 Overall strategy 
In order to compare the TEV protease with 3Cpro it is necessary to first engineer a new 
construct. This will be used to express the GST-ENLYFQC-PH fusion protein which links the 
GST tag to the PH domain by TEV cleavage site. This can therefore be used to directly 
compare TEV with 3Cpro and the GST-PAKQC-PH protein, as both cleavage sites will be found 
at the same place between GST and PH.  
The plasmid encoding the GST-PH fusion protein with the TEV linker was generated in two 
stages (Figure 3.7). Firstly pGEX_TEV plasmid was engineered to encode the sequence 
ENLYFQC, the cleavage site for TEV with a cysteine in the P1’ position, inserted into the 
commercial pGEX-4T-145. The second plasmid, pGEX_TEV_PH, contains a sequence coding 
the PKB-PH Domain, inserted downstream of the ENLYFQC site.  
 
Figure 3.7: Engineering of pGEX-4T-1 to generate the pGEX_TEV_PH, highlighting the restriction sites where 
DNA encoding for the TEV cleavage site and the PH domain were inserted 
It would have been possible to engineer the pGEX_TEV_PH plasmid in one step, by digesting 
pGEX_3C_PH to remove the PAKQC and ligating in ENLYFQC. However it would not be easy 
to use this plasmid to clone in and subsequently express any target protein. The decision 
was taken to do this two step approach, so that there would be the option of using the 
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pGEX_TEV system to generate N-terminal cysteinyl proteins, independently or in 
conjunction with pGEX_3C system, should the need arise.  
3.5.2 pGEX_TEV Plasmid 
The pGEX_TEV plasmid was engineered by ligating the TEV cleavage site into the pGEX-4T-1 
plasmid. This was inserted into BamH I and EcoR I sites in such a manner as to preserve the 
restriction sites, analogous to the pGEX_3C plasmid (Section 2.3.1). This will not only ensure 
ligation of the insert in the correct direction but will allow the cloning of further sequences 
directly downstream of this site, with the widest possible option of restriction sites to use. 
Firstly 1 µg pGEX-4T-1 was digested with 10 units of BamH I and EcoR I for 3 hrs at 37°C. The 
reaction was carried out in 50µl 2 x Tango Buffer to allow both digestions to be carried out 
simultaneously143. The plasmid was subsequently dephosphorylated using alkaline 
phosphatase, thus preventing the plasmid from religating to digested the section as a 5’ 
phosphate group is essential for ligation to occur144. Finally the cleaved plasmid is purified 
from these processing enzymes using the QIAquick® kit. 
The Invitrogen recommended TEV cleavage sequence with P1’ Cys, ENLYFQC, is coded by 
the DNA sequence GAA AAC CTG TAC TTT CAG TGT145. This sequence, flanked with BamH I 
at the 5’ end and EcoR I at the 3’ end, was added into the linearised vector in a 3:1 molar 
ratio and ligated together using the Promega LigaFast system. It is not necessary to purify 
the plasmid from the reaction mixture prior to transformation146.  
The ligation mixture containing the resultant pGEX_TEV plasmid was used to transform 
competent DH5α cells via heat shock. The cells were grown up in LB medium and plated out 
on ampicillin agar plates. 5 colonies were screened using PCR with the forward primer 
corresponding to a site upstream of the insertion and the reverse primer corresponding to 
the TEV insert, therefore only colonies containing the insert should show an amplified DNA 
product (Figure 3.8). 
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Figure 3.8: PCR verification of pGEX_TEV generation, analysed by agarose gel electrophoresis. Colonies 
transformed with the ligation product pGEX_TEV. Lane 1 – PCR molecular weight markers; lane 2 – pGEX 
control colony PCR product; lane 3 – colony 1 PCR product; lane 4 – colony 2 PCR product; lane 5 – colony 3 
PCR product; lane 6 – colony 4 PCR product; lane 7 – colony 5 PCR product.  1% agarose gel, run at 125 mV 
for 40 min, visualised by UV. 
These results show that all 5 colonies screened contain a PCR insert corresponding the 
presence of the TEV cleavage site insert, which is absent in the control pGEX-4T-1 colonies.  
This suggests the successful ligation of the insert in all the colonies. Colony 1 was grown up 
and the DNA extracted using a Qiagen mini-prep kit, and the plasmid was verified by DNA 
sequencing. This pGEX_TEV plasmid was used in subsequent experiments in this thesis. 
3.5.3 pGEX_TEV_PH Plasmid 
The pGEX_TEV_PH plasmid was engineered by ligating the gene encoding for the PKB 
PH domain into the pGEX_TEV plasmid. This was inserted into EcoR I and Sal I sites. The 
EcoR I site was chosen as this will allow expression of the protein directly downstream of 
PAKQC. Sal I was chosen as the next available restriction site and following successful 
cloning into these sites for the pGEX_3C_PH plasmid94. 
The PH domain was amplified from the pGEX_3C_PH vector by PCR using the high fidelity 
PfuUltra™ hotstart DNA polymerase. The primers used corresponded to the N-terminus and 
C-terminus of the PH domain flanked with EcoR I and Sal I restriction sites, respectively. The 
PCR product was purified on 2% agarose gel and extracted using QIAquick® Gel Extraction 
Kit.  
The resultant DNA and the pGEX_TEV plasmid were subjected to a double restriction digest 
at the EcoR I and Sal I sites, though due to the low efficiency of the Sal I enzyme, the digests 
were done sequentially. The linearised vector only was dephosphorylated and both DNA 
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samples were purified using QIAquick® kit. These were subsequently ligated together using 
the Promega LigaFast system as detailed above in Section 3.5.2. The resulting plasmid, 
pGEX_TEV_PH, was transformed into DH5α cells. 5 colonies were screened using PCR 
primers corresponding to sites either side of the multiple cloning site (Figure 3.9).  
 
Figure 3.9: PCR verification pGEX_TEV_PH generation, analysed by agarose gel electrophoresis. Colonies 
transformed with the ligation product pGEX_TEV_PH. Lane 1 – pGEX_TEV control colony PCR product; lane 2 
– PCR molecular weight markers; lane 3 – colony 1 PCR product; lane 4 – colony 2 PCR product; lane 5 – 
colony 3 PCR product; lane 6 – colony 4 PCR product; lane 7 – colony 5 PCR product. 1% Agarose gel, run at 
125 mV for 40 min, visualised by UV. 
The DNA amplification product for colony 3 (Figure 3.9 Lane 5) is approximately 400 bases 
larger than that for the pGEX_TEV plasmid, corresponding to the size of the PH domain 
insert, showing one positive hit from the five colonies screened. The low hit rate for this 
step as opposed to for the pGEX_TEV plasmid (Figure 3.9) is most likely due to the 
inefficiency of Sal I as a restriction enzyme. However this method has been sufficient to 
produce the plasmid in colony 3, so this was used to grown up and the plasmid was purified 
by mini-prep, for details see Section 3.5.2. This was sequenced to verify that is was indeed 
pGEX_TEV_PH and this was used in all subsequent experiments in this thesis. 
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3.6 Comparison of FMDV 3Cpro and TEV protease 
3.6.1 Protein expression 
The GST-ENLYFQC-PH fusion protein was expressed using the autoinduction protocol 
developed for GST-PAKQC-PH expression, see Section 2.3.2 for further details. The 
pGEX_TEV_PH plasmid was transformed into BL21 (DE3) cells and inoculated into 3 L of 
autoinduction medium containing ampicillin. This was incubated at 225 rpm at 30°C for 16 
hrs, followed by 18°C for 24hrs. The cells were lysed and the fusion protein immobilised on 
glutathione beads. GST-ENLYFQC-PH was eluted using 20 mM reduced glutathione, pH 8.0, 
yielding 0.2 mg of the fusion protein as determined by a Bradford Assay114. 
The expression of this GST-ENLYFQC-PH fusion protein linked with the TEV cleavage site, 
was compared to that for the GST-PAKQC-PH protein with the 3Cpro sequence. The typical 
yield from 3 L of the 3Cpro fusion protein is 5 mg (Section 2.3.2), which is about twenty 
five-fold higher the TEV fusion protein. An SDS-PAGE analysis of the protein level at a 
number of stages in the purification process was carried out to try and identify the reason 
for this discrepancy (Figure 3.10).  
 
Figure 3.10: Protein expression comparison of GST-PAKQC-PH and GST-ENLYFQC-PH, analysed by SDS-PAGE. 
GST –C-PH fusion proteins with (A) the 3C cleavage site PAKQ and (B) the TEV cleavage site ENLYFQ. Lane 1 – 
5 µL from 100 mL cell lysate; Lane 2 – 2 µL from 1 mL on-bead purification; Lane 3 – 10 µL from 0.5 mL 
elution from GST-beads. The gel was run at 180 mV for 30 mins and visualised by Coomassie staining.  
These gels (Figure 3.10) compares GST-PAKQC-PH (Figure 3.10A) with that GST-ENLYFQC-PH 
(Figure 3.10B) at the following stages; cell lysate (Lane 1), immobilisation on glutathione 
beads (Lanes 2) and elution from glutathione beads (Lanes 3). The level of GST-ENLYFQC-PH 
is consistently lower than GST-PAKQC-PH at each stage of the protein purification, which 
GST-(PAKQ/ENLYFQ)C-PH 
GST
1 2 3 1 2 3
(A) GST-PAKQC-PH 
3Cpro fusion protein
(B) GST-ENLYFQC-PH 
TEV fusion protein
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suggests that the decrease in yield of the TEV fusion protein is due to the protein expression 
and not the purification process. Expression was tried in normal LB medium, instead of 
autoinduction medium, but this did not increase the relative yield.  
As the 3Cpro fusion protein expresses well, and the only difference between this and the TEV 
fusion is the alteration of the residues PAKQC to ENLYFQC. These results indicated that the 
low yield of GST-ENLYFQC-PH is due to the sequence that contains the TEV cleavage site. 
The specific DNA encoding for TEV site is GAA AAC CTG TAC TTT CAG TGT was checked for 
E. coli codon usage147. It was found that each codon in this sequence has a high relative 
abundance (0.4 to 0.7) with respect to all the codons for that specific amino acid residue. 
Therefore the bacteria should be able to express this.  
The specific reason for the high yield GST-PAKQC-PH as compared with GST-ENLYFQC-PH is 
unclear. Whether the problem is due to the sequence specifically within this pGEX system or 
with the TEV cleavage site in general would require further investigation of protein 
expression in an alternative vector. However this result means that in terms of protein 
expression of fusion protein with 3Cpro or TEV site, then it is preferable to work with the 
3Cpro system. 
3.6.2 TEV Cleavage 
In order to compare the relative proteolytic abilities of TEV and 3Cpro, the conditions 
required for TEV to cleave the fusion protein GST-ENLYFQC-PH was determined. Literature 
values suggest that, 37°C for overnight incubation, a molar ratio of 1:20137 to 1:50138 
enzyme:protein is required, though this does not take into account the reported loss of 
activity when P1’ is Cys not Gly97. These values suggest that the TEV will show similar 
efficiency to that of 3Cpro. 
To allow direct comparison of the two proteases, a time course experiment was carried out 
for TEV cleavage using the 3C conditions; molar ratio of 1:25 enzyme:protein at 37°C for 
16 hrs. The reactions were boiled at 95°C in LDS loading buffer to stop the proteolysis, one 
after 8 hrs and the other after 16 hrs.  
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Figure 3.11: TEV protease cleavage conditions. 12% SDS PAGE gel showing the time course experiment to 
determine the cleavage conditions for TEV on GST-ENLYFQC-PH protein, in a 1:25 enzyme:protein ratio, at 
37°C. Lane 1 – 0 hrs; Lane 2 – 2 hrs; Lane 3 – 16 hrs. The gel was run at 180 mV for 30 mins and visualised by 
Coomassie staining. 
The results were analysed by SDS-PAGE (Figure 3.11). This shows that GST-ENLYFQC-PH 
(Lane 1) is digested by the protease TEV in a 1:25 molar ratio at 37°C, with the proteolysis 
for the most part complete after 8 hrs (Lane 2) and totally obtained after 16 hrs (Lane 3). 
This corresponds closely with the cleavage activity of 3Cpro, which also achieves complete 
proteolysis of its GST-PH fusion protein under the same conditions. 
3.6.3 Comparison with 3Cpro 
These experiments show that there are a number of similarities between the proteases TEV 
and 3Cpro. It has been shown that the cleavage sites, ENLYFQC (Section 3.5) and PAKQC 
(Section 2.3) respectively, can be inserted into a GST fusion protein and subsequently 
expressed and purified (Figure 3.10). Both enzymes cleave their GST-PH fusion protein at a 
reasonable rate, requiring 16 hrs, at 37°C with a 1:25 molar ratio (Figure 2.7, Figure 3.11). 
Moreover they can both tolerate a cysteine residue in the P1ʹ position97,111, allowing the 
production of proteins suitable for NCL.  
However there is an advantage to using 3Cpro over TEV, which is the protein expression level. 
Within this pGEX system, the fusion protein linked with PAKQC, the 3Cpro insert, was 
generated with a yield 25-fold higher than for the equivalent TEV protein. This is a 
significant difference, making it much quicker and easier to obtain useful amount of C-PH 
using 3Cpro when using this GST fusion protein approach. It is not clear what causes this 
reduction in expression levels and it is not known whether an alternative vector system 
would overcome this problem. However, whatever the reason, this does reduce the utility 
of this particular TEV cleavage vector. 
GST-ENLYFQC-PH 
GST-ENLYFQ
1 2 3
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There is also the process of protein purification to consider. TEV is know to perform poorly 
at on-bead cleavage, which is why the fusion protein needs to be purified, then cleaved and 
then the affinity tag removed71,137. This is fine when the affinity tag is the same as on the 
protease, in the case of TEV a His-tag, but when it is GST then the process of generating 
C-PH will require and extra purification step. In contrast 3Cpro can carry out effective on-
bead processing of the GST fusion protein (Section 2.4.2). Therefore with this system it is 
preferable to use 3Cpro over TEV for protein expression levels and ease of purification. 
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3.7 Orthogonal labelling 
The two enzymes, TEV and 3Cpro, are both highly selective proteases and with different 
optimal cleavage sites. Therefore there is the possibility of using them both in an orthogonal 
labelling system. This could be for differential labelling of co-expressed proteins, with the 
TEV and 3Cpro cleaved proteins labelled with FRET pairs of fluorophores to determine the 
interaction between them. Alternatively a single protein can be engineered with two 
cleavage sites to allow the full length and truncated protein to be expressed from the same 
prep and labelled with alternative fluorophores to compare activities. In order obtain such a 
system it must be determined if their individual specificity outweighs the similarity between 
these two enzymes. 
3.7.1 Similarities between 3Cpro and TEV 
There are a number of similarities between these two proteases. Firstly in their structure; 
both enzymes are cysteine proteases with a key cysteine residue in the active site and a 
chymotrypsin-like fold91,129. Also, both proteins have the same general function, namely to 
process their respective viral polyproteins into mature proteins86,128. In order to do this they 
both cleave a range of native sites. These cleavage sites have been probed to obtain the 
optimum cleavage site for the 3Cpro and TEV proteases91, and been successfully incorporated 
into expression systems for generating N-terminal cysteinyl proteins71,111. The difference lies 
in the nature of these cleavage sites, PAKQ↓C for 3Cpro111 and ENLYFQ↓C for TEV71. 
3.7.2 Cross cleavage reaction between 3Cpro and TEV 
In order to probe the orthogonal nature of the proteases, a cross cleavage reaction was set 
up. Both GST-PH fusion proteins (GST-PAKQC-PH with the 3Cpro insert and GST-ENLYFQC-PH 
with the TEV insert) were incubated with either 3Cpro or TEV or neither enzyme. Both 
proteases cleave in a 1:25 enyzme: protein ratio, at 37°C overnight, however in this 
experiment the ratio used was 1:10. This is to determine if in situations of an excess amount 
of protease is used, i.e. if exact protein concentration in a prep is not known, whether cross 
cleavage will occur. All reactions were at 37°C and after 16 hrs were boiled at 95°C in LDS 
loading buffer to stop the proteolysis. The samples were analysed by SDS-PAGE (Figure 3.12) 
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Figure 3.12: Cross cleavage comparison experiment between 3C
pro
 and TEV, analysed by SDS-PAGE. Lane 1 – 
GST-PAKQC-PH fusion protein in phosphate buffer; Lane 2 –fusion protein with 3C
pro
 in a 1:10 molar ratio; 
Lane 3 – GST-PAKQC-PH fusion protein with TEV in a 1:10 molar ratio; Lane 4 – GST-ENFLYQC-PH fusion 
protein in phosphate buffer; Lane 5 – GST-ENFLYQC-PH fusion protein with TEV in a 1:10 molar ratio; Lane 3 
– GST-ENFLYQC-PH fusion protein with 3C
pro
 in a 1:10 molar ratio. Each reaction was incubated at 37°C for 16 
hrs. The 12% gel was run at 180 mV for 30 mins and visualised by Coomassie staining. 
These results (Figure 3.12) show that there is a high, but not absolute, degree of selectivity 
between 3Cpro and TEV. The cleavable fusion protein, GST-PAKQC-PH (Lane 1) is totally 
digested by 3Cpro (Lane 2) but only slightly by TEV (Lane 3). In comparison GST-ENFLYQC-PH, 
the TEV cleavable protein, (Lane 4) is totally digested by TEV (Lane 5) but only slightly by 
3Cpro. Therefore, whilst 3Cpro and TEV are highly specific proteases, a small degree of cross 
cleavage is seen between these two enzymes. 
The reason for this can be found by looking at the nature of the two proteases cleavage 
sites. The optimum cleavage site for TEV is ENLYFQG, but studies have shown that it can 
tolerate other amino acids as the native cleavage sites in the TEV polyprotein do show 
variation97. However point mutations of this sequence reduce in vitro efficiency by 10 to 500 
fold132.  With 3Cpro a similar pattern is seen. The optimum sequence is PAKQ with variability 
found in the native sequence. Analysis of these sites in vitro showed a large variation in 
cleavage rates, with certain sequences remaining undigested after 24 hrs incubation in a 
1:50 enzyme:peptide ratio at 37°C91.   
TEV is preferentially used to process fusion proteins due to its high stringency when 
compared to other proteases133. The specificity of 3Cpro is believed to be just as high91, 
though this cannot be confirmed until the protease has been used in conjunction with a 
range of different proteins. There are no reported cases of significant secondary cleavage 
with TEV in the literature, however the specificity of these two proteases is clearly not 
absolute as demonstrated by this experiment. It must be noted that these results were 
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generated using relatively high protease concentrations, so it is important where possible to 
use the recommended amount of enzyme. However this in of itself will not guarantee that 
no secondary cleavage will occur. Therefore whilst TEV and 3Cpro are preferable to proteases 
such as thrombin due to their selectivity, it is important to always check the protein 
products generated in case of the unlikely occurrence of truncated products.  
3.7.3 Can 3Cpro and TEV be used in an orthogonal manner? 
Both proteases have an optimal cleavage site but due to their native function can cleave a 
number of sites, albeit with significant decrease in activity.  This was seen not only in 
literature analysis, but also in the cross cleavage experiment between them (Figure 3.12). 
That the sequences both proteases can sparingly tolerate correspond to each others 
optimum sequences is unfortunate but not wholly surprising; these are two viral proteases 
with similar structure and function that each have a glutamine in the P1 position (Section  
3.7.1). 
However this initial result still indicates that, with some care in selecting appropriate 
concentrations, 3Cpro and TEV might be used in an orthogonal, dual labelling system. Even at 
increased concentrations of enzyme, with their respective optimum cleavage sequences, 
there is only a small degree of cross cleavage (Figure 3.12). Therefore to achieve 
orthogonality there are two options: lower the amount of protease used or alter the 
cleavage sites. 
The simplest solution would be to decrease the amount of protease in the reaction. A time 
course would be needed in order to determine at what concentration, or after what length 
of time 3Cpro no longer cleaves the TEV fusion protein and vice versa. However this will 
result in a decrease in cleavage of the correct protein and extreme care will have to be 
taken to ensure the correct amount of protease is added so that cross cleavage does not 
occur. 
A more elegant approach might be to alter one cleavage site in such a way to knock out the 
cross cleavage. An interesting feature of cleavage site optimisation showed that 3Cpro can 
tolerate P1 Glu instead of Gln91, albeit with slightly decreased activity, but TEV cannot97. A 
PCR point mutation of PAKQC to PAKEC, altering the DNA sequence from CCG GCG AAA CAG 
TGT to CCG GCG AAA GAA TGT, would result in a fusion protein that should be cleavable by 
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3Cpro but not TEV. As long as the system is designed correctly so that TEV proteolysis is 
carried out first, 3Cpro concentration can be increased to compensate for the decrease in 
activity due to the altered cleavage site. Therefore this is potentially a route to an 
orthogonal, site specific labelling system using the proteases 3Cpro and TEV. 
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3.8 Conclusion 
This chapter has compared 3Cpro to the proteases thrombin and TEV with respect to 
engineering a recombinant protein suitable to for NCL from a GST fusion protein. It is found 
that 3Cpro can be used at least as well as these established proteases, and in certain 
situations is even preferable to them. The possibility of using 3Cpro alongside TEV in a dual 
labelling system has also been explored. 
First, 3Cpro was compared to thrombin. The pGEX system used to express the target GST-PH 
fusion protein has been designed to be cleaved by thrombin45, so this comparison showed 
how effective the 3Cpro is at processing these constructs, relative to the more widely used 
thrombin. A time course experiment demonstrated that thrombin is more active at 
processing the fusion protein, though both proteases can be used to successfully cleave the 
fusion protein in a feasible time scale. However the literature shows several examples of 
secondary cleavage with thrombin125-127, whereas 3Cpro shows a higher level of specificity. 
Therefore whilst thrombin is more active, a higher concentration of 3Cpro for a longer time 
can compensate for this. However, the selectivity of 3Cpro is a distinct advantage over 
thrombin. 
TEV has become a protease of choice in molecular biology due to its high stringency with 
respect to other proteases like thrombin133. In order to compare it to 3Cpro, it was first 
necessary to engineer a TEV cleavable GST fusion protein. The TEV site ENFLYQC was 
successfully incorporated into a pGEX vector and used to express the GST- ENFLYQC-PH. 
However this was found to express at a twenty five-fold lower amount then the 3Cpro fusion 
protein. 
The proteolytic activity of 3Cpro and TEV was compared. It was found that both enzymes 
cleave at the same rate. However there are difficulties expressing the TEV cleavable fusion 
protein, and carrying out on-bead TEV cleavage. Therefore 3Cpro is the preferable protease, 
within this system, to generate N-terminal cysteinyl proteins from a GST fusion. 
A cross cleavage experiment was carried out with 3Cpro and TEV to explore the option of 
using these in an orthogonal, dual labelling system. Both proteases were found to be 
selective towards their own cleavage sequence. However at the higher concentration of 
protease, a small degree of cross cleavage was observed. This is due to the high similarities 
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between these viral proteases. There no reported problems regarding the sequence 
specificity of TEV in the literature, which is why it is currently the gold standard of 
processing enzymes134, if 3Cpro acts with the same degree of stringency it will be a very 
useful tool. This result does not negate the specificity of these two proteases, though it does 
highlight the importance of characterising protein cleavage products and using the correct 
amount of protease. In terms of a route to the development of a dual labelling system, this 
result is very encouraging. 3Cpro and TEV can clearly differentiate their specific cleavage 
sites, suggesting that orthogonal cleavage is possible. 
This work has shown that 3Cpro expresses as well, if not better, than the established 
proteases thrombin and TEV, and is as specific, if not more so, that these proteases.  It 
should also be possible to use 3Cpro in conjunction with them. This exemplifies the use of 
3Cpro is not only a viable but also a preferable route to generating proteins suitable for NCL 
within this pGEX based system. 
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3.9 Materials and Methods 
3.9.1 Reagents and Equipment 
Components of the autoinduction and LB media, sugars and antibiotics were purchased 
from Sigma Aldrich. Buffer components were also bought from Sigma Aldrich. GST and Ni 
Purification kits were purchased from GE Healthcare. Thrombin protease and buffer was 
purchased from Sigma Aldrich, whilst the TEV protease and buffer was purchased from 
Invitrogen.  SDS-PAGE equipment, gels, and reagents were from Invitrogen. The agarose gel 
was purchased from VWR, with the gel running equipment was supplied by BioRad. The 
pGEX-4T-1 plasmid was purchased from GE Healthcare, whilst the DNA oligonucleotides 
were from Invitrogen. The ReadyMix™ RedTaq PCR was bought from Sigma Aldrich. 
Restriction enzymes, alkaline phosphatise and the ligation kit were purchased from 
Promega, with the Pfu PCR Kit, DH5α competent cells and the BL21 (DE3) competent cells 
from Stratagene. The miniprep kit and DNA gel extraction kit were bought from Qiagen. 
DNA sequencing was carried out by the genomic service Cogenics.  
3.9.2 Thrombin cleavage 
Expression of the GST-PAKQC-PH protein 
The GST-PAKQC-PH protein was expressed using the standard methodology developed in 
Chapter 2, see Section 2.8.2 for full details. 
Thrombin Time Course121 
500 µg, 35 nmols of GST-PAKQC-PH in 100 µl Thrombin Cleavage Buffer (50 mM Tris-Cl, 
150 mM NaCl, 2.5 nM CaCl2, pH 7.5) was incubated with 4 units, 0.06 nmols thrombin at 
37°C. 10 µL samples were taken after 0 mins, 15 mins, 30 mins, 60 mins and 90 mins, and 
immediately boiled at 95°C in LDS loading buffer. The results were analysed by SDS-PAGE, 
run at 180 mV for 30 mins and visualised by Coomassie staining. 
Thrombin / 3Cpro Cleavage Comparison111,121 
100 μL, 35 nmols GST- PAKQC-PH protein loaded glutathione beads was resuspended in 
100 µL Thrombin Cleavage Buffer and incubated with 4 units, 0.06 nmols thrombin at 37°C 
for 1 hrs. 100 μL, 35 nmols GST- PAKQC-PH protein loaded glutathione beads, from the same 
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protein expression, was resuspended in 100 µL 3Cpro Reaction Buffer (100 mM Sodium 
Phosphate Buffer pH 7.4, 1 mM EDTA, 1mM TCEP, 5% v/v Glycerol) and incubated with 7 µL, 
1.4 nmols 200 µM 3Cpro at 37°C for 16 hrs.  
After the set incubation times, the beads were centrifuged (3200 rcf, 4°C, 2mins) and the 
supernatant separated off. An equal volume of the beads and supernatants from both 
proteases were analysed by SDS-PAGE, run at 180 mV for 30 mins and visualised by 
Coomassie staining. 
3.9.3 TEV cleavable protein generation 
pGEX_TEV Plasmid - TEV Cleavage Site Insert45 
1 µg pGEX 4T-1 plasmid was digested by 10 units of BamH I and, 10 units of EcoR I in 50 μL 
of 2x Tango Buffer for 3hrs at 37°C. The vector was then desphosphorylated by 1 unit of calf 
intestinal alkaline phosphatase for 5 mins at 50°C. The cleaved vector DNA was purified 
using the QIAquick® kit. The TEV insert flanked with a 5’ BamH I and 3’ EcoR I overhangs 
(FWD – 5’-GA TCC GAA AAC CTG TAC TTC CAG TGT G, BamH I overhang-ENLYFQC; REV – 5’-G 
CTT TTG GAC ATG AAG GTC ACA CTT AA, ENLYFQC-EcoR I overhang) was added to the 
BamH I/EcoR I digested vector in a 3:1 molar ratio. The ends were ligated using 3 units of T4 
DNA Ligase in 15 μL of 1x rapid ligation buffer by incubating at room temperature for 
5 mins.  
The ligation mixture (2 µL) was used to transform Subcloning Efficiency™ DH5α™ Competent 
Cells. The mixture was incubated with 50 µL of cells on ice at 4°C for 30 mins. Subsequently 
the cells were heat shocked at 42°C for 45 seconds, 4°C for 2 mins and grown in 1 mL LB 
medium. Transformed cells containing the plasmid were therefore selected for on ampicillin 
LB agar plates.  
Colonies analysed in 50 μL of 1x ReadyMix™ RedTaq PCR Reaction Mix containing 0.2 μM 
pGEX FWD (5’-GGG CTG GCA AGC CAC GTT TGG, upstream of the multiple cloning site) and 
TEV REV primers (25 cycles of 94°C, 1min; 68.5°C, 2 mins; 72 ° C,1 min). A small aliquot of 
the PCR reaction was analysed on a 1 % agarose gel, run at 125 mV for 40 min, visualised by 
UV. Positive colonies were picked and DNA purified using the QIAprep® Miniprep kit and 
verified by DNA sequencing.  
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pGEX_TEV_PH PH Domain Insert45 
The PH domain gene was amplified from 500 ng pGEX_3C_PH plasmid by 1 μL, 2.5 units 
PfuUltra™ hotstart DNA polymerase in 50 μL of 1x Pfu reaction buffer containing 0.25 mM of 
each dNTP and 0.2 μM EcoR I PH5’ (5’- AAA CCG GAA TTC CGT ATG AGC GAC GTG GC) and 
PH3’SalI (5’- AAC GCG TCG ACC TCA GCC CGA ACG GAA G) primers (hotstart at 94°C; 
12 cycles of 94°C, 30secs; 63.5°C, 1 min; 72 ° C, 5 mins 10 secs; 10 mins extension at 72°C). 
The PCR product was purified on a 2% agarose Gel, 1 % agarose gel, run at 125 mV for 
40 mins, visualised by UV and extracted using QIAquick® Gel Extraction Kit. 
6 μL, 2 μg of pGEX_TEV and 5 μL, 1 μg of PH domain PCR product were digested separately 
by 2 μL, 20 units of Sal I in 50 μL of 1 x SH Buffer for 16 hrs at 37°C. This was further digested 
by 1 μL, 10 units of EcoR I in the 50 μL of 1 x SH Buffer for 3 hrs at 37°C. The DNA was then 
dephosphorylated by 1 μL, 1 unit of calf intestinal alkaline phosphatase 5 mins at 50°C. This 
was purified by QIAquick® kit (Qiagen). 2 μL, 40 ng of the PH domain gene was added to 4 
μL, 100 ng of the EcoR I/Sal I digested vector in a 4:1 molar ratio. These were ligated by 1.5 
μL, 3 units of T4 DNA Ligase in 15 μL of 1 x Rapid Ligation Buffer for 5 mins at room 
temperature.  
The ligation mixture (2 µL) was used to transform Subcloning Efficiency™ DH5α™ Competent 
Cells. The mixture was incubated with 50 µL of cells on ice at 4°C for 30 mins. Subsequently 
the cells were heat shocked at 42°C for 45 seconds, 4°C for 2 mins and grown in 1 mL LB 
medium. Transformed cells containing the plasmid were therefore selected for on ampicillin 
LB agar plates.  
Colonies analysed in 50 μL of 1 x ReadyMix™ RedTaq PCR Reaction Mix 0.2 μM pGEX FWD 
(5’-GGG CTG GCA AGC CAC GTT TGG, upstream of the multiple cloning site) pGEX REV 
(5’-CCG GGA GCT GCA TGT GTC AGA G, downstream of the multiple cloning site) primers. 
After 25 cycles of 94°C, 1 min; 68.5°C, 2 mins; 72°C, 1 min; 10 μL of each PCR amplification 
was analysed on a 1% agarose Gel,  run at 125 mV for 40 mins, visualised by UV. The positive 
colony was grown up, purified by QIAprep® Miniprep kit and verified by sequencing. 
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GST-ENLYFQC-PH protein expression105,111,113  
BL21 (DE3) E. coli cells were transformed by incubating 50 µL of cells on ice with 1 µL, 50 ng 
of the pGEX_TEV_PH plasmid at 4°C for 30 mins. Subsequently the cells were heat shocked 
at 42°C for 45 seconds, 4°C for 2 mins and grown in 1 mL LB medium. Transformed cells 
containing the plasmid were therefore selected for on ampicillin LB agar plates. 20% glycerol 
stocks of the 3Cpro BL21 (DE3) cells were created.  
Three litres of auto-induction LB medium containing 100 μg/mL ampicillin, 0.6% v/v glycerol, 
0.05% w/v glucose, 0.2% w/v lactose were made up. This was inoculated with a colony of 
BL21(DE3) containing the plasmid pGEX_TEV_PH and incubated at 30°C for 16 hrs at 
225 rpm, followed by a further incubation at 18°C for 24 hrs at 225 rpm. 
The cells were spun down (3200 rcf, 4°C, 20 mins), frozen at -20°C overnight and 
resuspended in GST Lysis Buffer (50 mM Tris-Base, 2 mM EDTA, 10 mM Benzamidine, 1 mM 
DTT, 1 % v/v Triton X-100), 25 mL per 1 L protein expression. The cells were then lysed by 
incubation with 10 mg/mL lysosyme at 4°C for 2 hrs followed by sonication for 3 x 30 secs. 
DNase, 0.1 mg/mL at 4°C for 30 mins, was used to digest the DNA present in the lysate. The 
lysaste was centrifuged (18000 rcf, 4°C, 30 mins) and the protein in the supernatant fraction 
was retained.  
GST_PAKQC_PH is eluted from the beads, if required, using GST Elution Buffer (50 mM 
Tris-Cl, pH 8, 20mM reduced glutathione). The buffer is added to an equivalent volume of 
beads and mixed at room temperature for 30 mins. This was spun down (3200 rcf, 4°C, 
2 mins) and the supernatant decanted. This procedure is repeated twice and the eluted 
fractions pooled. A 3 L prep typically gave a yield of 0.2 mg protein, as determined by 
Bradford Assay.  
3.9.4 TEV cleavage 
TEV Time course71 
Two reactions were set up, each containing 40 µg, 1 nmol of GST-ENLYFQC-PH in 10 µL TEV 
Cleavage Buffer (50 mM Tris-Cl, , 0.5 mM EDTA, 1 mM DTT, pH 8.0) incubated with 0.4 units, 
40 pmols, TEV at 37°C. The reactions were boiled at 95°C in LDS loading buffer to stop the 
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proteolysis, one after 8 hrs and the other after 16 hrs. The results were analysed by 
SDS-PAGE, run at 180 mV for 30 mins and visualised by Coomassie staining. 
TEV/3Cpro cross cleavage71,111 
40 µg, 1 nmol of both GST-PAKQC-PH and GST-ENLYFQC-PH fusion proteins were incubated 
with either 0.5 µL, 100 pmols 200 µM 3Cpro in 10 µL 3C Reaction Buffer, or 1 unit, 100 pmols, 
TEV in 10 µL TEV Cleavage Buffer. As a control 40 µg, 1 nmol of protein was incubated in 
10 µl 0.1M phosphate buffer, pH 7.2. All reactions were kept at 37°C and after 16 hrs were 
boiled at 95°C in LDS loading buffer to stop the proteolysis. The results were analysed by 
SDS-PAGE, run at 180 mV for 30 mins and visualised by Coomassie staining. 
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Chapter 4 Using the 3Cpro/NCL System to Produce Reagents for 
Imaging Studies 
 
A key advantage of labelling proteins via NCL is the versatility of this reaction59. Any 
label can be attached onto the N-terminus of the protein, as long as it can be 
derivatised into a thioester. Fluorescein has already been successfully ligated onto 
C-PH111, and the next stage of the work aimed to expand the scope of this 3Cpro/NCL 
labelling strategy. This chapter will explore:- 
• the development and validation of a thioester library, suitable for labelling 
proteins via NCL  
• the utilisation of this library for imaging experiments 
The initial components of this library, described in this chapter, are based on the 
fluorophores PromoFluor 488148 and Rhodamine Red149.  
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4.1.1 Chemical Fluorophore Labels for Imaging 
Fluorescence is a form of photoluminescence and is a property of molecules known as 
fluorophores6. It involves the ground-state of the molecule absorbing a photon at a specific 
wavelength (λex) in a process known as excitation to reach an excited state. This then 
returns to the ground state by emitting a photon at a longer wavelength (λem)6. Conjugation 
of these fluorophores to proteins has allowed the visualisation and investigation of these 
proteins, typically by fluorescence microscopy7.  
 
Figure 4.1: The generalised excitation and emission spectra of a fluorophore
6
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Whole cell imaging of a fluorescently labelled protein can provide useful detail of its 
localisation and interactions (Section 1.2). The spectral properties (Figure 4.1) of a 
fluorophore will affect its suitability for a particular imaging experiment6. The emission 
wavelength needs to be detectable on the fluorescence microscope, and if a range of 
fluorophores are being used they need to be selectively excited and detected. Also a large 
Stoke shift, the difference between λex and λem, is preferable as it lowers the background 
level of fluorescence. Other important characteristics of the fluorophore are brightness and 
susceptibility to photobleaching. It is also necessary to bear in mind physical and chemical 
properties such as solubility and ease of conjugation to proteins6. The effects of these 
fluorophore properties are detailed in Section 1.1.1. 
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A commonly used fluorophore is fluorescein, with a λex of 494 nm and a λem of 521150. Its 
excitation maximum makes it a easily detectable by an argon-ion laser (488nm) and 
therefore useful for fluorescence microscopy7. This readily available and inexpensive label 
was used to validate the 3Cpro/NCL labelling strategy, as shown in Chapter 2111.  
However there are a number of drawbacks associated with fluorescein. It has a rather broad 
emission spectrum, which can be problematic if multiple fluorophores are used150. Also the 
fluorescence of the molecule is greatly reduced by conjugation to biopolymers, as these can 
absorb and therefore quench the fluorescence151,152. However the biggest disadvantage of 
this fluorophore is its susceptibility to photobleaching8. This is caused by the accumulation 
of molecules in the long-lived triplet excited state, followed by an irreversible chemical 
change in the molecule that bleaches it153. This is problematic for the use of fluorescein in 
microscopy studies (Figure 4.2) 154.  
 
Figure 4.2: Photobleaching of fluorescein
154
. Fluorescein labelled actin in bovine endothelial cells under 
constant illumination on a fluorescence microscope. (A) Image captured after 1 secs; (B) Image captured 
after 30 secs. 
There is a need to have a selection of fluorescent probes for imaging studies above and 
beyond fluorescein that have a range of fluorescent spectra to allow alternative and even 
multicolour experiments. They must be suitable for microscopy experiments so it is 
important they are bright and do not easily photobleach. These fluorophores will be 
conjugated by NCL so it is vital that they can be converted into thioesters and that their 
fluorescence is not significantly affected by this conjugation to proteins. Development of 
this library is vital to the usefulness of the 3Cpro/NCL labelling strategy.  
(A) (B)
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4.2 Thioester Generation 
4.2.1 Standard method for thioester generation 
In order to fully exploit the potential of this 3Cpro/NCL system for labelling protein for 
imaging, it is necessary to have an accessible range of thioester labels. In this thesis, one 
method of generating thioester moieties was used to develop a standardised protocol that 
can be used for any label that bears a carboxylic acid functional group. 
The conditions for this reaction are relatively facile74. The required label, in the form of an 
NHS ester, is reacted with eleven equivalents of thiol. In this thesis the thiol of choice is 
MESNa 2, which has a sulfonate group that not only makes it water soluble but also results 
in lack of the foul smelling odour that is commonly associated with thiols. The two reagents 
are incubated in 0.1M sodium borate buffer, pH 8.3 at room temperature. After two hours 
the reaction is complete and the thioester product can be purified by RP-HPLC over a 
water/acetonitrile gradient74. 
 
Figure 4.3: Mechanism of thioester synthesis
13
. An NHS ester fluorophore is attacked by the MESNa thiol 2 at 
the carbonyl group, facilitated by a basic environment. This results in the formation of a fluorophore 
thioester with the release of the hydroxysuccinimide group. 
The mechanism for thioester generation proceeds as follows. The thiol, which is in excess, 
attacks the carbonyl group of the NHS ester on the fluorophore, releasing the NHS group13. 
The half life of hydrolysis of the NHS group is greatly decreased at higher pH155, though the 
formation of the thioester is faster than the breakdown of this group. Therefore this 
reaction is facilitated by the basic environment provided by the sodium borate buffer at pH 
8.3. This results in the generation of the fluorophore thioester.  
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There are number of reasons for choosing this method for thioester synthesis. First of all the 
starting material is an NHS ester, and many useful protein labels are supplied in this form 
because an NHS ester may be used to attach molecules non-specifically to free amine 
groups10 (Section1.1.2). Also the reaction conditions and purification methodology are very 
straightforward, with no specialised organic chemistry techniques. Therefore this method of 
thioester generation is accessible to non-chemists looking to carry out work on proteins. 
Thioester molecules are not very stable, as they can be subjected to hydrolysis to a 
carboxylic acid156. In order to avoid this it is important to store the labels in the correct 
manner that was developed throughout this project: as anhydrous lyophilised powders at 
-20°C. However they will only survive a limited number of freeze-thaw cycles so they are 
kept in separate aliquots. Samples stored this way were found to be stable for at least one 
year. 
4.2.2 PromoFluor 488 Thioester Generation 
PromoFluor 488 is a fluorophore that has λex 493 and λem 521148. Due to the spectral 
similarities, this is used as an alternative to fluorescein, especially because the slight 
structural modifications make it a better fluorophore148. PromoFluor 488 is reported to be 
brighter and more photostable than fluorescein. Also the fluorescence of the molecule is 
not diminished upon bioconjugation, unlike fluorescein, due to the amide linker region 
present. Therefore PromoFluor 488 was selected to serve as a green emitting fluorophore in 
the 3Cpro/NCL labelling library (Figure 4.4). 
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Figure 4.4: Reaction scheme for PromoFluor 488 thioester 5 synthesis from PromoFluor 488 NHS ester 4 
using 2. The reactants were incubated for 2 hrs at room temperature in 0.1 M sodium borate buffer, pH 8.3.  
The PromoFluor 488 thioester 5 was synthesised using the standard conditions for thioester 
generation74 (Figure 4.4). PromoFluor 488 NHS ester 4, in DMF, was added to eleven 
equivalents of 2, in sodium borate buffer pH 8.3. The reaction flask was covered in foil, to 
protect the fluorophore from photobleaching, and stirred at room temperature.  
 
Figure 4.5: HPLC analysis of PromoFluor 488 thioester synthesis. Section of HPLC traces for conversion of 
synthesis of (A) PromoFluor 488 NHS ester 4 to (B) PromoFluor 488 Thioester 5. The traces were obtained on 
a C-18 reverse phase column over a 2-98% water/acetronitrile solvent gradient at a UV absorbance 
wavelength of 493 nm. 
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The reaction was monitored by RP-HPLC over a 2-98% water/acetronitrile solvent gradient, 
with the traces detected at a wavelength of 493 nm, corresponding to the λex 493 of 
PromoFluor 488 (Figure 4.5). This showed that the reaction was complete after 2 hrs. 5 was 
purified by RP-HPLC using the same conditions and lyophilised directly into 30 Eppendorf 
aliquots, each containing 0.2 mg, and stored at -20°C.  
4.2.3 Rhodamine Red Thioester Generation 
Rhodamine Red is a red fluorescent molecule, with λex 560 and λem 580149. It contains a 
seven-atom aminohexanoyl spacer between the fluorophore and the point of protein 
attachment to prevent a loss of brightness on conjugation. It has been found that proteins 
labelled with this fluorophore are brighter and less likely to precipitate than the alternative 
Lissamine rhodamine B red label149. Rhodamine Red will be derivatised into a thioester, 
allowing it to be used as a red fluorescent alternative to the green PromoFluor 488 in the 
3Cpro/NCL labelling library (Figure 4.6). 
 
Figure 4.6: Reaction scheme for synthesis of the Rhodamine Red thioester 7 from the Rhodamine Ref NHS 
ester 6 using 2. The reactants were incubated in 0.1 M sodium borate buffer, pH 8.3, for 2 hrs at room 
temperature. 
The Rhodamine Red thioester 7 was synthesised using standard thioester generating 
conditions as for PromoFluor 488 (Section 4.2.2)74, and lyophilised directly into 26 
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Eppendorf aliquots, each containing 0.2 mg, for storage at -20°C. The HPLC trace, detected 
at the Rhodamine Red excitation wavelength of 560 nm (Figure 4.7), shows the instability of 
this fluorophore 7 compared to 5, with the NHS ester 6 rapidly breaking down. This is most 
likely the reason for the decrease in yield. However the reaction was still successful enough 
to produce a useful amount (26 aliquots) of thioester 7. 
 
Figure 4.7: Reaction scheme of Rhodamine Red thioester synthesis. Section of HPLC traces for conversion of 
synthesis of (A) Rhodamine Red NHS ester 6 to (B) Rhodamine Red Thioester 7. The starting material was 
incubated with 2 for 2 hrs at room temperature to generate the thioester. The traces were obtained on a 
C-18 reverse phase column over a 2-98% water/acetronitrile solvent gradient at a wavelength of 560 nm. 
Thioester derivatives of PromoFluor 488 5 and Rhodamine Red 7 have been successfully 
synthesised. In both cases this was done using the standard method for thioester generation 
by converting an NHS ester using the thiol 2 (Figure 4.3)74. The yields for these reactions 
were 6.0 mg, 60% for 5 and 5.2 mg, 52% for 7, useful amounts for subsequent NCL 
reactions. This indicated the versatility of this method as a facile and effective approach for 
producing a range of thioester labels.  
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4.3 Peptide Labelling 
The thioesters 5 and 7 have been synthesised in order to label proteins via NCL. However 
before this is attempted, their suitability to undergo this reaction must be verified. 
Therefore these fluorophores will be attached to a peptide bearing an N-terminal cysteine 
to determine the conditions required for successful ligation. 
4.3.1 PromoFluor 488 
The suitability of 5 was determined by ligation to the N-terminal cysteinyl peptide, 
CLDFDLLK 8 under standard NCL conditions59. 0.1 mg of the peptide was four equivalents of 
the thioester. No thiol catalyst was required because there are no other cysteines in the 
peptide, and therefore there is no need to regenerate the thioester. After 5 hrs a sample of 
the reaction was taken, desalted with C-18 tips and analysed by MALDI-TOF.  
 
Figure 4.8: MALDI-TOF analysis of the peptide NCL reaction of PromoFluor 488 (A) PromoFluor 488 thioester 
5; (B) peptide 6; (C) desalted product obtained after an NCL reaction under standard conditions; 0.1 M 
phosphate buffer, pH 7.2, fourfold excess of thioester, room temperature, 5 hrs. The main peak corresponds 
to the mass +1 (MH
+
), with the secondary peaks corresponding to the species plus Na
+
 and K
+
. 
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These results (Figure 4.8) show the successful completion of the NCL reaction between 
thioester 5 and peptide 8. After 5 hrs the MALDI-TOF trace shows the presence of a peak at 
1438 MW, (Figure 4.8C) corresponding to the labelled peptide (MH+, expected mass 1438) 
and the absence of a peak at 967 MW (Figure 4.8B), corresponding to the starting peptide 
(MH+, expected mass 967). This shows that the reaction has gone to completion. There is no 
peak at 614 MW (Figure 4.8A), the value that corresponding to the thioester plus H+ 
(expected mass 614), after 5 hrs even though it was in excess in the reaction mixture. This is 
probably due to hydrolysis to a carboxylic acid that has a mass of 487, below the 500 MW 
lower detection limit of this MALDI-TOF system112. Therefore it can be concluded that the 
PromoFluor 488 thioester 5 is able to undergo NCL under standard conditions. 
4.3.2 Rhodamine Red 
The ability of 7 to undergo NCL was also investigated by ligation to the N-terminal cysteinyl 
peptide, CLDFDLLK 8 in the same manner. Initial results showed that the standard four 
equivalents of thioester were insufficient to achieve complete labelling of peptide 8. 
Therefore ten equivalents of the thioester were used. MALDI-TOF analysis was carried out 
after 5 hrs. 
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Figure 4.9: MALDI-TOF analysis of the peptide NCL reaction of Rhodamine Red. (A) Rhodamine Red thioester 
7, with Rhodamine Red carboxylic acid breakdown product visible; (B) peptide 8; (C) desalted product 
obtained after an NCL reaction under modified conditions; 0.1M phosphate buffer, pH 7.2, tenfold excess of 
thioester, room temperature, 5 hrs. The main peak corresponds to the MH+, with the secondary peaks 
corresponding to the species plus Na
+
 and K
+
, and other peaks corresponding to thioester breakdown 
products. 
These results (Figure 4.9) show the successful completion of the NCL reaction between 
thioester 7 and peptide 8. After 5 hrs the MALDI-TOF trace shows the presence of a peak at 
1620 MW (Figure 4.9C) corresponding to the labelled peptide (MH+, expected mass 1620), 
and the absence of a peak at 967 MW (Figure 4.9B), corresponding to the starting peptide 
plus (MH+, expected mass 967). This shows that the reaction has gone to completion.  
There are peaks corresponding to thioester plus (MH+, expected 796) and the carboxylic acid 
(MH+, expected 669) of Rhodamine Red, as well as breakdown products. These are not only 
in the NCL reaction mixture (Figure 4.9C) but also in the thioester starting material (Figure 
4.9A).  This shows that the Rhodamine Red thioester is less stable than the PromoFluor 488 
thioester and subsequently is more susceptible to hydrolysis. This may be due to the 
internal basic group present in the molecule that could catalyse its hydrolysis156. The 
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breakdown of the thioester 7 is the reason why an apparent increased excess (to ten 
equivalents) is required for complete ligation to peptide 8 via NCL.  
PromoFluor 488 thioester 5 and Rhodamine Red thioester 7 can be successfully used to 
label an N-terminal cysteine peptide via NCL. However the stability of 7 means that an 
increased quantity of starting material is needed to achieve the standard amount of 
thioester in situ for NCL. These results highlight the importance of testing thioester with 
peptides before protein labelling occurs to ascertain the required conditions, especially if 
the thioester is susceptible to hydrolysis.  
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4.4 Protein Labelling 
PromoFluor 488 thioester 5 and Rhodamine Red thioester 7 are suitable labels for NCL in 
peptides. In order to verify their usefulness for protein labelling, they will be attached to an 
N-terminal cysteinyl protein via NCL. The conditions used for peptide labelling will be used 
for the protein labelling. The protein that will undergo NCL is C-PH. This is generated from 
the GST-PAKQC-PH fusion protein by 3Cpro, as detailed in Section 2.4. C-PH is known to 
undergo NCL and has been characterised by both SDS-PAGE and MALDI-TOF111. Therefore 
the success of labelling by 5 and 7 can be easily assessed. 
4.4.1 PromoFluor 488 Thioester 
1 mg of C-PH in was incubated with a four-fold excess 5 under the standard NCL conditions, 
with a forty-fold excess of the thiol 2 as a catalyst. This corresponds to the amount of label 
used in the peptide labelling experiment (Section 4.3.1). After the standard NCL reaction 
time of 5 hrs a sample of the reaction mixture was removed, desalted with C-18 tips and 
analysed by MALDI-TOF (Figure 4.10).  
 
Figure 4.10: MALDI-TOF analysis of the protein NCL reaction of PromoFluor 488. (A) C-PH protein; (B) 
desalted product obtained after an NCL reaction under standard conditions; 0.1M phosphate buffer, pH  7.2, 
fourfold excess of thioester, room temperature, 5 hrs. 
These results show that after 5 hrs the C-PH domain (expected mass 14,099, found 14,094) 
(Figure 4.10A) has been converted to a single product peak (Figure 4.10B). The mass of this 
peak corresponds to C-PH plus a PromoFluor 488 label (expected mass 14,571, found 
14,601), falling within the intrinsic error of protein MALDI-TOF analysis112. Moreover in this 
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trace there is no C-PH peak and only one product peak is observed. Therefore this shows 
that the thioester 5 can be successfully ligated onto C-PH under standard NCL conditions. 
4.4.2 Rhodamine Red Thioester 
1 mg C-PH was incubated with 10 equivalents of 7, as per the peptide labelling experiment 
(Section 4.3.2), under standard NCL conditions. A hundred fold-excess of the thiol catalyst 2 
was used due to the increase in the amount of thioester used. After time of 5 hrs a sample 
of the reaction mixture was removed, desalted with C-18 tips and analysed by MALDI-TOF 
(Figure 4.11).  
 
Figure 4.11: MALDI-TOF analysis of the protein NCL reaction of Rhodamine Red. (A) C-PH protein; (B) 
desalted product obtained after an NCL reaction under modified conditions; 0.1M phosphate buffer, pH 7.2, 
tenfold excess of thioester, room temperature, 5 hrs. 
These results for Rhodamine Red (Figure 4.11) mirror those found with the PromoFluor 488 
thioester. The C-PH domain (expected mass 14,099, found 14,094) (Figure 4.11A) has been 
converted to a single product peak (Figure 4.11B), corresponding to addition of a 
Rhodamine Red label (expected mass 14,753, found 14,729), and within the intrinsic error of 
protein MALDI-TOF analysis112. Therefore this shows that the thioester 7 can be successfully 
ligated onto C-PH under the revised NCL conditions found during peptide labelling. 
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These results show that both PromoFluor 488 (Section 4.4.1) and Rhodamine Red (Section 
4.4.2) can be attached onto C-PH in a selective manner via NCL. The conditions for these 
reactions were obtained directly from the peptide labelling studies (Section 4.3) and proved 
transferrable to protein labelling. Both thioesters 5 and 7 were able to undergo successful 
NCL in the expected controlled and site specific manner. Therefore two new NCL suitable 
fluorophores have been created.  
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4.5 Imaging 
4.5.1 Gel Imaging 
C-PH has been labelled by both PromoFluor 488 5 and Rhodamine Red 7 thioesters via NCL, 
as verified by MALDI-TOF analysis (Figure 4.10 and Figure 4.11). If these are to be used in 
imaging experiments, it is vital that these labels have made the protein fluorescent. This can 
be easily shown by fluorescent gel analysis. The protein samples are first run on standard 
SDS-PAGE denaturing gel. This is analysed on an Ettan DIGE imager from GE Healthcare, 
using the Cy2 and Cy 3 channels with excitation wavelengths of 465–495 and 525-555 
respectively. The image was processed using ImageQuant TL software. 
 
Figure 4.12: Fluorescent gel analysis of C-PH labelling via NCL. Lane 1 – PromoFluor 488; Lane 2 – Rhodamine 
Red. 
The two labelled proteins were successfully visualised by fluorescence from the gel (Figure 
4.12). The PromoFluor 488 label has produced a green fluorescent C-PH (Lane 1), whilst the 
Rhodamine Red labelling has resulted in a red fluorescent protein (Lane 2). This gel confirms 
the MALDI-TOF data (Figure 4.10 and Figure 4.11) that verified attachment of these groups 
to the protein C-PH via NCL. Moreover, the gel shows that this attachment of PromoFluor 
488 or Rhodamine Red results in fluorescent proteins that can be imaged. 
4.5.2 Fixed Cell Imaging 
These green and red fluorescent proteins can be used for cell imaging experiments. In order 
to demonstrate this, the fluorescently labelled C-PH proteins (Figure 4.12) were applied in a 
fixed cell imaging experiment. Cells were stimulated to produce the PIP3 ligand of the 
protein, fixed, stained and imaged105, as previously detailed in Section 2.6. 
Rhodamine Red 
PH domain
PromoFluor 488 
PH domain
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The NIH 3T3 mouse fibroblast cells, either stimulated with insulin or inhibited with LY, were 
then fixed in PFA and permeabilised by freeze/thaw. After blocking with BSA, the cells were 
stained with 1 µg/mL of either the PromoFluor488 PH domain or the Rhodamine Red PH 
domain for 1 hrs. Finally the cells were counterstained with the blue nuclear probe DAPI. 
The coverslips were then mounted on glass slides, sealed and dried overnight. The stained 
fibroblast cells were imaged using a Nikon TE2000 inverted fluorescence microscope and 
visualised in the DAPI and FITC channels for PromoFluor 488 or the TRITC channel for 
Rhodamine Red. Images were digitally acquired with a CCD camera for each fluorophore 
separately, and processed using IPLab software and ImageJ. 
 
Figure 4.13: Fixed cell imaging of PromoFluor 488 labelled PH-domain binding to PIP3 (green) in fibroblast 
cells, counter-stained with DAPI to show the nucleus (blue). (A) cells stimulated with insulin to produce PIP3. 
(B) cells inhibited with LY to prevent PIP3 production. 
The PromoFluor 488 labelled protein shows the characteristic binding of the PKB 
PH domain105 (Figure 4.13). In the insulin stimulated cells (Figure 4.13A) the protein (green) 
binds to PI(3,4,5)P3 and PI(3,4)P2 present on the cell membrane, as well as on organelles and 
vesicles within the cell. In the LY inhibited cells (Figure 4.13B), when the ligands are no 
longer present, this binding has been significantly decreased. In both cases the nuclei have 
been counterstained in blue.  
(A) (B)
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Figure 4.14: Fixed cell imaging of Rhodamine Red labelled PH-domain binding to PIP3 (red) in fibroblast cells, 
counter-stained with DAPI to show the nucleus (blue). (A) cells stimulated with insulin to produce PIP3. (B) 
cells inhibited with LY to prevent PIP3 production. 
The Rhodamine Red labelled PH domain also displays this characteristic binding pattern105 
(Figure 4.14). In the insulin stimulated cells (Figure 4.14A) the protein (red) binds to ligands 
present on the cell membrane, organelles and vesicles within the cell, whilst in the LY 
inhibited cells (Figure 4.14B) this binding almost completely knocked down. Once again the 
nuclei have been counterstained in blue.  
An interesting feature to note is that the background fluorescence level in the inhibited cells 
is much lower for the Rhodamine Red protein (Figure 4.14B) then the PromoFluor 488 
protein (Figure 4.13B). This is because cells autofluoresce at 488 nm157. Therefore when 
PromoFluor 488 is excited at this wavelength other components within the cell also 
fluoresce, increasing the background in the image taken. This is not seen at 560 nm, the 
wavelength used for Rhodamine Red.  
These results show that both PromoFluor 488 and Rhodamine Red proteins, fluorescently 
labelled via NCL, can be used in imaging experiments (Figure 4.13 and Figure 4.14). Both of 
these molecules are efficient fluorophores for the fixed cell imaging of the PH domain. The 
advantage of having two labels with different fluorescence is that the most suitable one can 
(A) (B)
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be chosen for a specific experiment. This can be seen in this experiment, with Rhodamine 
Red being the label of choice as it decreases the background seen when cells autofluoresce 
at 488 nm. Two distinct fluorescent labels also give the option of carrying out a multicolour 
experiment using two different proteins. 
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4.6 Further uses of proteins labelled with PromoFluor 488 and 
Rhodamine Red 
Green and red fluorescent proteins have been produced via NCL with 5 and 7 respectively 
(Section 4.5). These have been successfully used to determine protein localisation as shown 
in fixed cell imaging experiments (Section 4.5.2). It is also possible using software to turn 
these fluorescent images into numbers, in order to carry out quantitative, statistical analysis 
of these results158. However the usefulness of fluorescent labelled proteins extends beyond 
just imaging to a range of different techniques to further elucidate their function5. Two key 
examples of such assays are flow cytometry and FRET. 
4.6.1 Flow cytometry 
Flow cytometry is a method for counting, examining or sorting a stream of particles27 
(Section 1.2.4). This technique is often used to investigate cells on a single cell level, typically 
via fluorescently tagged probes to specific features of the cell42. The fluorescence emitted 
by cells passing through the beam can be detected and analysed to give information about 
the cell.  It is also possible to measure a number of wavelengths simultaneously allowing a 
number of different probes to be tested42. This fluorescence flow cytometry can also be 
used to sort cells, known as fluorescence-activated cell sorting (FACS)43. This involves the 
separating and then collecting the cells based on their fluorescence.  
Analysis of cells based on fluorescently bound probes relies on the homogenous nature of 
these probes159. In the case of flow cytometry the cell is characterised based not only on the 
emission wavelength but also on brightness, which is proportional to the amount of 
fluorophore present. NCL gives a reliable way of selectively labelling a protein with a single 
molecule, which is important for this application59. Therefore a protein fluorescently tagged 
by NCL that could probe for specific characteristics of a cell would be a useful tool for flow 
cytometry or FACS above and beyond simple cell imaging.  Moreover differentially tagged 
proteins, for example one with PromoFluor 488 and another with Rhodamine Red, could be 
used in conjunction with each other to probe and sort two features within one cell.  
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4.6.2 FRET 
Förster Resonance Energy Transfer (FRET) is a technique that can be used to quantify the 
distance between two fluorophores38 (Section 1.2.3). The principle behind FRET is that 
excitation of one fluorophore, the donor, is transferred by resonance to the other, the 
acceptor, without the emission of a photon. This can only occur if the emission spectrum of 
the donor overlaps with the absorption spectrum of the acceptor, and when two groups are 
within 100 Å of each other38. Therefore this is a very useful technique for binding studies39. 
The two fluorophores are coupled to potentially interacting partners and their proximity to 
each other can be measured by FRET40.  
FRET is based on energy transfer between a donor molecule and an acceptor molecule38. 
Therefore it is important when performing FRET calculations that there is only one 
fluorophore on the species being studied, as non-specific multiple labelling can distort the 
results. It is also important to know the position of the fluorophore as this will allow a more 
accurate prediction of the distance between the two groups if binding does occur39.  
Therefore an ideal way of labelling proteins for FRET studies, provided that their N-terminus 
is not required for binding or activity, is via NCL. In fact there is a high overlap between the 
emission spectrum of PromoFluor 488148 and the excitation spectrum of Rhodamine Red149, 
so these two molecules can be used as a FRET pair. The thioesters 5 and 7 can be used to 
fluorescently label two difference proteins using NCL, that can then be investigated using 
FRET. 
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4.7 Conclusion 
This chapter has concentrated on the expansion of this 3Cpro/NCL labelling strategy111, as 
well the use of NCL in general for protein labelling, by initial development of a 
thioester-based labelling library. The work has specifically focused on two fluorophores, the 
green PromoFluor 488148 and the red Rhodamine Red149. These have been successfully 
developed into imaging labels suitable for NCL. In addition they have been synthesised and 
ligated onto a protein using standard protocols so this library can easily be extended to 
other labels. 
The thioesters of both fluorophores were synthesised using the standard thioester 
protocol74. Each thioester was generated in the expected yield, with no need to optimise the 
reaction (Section 4.2). This suggests that this methodology is transferable and may be used 
in the future to generate further thioesters for the library. 
Peptide studies, using an N-terminal cysteinyl peptide, were performed to determine the 
conditions required for NCL (Section 4.3). It was found that the standard four-fold excess of 
thioester59 was suitable for PromoFluor 488 (Figure 4.8) but a larger ten-fold excess was 
necessary for Rhodamine Red (Figure 4.9). This requisite increased amount is due to the 
instability of the latter thioester. It is important to carry out this preliminary test because 
the propensity of the Rhodamine Red thioester to hydrolyse has implications for long-term 
storage as well as the reactivity of the label. 
The two thioesters were successfully attached to the protein C-PH via NCL, as determined 
by MALDI-TOF analysis (Section 4.4). It was found that the conditions required for peptide 
NCL were directly transferable to protein NCL. This illustrates the usefulness of carrying out 
the initial peptide screening of thioesters, since the data collected can be used to 
characterise the NCL reaction quickly and effectively in preparation for protein labelling. 
The labelling of C-PH with PromoFluor 488 and Rhodamine Red produced green and red 
fluorescent proteins respectively. This was demonstrated by the fluorescent gel analysis of 
the protein after NCL (Figure 4.12). The value of generating fluorescently labelled proteins 
was exemplified by using these proteins in a fixed cell imaging experiment105, which showed 
the localisation of the PH domain in different physiological conditions (Figure 4.13 and 
Figure 4.14).  
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These two labels are useful additions to the 3Cpro/NCL labelling strategy. The choice of more 
than one fluorophore allows the use of the most suitable reagent in a given situation as well 
as the option of carrying out multicolour imaging experiments. These labels have further 
value since they could potentially also be used for quantitative assays above and beyond cell 
imaging that require the controlled and site-specific fluorescent labelling of proteins. 
Examples of this could include flow cytometry27 as well as FRET experiments38. 
In this chapter some initial components of a labelling library have been created via the 
development of PromoFluor 488 and Rhodamine Red thioesters. Moreover these NCL 
suitable labels have been generated and validated using standard procedures. This will 
facilitate the growth of this library to encompass a rainbow of imaging labels, suitable for a 
wide range of fluorescent applications. 
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4.8 Materials and Methods 
4.8.1 Reagents and Equipment 
PromoFluor 488-NHS ester was purchased from PromoKine, Rhodamine Red thioester was 
purchased from Invitrogen and MESNa was bought from Sigma Aldrich. Protected amino 
acids, peptide reagents and all resins were purchased from National Diagnostics and Merck 
Biosciences. SDS-PAGE equipment, gels, and reagents Eppendorf® PerfectPure C-18 tips 
were purchased from VWR. NIH 3T3 fibroblasts cells were purchased from the American 
type culture collection, coverslips from VWR, DAPI from molecular probes and all other 
reagents for the fixed-cell imaging from Sigma Aldrich. 
HPLC was carried out on a Gilson system with 322 Pump, a 234 Autoinjector and 151 UV/vis 
detector. Purification via HPLC was carried out on a Gilson semi-preparative RP-HPLC system 
equipped with 306 pumps and a Gilson 151 UV/vis detector. Both systems were fitted with 
an ACE 5 C18 column (250x4.6 mm) and a SecurityGuard cartridge system (C18, 4x3.0 mm). 
The purity was determined from the peak integration of the analytical trace. For peaks 
integrating more than 98% the purity is stated as >98%. Masses were determined by MALDI-
TOF using the Micromass MALDI-TOF. High resolution MS (HRMS) was found by ESI-TOF-MS. 
Melting point determination was carried out on Standford Reaserch Systems Optimelt. 
Automated peptide synthesis was carried out on an Advanced ChemTech Apex 396 multiple 
peptide synthesiser.  
Fluorescent gels were analysed on an Ettan DIGE imager from GE Healthcare, using the Cy2 
and Cy 3 channels. Fluorescence in cells was imaged in the DAPI and FITC channels, using a 
Nikon TE2000 inverted fluorescence microscope, captured on a Hamamatsu camera and 
processed using IPLab software and ImageJ. 
4.8.2 Thioester Synthesis 
PromoFluor 488-MES Thioester 5
74  
10 mgs, 16 µmol PromoFluor 488 4 in 0.25 mL DMF was combined with 29 mg, 176 µmol 2 
in 5 mL sodium borate buffer (0.1M, pH 8.3) and stirred at room temperature for 2 hrs. The 
orange solution was purified by reverse phase HPLC and lyophilised into 0.2 mg aliquots. 
6 mg, 10 µmols, of an orange solid (63%) 5 was obtained. Rt = 12.5 mins (2-100 MeCN in 
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H2O over 20 mins), purity >98%; Absorption spectra λ
ex 493, λem 518; Melting point not 
obtained, decomposes at 252°C; HRMS (ESI) 614.116 (requires 614.108).  
Rhodamine Red-MES Thioester 7
74
  
10 mgs, 13 µmol Rhodamine Red 6 in 0.25 mL DMF was combined with 29 mg, 176 µmol 2 in 
5 mL sodium borate buffer (0.1M, pH 8.3) and stirred at room temperature for 2 hrs. The 
pink solution 7 was purified by reverse phase HPLC and lyophilised into 0.2 mg aliquots. 
6.4 mg, 8 µmols, of a red solid (62%) was obtained. Rt = 14.1 mins (2-100 MeCN in H2O over 
20 mins), purity 85%; Absorption spectra λex 558, λem 581; Melting point not obtained, 
decomposes at 231°C; HRMS (ESI) 794.192 (requires 794.192).   
4.8.3 Peptide Labelling 
Peptide Synthesis160 
Peptide CLDFDLLK 8 was synthesised using the Fmoc/tBu Solid Phase Peptide Synthesis 
technique. Fmoc was used for N-α-amino acid protection, with the chain being built up from 
the C-terminus. Side chain protecting groups of amino acids used were tBu (aspartic acid), 
Trt (cysteine) and Boc (lysine).  
25 μmol amino acid-loaded Wang resin was swelled in peptide grade DMF for 1 hr prior to 
the start of synthesis. Elongation of the peptide chain begins with deprotection of the Fmoc 
group via 20% (v/v) piperidine in DMF. The next amino acid (125 μmol) was coupled by 
HOBt/HBTU “in situ” activation (125 μmol, 1:1), and DIPEA (250 μmol). The cycle was 
repeated for the entire peptide with extensive deprotection, the peptidyl-resin was washed 
in 3 x DMF, 3 x DCM and 3 x MeOH before being dried in vacuo. 
Simultaneous side chain deprotection and cleavage from the resin was carried out in 1 mL 
TFA:H2O:EDT:TIS (94:2.5:2.5:1) for 2 hrs. The solution was filtered and the resin washed with 
the TFA mixer. The filtrate was precipitated and washed (x3) in cold TBME, centrifuged 
(4000 rpm, -4°C, 10 mins) and the supernatant discarded. The crude peptide was dried in 
vacuo overnight and purified using reverse phase HPLC.  
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PromoFluor 488 Peptide Labelling111 
0.2 mg, 300 nmol 5 was added with 0.14 mg, 70 µmols peptide 8 in 100 µL phosphate buffer 
(0.1M, pH 7.4). This was incubated at room temperature for 5 hrs. A sample was analysed by 
reverse phase HPLC and, after desalting with Eppendorf® PerfectPure C-18 tips, by MALDI-
TOF.  
Rhodamine Red Peptide Labelling 111 
0.8 mg, 700 nmol 7 was added with 0.14 mg, 70 µmols peptide 8 in 100 µL phosphate buffer 
(0.1M, pH 7.4). This was incubated at room temperature for 5 hrs. A sample was analysed by 
reverse phase HPLC and, after desalting with Eppendorf® PerfectPure C-18 tips, by MALDI-
TOF.  
4.8.4 Protein Labelling 
Expression of the GST-PAKQC-PH protein 
The GST-PAKQC-PH protein was expressed using the standard methodology developed in 
Chapter 2, see Section 2.8.2 for full details. 
PromoFluor 488 Protein Labelling111 
0.2 mg, 300 nmol 5 and 0.2 mg, 1.2 µmol 2 was added to 1 mg, 70 nmol C-PH in 100 µL 
phosphate buffer (0.1M, pH 7.4). This was incubated at room temperature for 5 hrs. A 
sample was desalted with Eppendorf® PerfectPure C-18 tips and analysed by MALDI-TOF. A 
sample was also analysed on SDS-PAGE and the fluorescence visualised using an Ettan DIGE 
imager from GE Healthcare, in the Cy 2 channel with the excitation wavelength of 465–495. 
The image was processed the ImageQuant TL software. 
Rhodamine Red Protein Labelling111 
0.8 mg, 700 nmol 7 and 0.5 mg, 2.8 µmol 2 was added to 1 mg, 70 nmol C-PH in 100 µL 
phosphate buffer (0.1M, pH 7.4). This was incubated at room temperature for 5 hrs. A 
sample was desalted with Eppendorf® PerfectPure C-18 tips and analysed by MALDI-TOF. A 
sample was also analysed on SDS-PAGE and the fluorescence visualised using an Ettan DIGE 
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imager from GE Healthcare, in the Cy 3 channel with the excitation wavelength of 525-555. 
The image was processed the ImageQuant TL software. 
4.8.5 Fixed Cell Imaging 
Coverslip and cell preparation 
Poly-L-lysine coated coverslips were prepared; see Section 2.8.2 for full details. 
NIH 3T3 fibroblast cells were prepared and either stimulated with 500 µL, 1 µg/mL of insulin 
or inhibited with 500 µL, 50µM LY; see Section 2.8.2 for full details 
Fixing and staining105 
The cells were fixed in 4% (w/v) PFA for 10 mins and washed in 3 x 500 µL PBS. The fixed 
cells were then permeabilised by 3 x freeze/thaw cycles at -78°C/37°C. Non-specific protein 
interactions were blocked with 500 µL 3% (w/v) BSA / PBS for 1 hr at room temperature, 
followed by 3 x 500 µL PBS washes. Cells were then incubated with the 100 µL 1 µg/mL 
PromoFluor 488-PH domain or Rhodamine Red-PH domain for 1 hrs, followed by 3 x 500 µL 
PBS washes. Nuclear counterstaining was carried out using 100 µL 1 µg/mL DAPI for 
10 mins. Coverslips were thoroughly washed in 10 x PBS and 1 x H2O.   
Imaging105  
The coverslips were mounted on glass slides using Mowiol supplemented with 0.6% (w/v) 
DABCO, sealed and dried overnight. The cells were imaged using a Nikon TE2000 inverted 
fluorescence microscope. The fluorescence was imaged on the microscope using a 100x 
Fluor oil lens, in the DAPI channel with excitation wavelength of 340–380, and the FITC 
channel with excitation wavelength of 465–495 for PromoFluor 488 or the TRITC channel 
with excitation wavelength of 540-580 for Rhodamine Red.  Images were digitally acquired 
with a CCD camera (Hamamatsu) for each fluorophore separately and processed using IPLab 
software and ImageJ. 
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Chapter 5 Using the 3Cpro/NCL System for Pull Down Studies 
 
It has been shown in this thesis that the 3Cpro/NCL strategy is a useful approach for 
protein labelling. It has been successfully applied to the generation of fluorescent 
proteins using a standardised methodology. This chapter will expand the utility of this 
reaction by looking at two issues:- 
• Can this 3Cpro/NCL labelling strategy be transferred to the affinity labelling of 
proteins? 
• In it possible to use this site-specific reaction to selectively label a single protein 
within a protein mixture? 
This work will look at the addition of biotin and accompanying protocols to the 
thioester labelling library that has been developed so far.    
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5.1 Biotin in Molecular Biology 
Biotin, or vitamin H, is an essential enzyme cofactor50. It has a key role in the transfer of 
carbon dioxide in carboxylase enzymes and as such is a vital component of fatty acid 
synthesis and the citric acid cycle.  Biotin is found both in animal and vegetable food 
sources, though a significant proportion of the body’s biotin is biosynthesised by intestinal 
microflora. 
 
Figure 5.1: Structure of the avidin tetramer binding biotin
161
. The protein is made up of four identical 
subunits in a dimer of dimers (cyan/blue and magenta/red). The four bound biotin molecules are shown in 
yellow.  
An interesting feature of biotin is its very high affinity for the protein avidin51. Avidin has 
four identical subunits and each binds to biotin with a binding constant of 1015M−1 (Figure 
5.1). Different technologies have been developed to exploit this extremely strong yet 
non-covalent bond51. Biotin is attached to known or unknown proteins of interest, and can 
be indentified and/or characterised using a range of tools based on avidin161 or analogues 
streptavidin161 and neutravidin162 (Section 1.3.1).   
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One simple yet very effective way of using the biotin-avidin system is using affinity-pull 
down studies163. If a protein mixture is passed though immobilising (strept)avidin beads, 
only the biotinylated proteins will bind. This can be used to purify biotinylated proteins from 
a mixture, which can then be eluted164 and identified using standard techniques like gel 
analysis or mass spectroscopy112. An example of this is the biotinylation and subsequent 
pull-down of membrane proteins in latent and parental HIV infected cells, resulting in the 
potential discovery of new biomarkers of the virus165. Alternatively, a known biotinylated 
protein can be allowed to interact with a protein mixture and then extracted from the 
mixture along with any binding partners present163. This has been used to identify several 
distinct transcription factor complexes by simply biotinylating one protein, the 
hematopoietic transcription factor GATA-1166. 
In more advanced applications the biotin-avidin system can be used to visualise and/or 
quantify a target protein51. This in acheived by the indirect method of binding the avidin to a 
biotinylated protein and then using an avidin antibody to visualise the complex via its 
conjugation with a probe, either a fluorescent tag or an appropriate enzyme. Alternatively 
the probe can be directly coupled onto the avidin. Typically the indirect method is more 
sensitive whereas the direct approach is quicker and more economical54. This has been used 
in a wide range of techniques167: cell imaging of a biotinylated protein168, identification of 
the protein on a gel via western blotting169, and quantification of a specific protein by 
ELISA170.  
A biotin thioester would be a very useful addition to the 3Cpro/NCL labelling library, as this 
would facilitate the facile, site-selective biotinylation of an N-terminal cysteine protein71. A 
biotin label would serve to expand the use of this strategy beyond fluorescence. By utilising 
its strong affinity to avidin, this would allow a range of new investigations to be carried out 
on the target protein. 
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5.2 Biotin Thioester  
An analogue of biotin containing a thioester was synthesised using the standard thioester 
generation protocol74 (Section 4.2.1). This involves taking an activated ester derivative of 
the label, an NHS ester, and reacting it with eleven equivalents of a suitable thiol, MESNa 2, 
to generate the thioester. This method has been successfully used to generate thioesters of 
carboxyfluorescein 3 (Section 2.1), PromoFluor 488 5 (Section 4.2.2) and Rhodamine Red 7 
(Section 4.2.3), and will now be employed on biotin (Figure 5.2). 
 
Figure 5.2: Reaction scheme for synthesis of the biotin thioester 10 from biotin NHS ester 9 using MESNa 2. 
The reactants were incubated in 0.1 M sodium borate buffer, pH 8.3, for 2 hrs at room temperature. 
The biotin thioester 10 was synthesised using the standard conditions for thioester 
generation74, (Figure 4.4). The reaction was monitored by RP-HPLC on a C-18 column using a 
2-98% water/acetonitrile gradient. The wavelength used was 203nm, which has been shown 
to be the optimal wavelength for detecting biotin171.  
The HPLC data (Figure 5.3) showed that the reaction was complete after 2 hrs. 10 was 
purified by RP-HPLC using the same conditions and lyophilised directly into 32 Eppendorf 
aliquots, each containing 0.2 mg, and stored at -20°C. The identity of the product was 
verified by ESI mass spectrometry. 
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Figure 5.3: Reaction scheme of biotin thioester synthesis. Section of HPLC traces for conversion of (A) biotin 
NHS ester 9 to (B) biotin thioester 10. The starting material was incubated with 2 for 2 hrs at room 
temperature to generate the thioester. The traces were obtained on a C-18 reverse phase column using a 2-
98% water/acetronitrile solvent gradient, at a wavelength of 203nm. 
This experiment shows that the biotin thioester 10 can be successfully synthesised using the 
standard thioester generation method. The yield of this reaction after purification was 6.4 
mgs (59%); this is in line with the other thioester labels that have been generated by this 
procedure.  
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5.3 Peptide Labelling 
The suitability of 10 for labelling was determined by ligation to the N-terminal cysteinyl 
peptide, CLDFDLLK 8 under standard NCL conditions59, as described in Section 4.3.  It has 
been found be necessary to test the reaction in this way as some thioesters have lower 
stability and therefore require modified conditions. The importance of this was 
demonstrated by Rhodamine Red thioester 7 (Section 4.4.2), where the peptide reaction 
identified the need for an increased concentration of the label to achieved the desired 
result.  
Peptide 8 was labelled with four equivalents of the thioester 10. They were incubated in 
phosphate buffer under standard NCL conditions. After 5 hrs a sample of the reaction was 
taken, desalted with C-18 tips and analysed by MALDI-TOF (Figure 5.4).  
 
Figure 5.4: MALDI-TOF analysis of the peptide NCL reaction of biotin. MALDI-TOF traces of the NCL reaction 
between a cysteine N-terminal peptide 8 and the biotin thioester 10. (A) peptide 6; (B) desalted product 
obtained after an NCL reaction under standard conditions; 0.1M phosphate buffer, pH 7.2, fourfold excess of 
thioester, room temperature, 5 hrs. The main peak corresponds to the mass +1 (MH
+
), with the secondary 
peaks corresponding to the species plus Na
+
 and K
+
. 
These results (Figure 5.4) show the successful completion of the NCL reaction between 
thioester 10 and peptide 8. After 5 hrs the MALDI-TOF trace shows the presence of a peak at 
1197 MW (Figure 5.4B), corresponding to the labelled peptide (MH+, expected mass 1197) 
and the absence of a peak at 967 MW (Figure 5.4A) corresponding to the starting peptide 
(MH+, expected mass 967), showing that the reaction has gone to completion. There is no 
peak corresponding to 10 because it has a mass of 367 which is below the 500 MW 
750 1000 1250 1500 1750500
967
750 1000 1250 1500 1750500
1197
(A) Peptide 8
(B) Biotin NCL Product
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detection limit of this MALDI-TOF system112. Therefore it can be concluded that the biotin 
thioester 10 is able to undergo NCL under standard conditions. A four-fold excess of 10 
completely and specifically labelled an N-terminal cysteine peptide 8 in 5 hrs.  
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5.4 Protein Labelling 
Biotin thioester 10 is a suitable label for NCL in peptides. The conditions required for 
peptide NCL have been transferable to protein labelling with the other thioesters used in 
this thesis (Section 2.5 and Section 4.4). Therefore the conditions used for peptide labelling 
(Section 5.3) were used for protein labelling with 10 via NCL. This is generated from the GST-
PAKQC-PH fusion protein by 3Cpro, as detailed in Section 2.4, once again allowing direct 
comparison with the existing NCL thioester labels. 1 mg of C-PH in was incubated with a 
four-fold excess 10 under the standard NCL conditions, with a sixteen-fold excess of the 
thiol 2 as a catalyst. The reaction was incubated at room temperature for 5 hrs under 
standard NCL conditions.  
5.4.1 MALDI-TOF verification  
MALDI-TOF has proved a useful technique for analysing the success of NCL labelling. After 
the 5 hrs, a sample of the NCL was removed and desalted with C-18 tips. This was analysed 
by MALDI-TOF and compared to the spectrum obtained from C-PH111 (Figure 5.5).  
 
Figure 5.5: MALDI-TOF analysis of the protein NCL reaction of biotin. MALDI-TOF traces of the NCL reaction 
between C-PH and the biotin thioester 10. (A) C-PH protein; (B) desalted product obtained after an NCL 
reaction under standard conditions; 0.1M phosphate buffer, pH 7.2, fourfold excess of thioester, room 
temperature, 5 hrs. 
These results show that after 5 hrs the C-PH domain (expected mass 14,099, found 14,094) 
(Figure 5.5A) has been converted to a single product peak (Figure 5.5B). The mass of this 
peak corresponds to C-PH plus a biotin label (expected mass 14,329, found 14,334), falling 
within the intrinsic error of the protein MALDI-TOF analysis 112. Moreover in this trace there 
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is no C-PH peak and only one product peak is observed. The standard NCL conditions used 
for peptide labelling have once again been successfully transferred to protein labelling. 
Therefore this shows that the thioester 10 can be ligated onto C-PH in a controlled, 
site-specific manner via NCL.  
5.4.2 Western blot verification 
Western blotting is an analytical technique used to identify specific proteins from within a 
mixture172. It involves running the proteins on a gel and then transferring them onto a 
nitrocellulose membrane. The target protein is then visualised using a specific probe. In the 
case of biotin a Neutravidin-HRP probe is used: neutravidin is an analogue of avidin and as 
such has a high and specific affinity to biotin162. As a conjugate the HRP it can be detected 
by a chemiluminescent reaction without the need for a secondary probe173.  
Western blot analysis was performed on the product of the protein NCL reaction to confirm 
that C-PH had been labelled with biotin172. A sample of C-PH and the NCL reaction product 
were run on a standard SDS-PAGE and then transferred onto a nitrocellulose membrane at 
20V for 26 mins. After the blocking of non-specific binding with, the membrane was 
subsequently probed with Neutravidin-HRP conjugate. Finally the membrane was visualised 
using an HRP substrate to produce a chemiluminescent product174, and imaged using a CCD 
camera. 
 
Figure 5.6: Western blot analysis of the protein NCL reaction of biotin. Lane 1 – C-PH; Lane 2 – NCL reaction 
mixture after 5 hrs. The samples were run on a 12 % SDS-PAGE at 180 mV for 30 mins and (A) transferred 
onto a nitrocellulose membrane at 20V for 26 mins, detected by a Neutravidin-HRP probe and visualised by 
chemiluminescence; (B) visualised by Coomassie Blue staining. 
This result (Figure 5.6) shows that a biotin tag has been ligated onto the protein C-PH. The 
neutravidin Western blot (Figure 5.6A) shows the presence of a band after the NCL reaction, 
which is not present in the C-PH starting material. Equal protein loading of the two samples 
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is verified by the Coomassie stain of the gel (Figure 5.6B). These results corroborate the 
MALDI-TOF data (Figure 5.5), confirming that the biotin thioester 10 has been successfully 
incorporated into C-PH. This also shows that a neutravidin Western blot can be used to 
indicate the presence of biotin on a protein can therefore be used to monitor subsequent 
biotin NCL reactions. 
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5.5 Labelling in a protein mixture 
The use of biotin NCL can be taken a step beyond simply labelling a sample of purified 
protein. A key advantage of tagging a protein with biotin is that it can then be separated 
from a protein mixture to identify its binding partners163. NCL is a site-specific reaction that 
will attach a thioester moiety only onto an N-terminal cysteine59. As long as there is only 
one such protein, there is no reason why this labelling cannot occur within a protein 
mixture. This would simplify the biotin pull down experiment, as there would be no need to 
carry out a separate NCL step, and also allow the proteins to interact in their native state 
before a tag is attached.   
5.5.1 Initial results 
An NCL reaction was carried out using biotin thioester 10 on a protein mixture containing 
C-PH. 0.1 mg of C-PH was added to a protein mixture comprising of E. coli cell lysate 
obtained from an earlier protein expression, giving a final protein concentration of 5 mg/mL. 
This was incubated with four equivalents of 10 and forty equivalents of thiol 2, for 16 hrs at 
4°C. These modified conditions were used to ensure that any native proteases present in the 
lysate did not digest the C-PH or other proteins.  
 
Figure 5.7: Western blot analysis of the initial biotin NCL reaction on a protein mixture. The samples were 
run on SDS-PAGE at 180 mV for 30 mins and (A) transferred onto a nitrocellulose membrane at 20V for 26 
mins, detected by a Neutravidin-HRP probe and visualised by chemiluminescence; (B) visualised by 
Coomassie Blue staining. 
This experiment was analysed by a western blot (Figure 5.7), as this is an ideal technique for 
the differentiation of a specific protein from within a mixture172. The probe for this was 
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neutravidin-HRP, as it has been shown to successfully visualise the NCL biotinylated C-PH, 
(Section 5.4.2). This neutravidin western blot analysis (Figure 5.7A) shows a very high degree 
of non specific labelling, with the amount protein visualised almost comparable to the 
Coomassie Blue stain (Figure 5.7B). Therefore, using these standard NCL quantities of 
reagents 10 and 2, it is not possible to specifically label the protein C-PH.  
5.5.2 Non-specific binding 
The initial biotin NCL experiment to label C-PH with 10 in a protein mixture proved 
unsuccessful (Section 5.5.1). This is due to the high level of non-specific binding of biotin to 
the other proteins present. However NCL is supposed to be a highly selective reaction with 
only an N-terminal cysteine residue being able to undergo ligation to the thioester. How is it 
then that multiple proteins appear to be labelled under these standard NCL conditions? 
The reason for the observed phenomenon of non-specific labelling can be understood by 
looking at the NCL mechanism62, see Section 1.5.1 for full details. The first step is a 
transthioesterification reaction which takes place between the thioester and the thiol group 
of a cysteine residue. This is followed by an acyl transfer of the label onto the protein. The 
specificity is conferred onto the NCL reaction by this second step, which can only occur 
when the cysteine residue is on the N-terminus of the protein and therefore has a free 
amino group. Therefore the reason for the non-specific labelling must lie in the first step.  
The initial transthioesterification step of NCL can occur at any cysteine present in the 
reaction62. This will result in the reversible attachment of the label onto these residues. The 
thiol 2 is present to combat this62. As the reaction is reversible, 2 can regenerate the 
thioester until it reacts with the N-terminal cysteine and undergoes irreversible ligation. 2 is 
added to the NCL reaction in a forty-fold excess with respect to the protein under standard 
conditions74. This is adequate for the few cysteine residues present in a protein, as seen 
with C-PH111 which itself contains two internal cysteines as well as the one on the 
N-terminus109. However there are multitudes of cysteine residues present within a mixture 
of proteins. Therefore it is likely that there is insufficient 2 present to prevent the non-
specific protein labelling that occurs via transthioesterification of the thioester onto the 
thiol of internal cysteine residues. 
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5.5.3 Increased MESNa concentration 
It has been hypothesised that the non-specific binding observed in an NCL reaction within a 
protein mixture (Figure 5.7) is due to insufficient amounts of 2, see Section 5.5.2. In order to 
test this, the effect of increasing the concentration of 2 was investigated.  The NCL reaction 
between biotin 10 and C-PH will be carried out in the same protein lysate mixture and using 
the same conditions as in the initial experiment, except in this case a range of 2 
concentrations will be explored. 
The NCL reaction was carried out using biotin thioester 10 on a protein mixture containing 
C-PH at four different thiol 2 concentrations. The C-PH / protein mixture was incubated with 
2 at a molar excess of one hundred, two hundred, four hundred and eight hundred 
respectively. The thioester 10 was added to each of these reactions in a four-fold excess for 
16 hrs at 4°C.  
 
Figure 5.8: Western blot analysis of the effect of MESNa on the biotin NCL reaction on C-PH in a protein 
mixture. MESNa concentration excesses, with respect to the protein C-PH, of Lane 1 - 100x; Lane 2 - 200x; 
Lane 3 - 400x; Lane 4 - 800x. The samples were run on 12% SDS-PAGE at 180 mV for 30 mins and (A) 
transferred onto a nitrocellulose membrane at 20V for 26 mins, detected by a Neutravidin-HRP probe and 
visualised by chemiluminescence; (B) visualised by Coomassie Blue staining.  
The results of the MESNa concentration experiment were analysed using a neutravidin 
Western blot (Figure 5.8A), with the Coomassie stain (Figure 5.8B) showing the equal 
loading of the protein samples.  This analysis shows that, as expected, the amount of 2 
affects the NCL reaction; an increase in thiol concentration causes a decrease in biotin 
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labelling. However the results did not show the predicted decrease in non-specific labelling, 
but instead in an overall decrease. Therefore increasing the concentration of 2 diminishes 
the ability of the thioester 10 to bind to proteins. 
The thiol catalyst appeared to decrease the binding efficiency of the thioester in NCL. The 
role of thiol is to regenerate the thioester upon binding to an internal cysteine residue via 
the reversible transthioesterification reaction62. Whilst the correct level of 2 will prevent 
non-specific binding, too much will push this equilibrium far over to the left. This results in a 
significant amount of the label remaining as a MES-thioester and therefore retards the 
reaction.  Consequently not only does an increase in 2 fail to prevent non-specific binding, it 
decreases the rate of the rate of protein labelling. Therefore raising the concentration of the 
thiol catalyst in an NCL reaction will not result in the successful site selective labelling of a 
protein. Moreover the correct level of thiol is vital to ensure that the reaction proceeds at 
all. 
5.5.4 Dialysis 
Theoretical and experimental analysis of NCL in a protein mixture suggests that the level of 
MESNa needs to be high enough to overcome the non-specific binding (Section 5.5.2), but 
also be low enough in order to allow labelling to happen (Section 5.5.3). This can be 
achieved by carrying out the reaction in two stages. Firstly the standard NCL will take place 
between 10 and protein mixture containing C-PH. This will allow the biotin to attach onto 
the N-terminus. Then the reaction mixture will be dialysed into a high MESNa concentration 
buffer, containing 100 mg/mL 2, to wash away the remaining reversibly bound label.  
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Figure 5.9: Western blot analysis of biotin NCL reaction in a protein mixture, followed by the dialysis into a 
high MESNa buffer. Lane 1– protein lysate mixture spiked with C-PH; Lane 2 – protein mixture after NCL with 
biotin under standard NCL conditions; Lane 3 - protein mixture after NCL with biotin and dialysis into 100 
mg/mL MESNa buffer. The samples were run on 12% SDS-PAGE at 180 mV for 30 mins and (A) transferred 
onto a nitrocellulose membrane at 20V for 26 mins, detected by a Neutravidin-HRP probe and visualised by 
chemiluminescence; (B) visualised by Coomassie Blue staining.  
A neutravidin Western blot analysis shows the conditions required for NCL in a protein 
mixture (Figure 5.9A). The biotin NCL reaction, carried out under standard conditions 
(Lane 2), results in non-specific labelling of the protein mixture. However subsequent 
dialysis into the thiol buffer (Lane 3) removed this to leave the biotinylated C-PH. Other faint 
bands present after dialysis are attributed to a background level of biotin, as seen in the 
pre-NCL protein mixture (Lane 1). The Coomassie stain (Figure 5.9B) demonstrates the equal 
loading of the protein samples. 
The two step approach to NCL in a protein mixture has proved successful, reconfirming the 
key role of the thiol catalyst within the reaction. The standard MESNa excess allowed the 
irreversible ligation to occur, and the dialysis served to wash off any reversibly and non-
specifically bound biotin. This work has resulted in the development of a protocol for the 
selective labelling of a single protein from within a mixture via NCL.  
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5.6 3Cpro/NCL labelling in a crude cell lysate mixture 
3Cpro is a highly selective protease that can cleave the sequence PAKQC (Section 2.4.1), 
whilst NCL can be used to label just one protein in a cell lysate (Section 5.5.4). Therefore it 
should be possible to take advantage of these two specific reactions; to cleave a fusion 
protein with 3Cpro to generate a cysteine N-terminus and subsequently tag it with biotin 
from within a mixture of proteins.  
The first stage of this approach is to cleave the GST-PAKQC fusion protein in the crude cell 
lysate. The protein was expressed by BL21 (DE3) cells, transformed with the pGEX_3C_PH 
plasmid and grown in 0.5 L autoinduction media, and lysed, see Section 2.3.2 for further 
details. The cell lysate was kept at 4°C for the remainder of the experiment. Previous studies 
have shown that at this temperature 3Cpro is still active, achieving complete cleavage of a 
PAKQC fusion protein in 16 hrs when used at an increased concentration175. The crude 
lysate contains approximately 1 mg of fusion protein, so 25 µL of 200 µM 3Cpro was added. 
This gives a molar ratio of 1:5, an increase on the standard 1:25 ratio. The mixture was then 
incubated at 4°C overnight.  
 
Figure 5.10: 3C
pro
 cleavage of GST-PAKQC-PH in a protein mixture. Lane 1 - cell lysate from E. coli expressing 
the fusion protein; Lane 2 – cell lysate after incubation with 3C
pro
 at 4°C for 16 hrs. The 12% gel was run at 
180 mV for 30 mins and visualised by Coomassie Blue staining.  
GST-PAKQC-PH was cleaved by 3Cpro whilst within a protein mixture (Figure 5.10). The 
SDS-PAGE gel shows that the fusion protein present in the cell lysate (Lane 1) has been 
digested by the protease (Lane 2). This result verified other studies done on 3Cpro, showing 
that the protease can cleave at the site PAKQC at low temperatures; a 1:5 molar ratio 
resulted in complete cleavage of the fusion in 16hrs at 4°C. 
3Cpro
GST-PAKQ
GST-PAKQ -PH
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The N-terminal cysteinyl protein present in the cell lysate can now undergo NCL with the 
biotin thioester 10. This will not only show that GST-PAKQC-PH has been processed by 3Cpro 
in the protein mixture to produce C-PH, but also validate the NCL/dialysis conditions 
developed in Section 5.5. 0.5 mL of the lysate/cleavage mixture, containing approximately 
20 µg C-PH, was incubated with four equivalents of 10 and forty equivalents of 2 under the 
modified conditions of 16hrs at 4°C. This was subsequently dialysed the high MESNa 
concentration buffer. 
 
Figure 5.11: Western blot analysis of biotin NCL reaction on C-PH generated in a protein lysate. The samples 
were run on 12% SDS-PAGE at 180 mV for 30 mins and (A) transferred onto a nitrocellulose membrane at 
20V for 26 mins, detected by a Neutravidin-HRP probe and visualised by chemiluminescence; (B) visualised 
by Coomassie Blue staining. Lane 1– cell lysate after 3C
pro
 cleavage of GST-PAKQC-PH to produce C-PH; Lane 
2 – protein mixture after NCL with biotin under standard NCL conditions and dialysis into 100 mg/mL MESNa 
buffer. 
A single protein from within the cell lysate has been labelled with biotin (Figure 5.11). Lysate 
from GST-PAKQC-PH expressing E. coli was first incubated with 3Cpro (Lane 1), followed by 
biotin NCL and dialysis (Lane 2). The Western blot of these samples (Figure 5.11A) shows 
only one band present (Lane 2A), corresponding to biotinylated C-PH. The Coomassie stain 
(Figure 5.11B) demonstrates the equal loading of the protein samples  
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(B) Coomassie Stain(A) Neutravidin Western Blot
1 2 1 2
168 
 
5.7 Development of 3Cpro/NCL protein mixture labelling method 
5.7.1 Optimising this system 
This result is a very exciting development for the use of NCL for pull-down studies. The 
ability to generate C-PH and label it with from within a crude cell lysate simplified the 
protocol considerably. There is now no need to purify the protein using glutathione and 
nickel beads, carry out the labelling111 and then reinsert the protein to then pull it out again.  
However before this technique can be used for pull down studies it needs to be optimised. 
This will not only make the system more efficient but moreover minimise the potential 
denaturing effects on the proteins. Work has been done to determine sufficient conditions 
for labelling in a protein mixture (Section 5.5). However this only showed that the standard 
concentration of thioester and thiol concentration was necessary for the NCL reaction and 
did not take into account other factors. 
The first step that can be optimised is this initial NCL reaction. The C-PH was biotinylated 
after 16 hrs at 4°C (Figure 5.9), however the extent of the reaction or the time at which it 
was complete is unknown. It has been shown that at room temperature NCL is complete 
after 5 hrs but not after 2 hrs (Section 2.5) but this has not been done at this lower 
temperature. It would be useful to characterise this reaction at 4°C, as this is the 
temperature used for working with cell lysates that are commonly used in pull-down 
studies. 
The next area that needs to be looked at is the dialysis step. It was shown that dialysis into a 
100 mg/mL, 0.6M MESNa buffer will remove and non-specifically bound biotin (Figure 5.9), 
though it is currently unknown what effect this high concentration thiol buffer will have on 
the proteins. Firstly the minimal concentration of thiol buffer required needs to be 
identified. Then the activity of a range of proteins will need to be investigated in these 
conditions to determine the effect this will have, and if it does have an effect can this be 
reversed by dialysis into a low thiol buffer. Once working conditions, with respect to the 
thiol concentration, have been found then this approach can be used to generate 
specifically labelled proteins from within a mixture. 
The final stage that needs further work is the fusion protein processing by 3Cpro within the 
crude lysate. Whilst a molar ratio of 1:5 enzyme:protein can cleave a fusion protein in 16 hrs 
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at 4°C (Figure 5.10), it has previously been shown that a 1:10 molar ratio for 16 hrs at 37°C 
can cause a small amount of secondary site cleavage (Figure 3.12).  Therefore it is important 
to determine the lowest protease concentration required to cleave a fusion protein at 4°C to 
minimise the potential for off site cleavage of a lysate protein. 
5.7.2 Utilising this system 
The ability to label a protein within a protein mixture is very useful for pull-down studies163. 
In this case a protein with a cysteine N-terminal can be generated within a cell lysate, 
interact with binding partners and then biotinylated (Section 5.6).  It may now possible to 
pull this protein out of the mixture using streptavidin coated beads along with the bound 
protein. These protein complexes can then be eluted from the beads using biotin and 
analysed by gel electrophoresis or mass spectrometry. By generating the target protein in 
this new manner, it can interact with any possible binding partners without the GST or a 
label attached. This allows the protein-protein interactions to occur in an environment more 
representative of native conditions and therefore has the potential to generate better 
results.  
Alternatively this technique can be used as a simplified way of producing biotinylated 
proteins, which can be purified from the crude lysate using streptavidin beads164. This will 
remove the need for glutathione bead purification of the fusion protein and nickel bead 
purification of the protease, replacing it with just a single purification step. This will not only 
save time but also saves resources. The affinity-labelled protein can now be used for a 
number of applications from affinity studies to immunological visualisation techniques51, 
see Section 5.1 for further details.  
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5.8 Conclusion 
This chapter has explored the scope of the generic 3Cpro/NCL strategy111. The use of this 
reaction has been expanded from fluorescent labelling to biotinylation of proteins. This has 
useful applications for pull-down studies163 that have been made more accessible by the 
development of a novel protocol to successfully label a protein from within a crude lysate 
mixture.  
Biotin has been successfully derivatised into a thioester (Section 5.2). This was achieved 
using the standard thioester generation protocol74, showing that once again this 
methodology has been successfully transferred to generate new thioester tags. This new 
biotin label is able to undergo Native Chemical Ligation. Both peptide (Section 5.3) and 
protein NCL studies (Section 5.4) resulted in the incorporation of a single biotin molecule 
into the N-terminal cysteine protein C-PH as verified by MALDI-TOF. The biotinylation of 
C-PH was also confirmed by a neutravidin Western blot. This ligation was achieved using the 
standard NCL procedure59 and once again the conditions determined in the peptide studies 
were directly transferable to the protein system.  
This biotinylation of a protein for pull-down studies would be more useful if it can be carried 
out within a mixture. This is theoretically possible as NCL is a site specific reaction that will 
only occur on an N-terminal cysteine protein, i.e. C-PH. However when this was attempted, 
there was a very high degree of non-specific labelling of all the proteins in the mixture 
(Figure 5.7)  Analysis of the NCL mechanism59, coupled with experimental studies (Section 
5.5), highlighted the importance of the role of the thiol catalyst MESNa in the reaction. It is 
vital in preventing non-specific protein labelling by regenerating the thioester label when it 
reversibly binds to internal cysteine residues present, however too high a volume will retard 
the reaction. 
This investigation resulted in the development a two-step protocol for site-selective 
labelling via NCL in protein mixture (Figure 5.9). Firstly NCL is carried out as normal, to allow 
the biotin to attach to the protein’s N-terminus. This is followed by dialysis into a high 
MESNa buffer to wash off the biotin from the internal cysteines present in the protein 
mixture. This approach was validated, and taken further, by the cleavage of the GST-PAKQC-
PH fusion protein by 3Cpro in a crude lysate mixture, followed by the labelling of the 
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generated C-PH via NCL (Figure 5.11). Following further optimisation, it should be possible 
to take this processing of a fusion protein and subsequent biotinylation on to other proteins 
for a simplified purification technique as well as pull-down studies163 (Section 5.7.2).  
The usefulness of the 3Cpro/NCL site-specific labelling strategy111 has been taken to a new 
level. In this chapter work has been done to successfully use this approach for the 
biotinylation of proteins. Moreover by then developing a protocol for the selective labelling 
a protein from within mixture, this becomes an ideal technique for protein pull-down 
studies. 
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5.9 Materials and Methods 
5.9.1 Reagents and Equipment 
Biotin-NHS ester and MESNa were purchased from Sigma Aldrich, as were the buffer 
components. SDS-PAGE and Western Blotting equipment, gels, membranes and reagents 
were purchased from Invitrogen, except the ECL Plus Western Blotting Detection System 
from GE Healthcare. Eppendorf® PerfectPure C-18 tips were purchased from VWR.  
HPLC was carried out on a Gilson system with 322 Pump, a 234 Autoinjector and 151 UV/vis 
detector. Purification via HPLC was carried out on a Gilson semi-preparative RP-HPLC system 
equipped with 306 pumps and a Gilson 151 UV/vis detector. Both systems were fitted with 
an ACE 5 C18 column (250x4.6 mm) and a SecurityGuard cartridge system (C18, 4x3.0 mm). 
The purity was determined from the peak integration of the analytical trace. For peaks 
integrating more than 98% the purity is stated as > 98%. Masses were determined by 
MALDI-TOF using the Micromass MALDI-TOF. High resolution MS (HRMS) was found by ESI-
TOF-MS. Melting point determination was carried out on Standford Reaserch Systems 
Optimelt. 
5.9.2 Biotin labelling 
Biotin-MES Thioester 1074  
10 mg, 29 µmol biotin-NHS ester 9 in 0.25 mL DMF was combined with 29 mg, 176 µmol 2 in 
5 mL sodium borate buffer (0.1M, pH 8.3) and stirred at room temperature for 2 hrs. The 
colourless solution 10 was purified by reverse phase HPLC and lyophilised into 0.2 mg 
aliquots. 7.2 mg, 20 µmols, of a white solid (69%) was obtained. Rt = 13.0 mins(2-100 MeCN 
in H2O over 20 mins), purity >98%; Melting point 198°C; HRMS (ESI) 367.046 (requires 
367.046).    
Peptide Synthesis160 
The peptide CLFDFLLK 8 was synthesised using SPPS, see Section 4.8.3 for full details 
Peptide Labelling111  
0.1 mg, 300 nmol 5 was added with 0.14 mg, 70 µmols peptide 8 in 100 µL phosphate buffer 
(0.1M, pH 7.4). This was incubated at room temperature for 5 hrs. A sample was analysed by 
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reverse phase HPLC and, after desalting with Eppendorf® PerfectPure C-18 tips, by MALDI-
TOF.  
Expression of the GST-PAKQC-PH protein111 
The GST-PAKQC-PH protein was expressed using the standard methodology developed in 
Chapter 2, see Section 2.8.2 for full details. 
Protein Labelling111 
0.1 mg, 300 nmol 5 and 0.2 mg, 1.2 µmol 2 was added to 1 mg, 70 nmol C-PH in 100 µL 
phosphate buffer (0.1M, pH 7.4). This was incubated at room temperature for 5 hrs. A 
sample was desalted with Eppendorf® PerfectPure C-18 tips and analysed by MALDI-TOF. 
Western Blot172 
Biotin-PH domain was run on a standard SDS-PAGE at 180 mV for 30 mins and then 
transferred onto a nitrocellulose membrane at 20 V for 26 mins. The membrane was 
blocked with 10 mL of 5% BSA in Tris-Buffered Saline with 0.1% TWEEN (TBS-T) for 1 hr 
shaking, which was removed by 3 x 10 mins TBS-T washes. The membrane was probed using 
2 µL of 1 mg/mL Neutravidin-HRP conjugate in 10 mL TBS-T for 1 hrs, followed by 3  x 10 
mins TBS-T washes to remove the probe. The membrane was visualised using the ECL Plus 
Western Blotting Detection System, and the resultant chemiluminescent product was 
imaged using a CCD camera. 
5.9.3 Biotin labelling in a protein mixture 
Initial reaction172 
0.1 mg, 7 nmols C-PH was added to 100 µL of cell lysate giving a final protein concentration 
of 5 mg/mL. This was incubated with 10 µg, 30 nmols 10 and 20 µg, 120 nmols 2 for 16 hrs 
at 4°C. The reaction was analysed SDS-PAGE 180 mV for 30 mins and visualised by Western 
blotting using a Neutravidin-HRP probe for biotin. 
Effect of MESNa concentration on NCL 
Four reactions were set up, each containing 0.1 mg, 7 nmols C-PH in 100 µL of cell lysate 
giving a final protein concentration of 5 mg/mL. 100 µg, 0.7 µmols; 200, 1.4 µmols; 400, 
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2.8 µmols; or 800, 5.6 µmols 2 was added. Each reaction was incubated with 10 µg, 
30 nmols 10 for 16hrs at 4°C. The reaction was analysed SDS-PAGE 180 mV for 30 mins and 
visualised by Western blotting using a Neutravidin-HRP probe for biotin. 
Protein mixture labelling 
0.1 mg, 7 nmols C-PH was added to 100 µL of cell lysate giving a final protein concentration 
of 5 mg/mL. This was incubated with 10 µg, 30 nmols 10 and 20 µg, 120 nmols 2 for 16 hrs 
at 4°C. The reaction mixture was then dialysed into a 0.1 M phosphate buffer, pH 7.2, 
containing 100 mg/mL 2. The reaction was analysed SDS-PAGE 180 mV for 30 mins and 
visualised by Western blotting using a Neutravidin-HRP probe for biotin. 
5.9.4 Biotin labelling in a crude lysate mixture 
3Cpro cleavage in a crude lysate111,175 
300 mL of auto-induction LB medium containing 100 μg/mL ampicillin, 0.6% v/v glycerol, 
0.05% w/v glucose, 0.2% w/v lactose, was inoculated with a colony of BL21(DE3) containing 
the pGEX_3C_PH plasmid. This was incubated at 30°C for 16hrs at 225 rpm, followed by a 
further incubation at 18°C for 16hrs at 225 rpm. 
The cells were spun down (3200 rcf, 4°C, 20 mins), frozen at -20°C overnight and 
resuspended in 5 mL GST Lysis Buffer (100 mM Sodium Phosphate Buffer pH 7.4, 1 mM 
EDTA, 1mM TCEP, 5% v/v Glycerol). The cells were then lysed by incubation with 10 mg/mL 
lysosyme at 4°C for 2 hrs followed by sonication for 3 x 30 secs. DNase, 0.1 mg/mL at 4°C for 
30 mins, was used to digest the DNA present in the lysate. The lysaste was centrifuged 
(18000 rcf, 4°C, 30 mins) and the supernatant fraction was retained.  
5 mL of 3Cpro Reaction Buffer (100 mM Sodium Phosphate Buffer pH 7.4, 1 mM EDTA, 1 mM 
TCEP, 5% v/v Glycerol) was added to the 5 mL of crude lysate, which contained 
approximately 1 mg, 25 nmols GST-PAKQC-PH. This was incubated with 25 µL, 5 nmols of 
200 µM 3Cpro at 4°C for 16 hrs. The reaction was analysed by SDS-PAGE 180 mV for 30 mins 
and visualised by Coomassie staining.  
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Protein labelling in a crude lysate 
1 mL of the lysate/cleavage mixture, containing approximately 50 µg, 4 nmols C-PH, was 
incubated with 5 µg, 15 nmols of 10 and 10 µg, 60 nmols of 2 for 16hrs at 4°C. The reaction 
mixture was then dialysed into a 0.1M phosphate buffer, pH 7.2, containing 100 mg/mL 2. 
The reaction was analysed SDS-PAGE 180 mV for 30 mins and visualised by Western blotting 
using a Neutravidin-HRP probe for biotin. 
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Chapter 6 Conclusion  
 
This thesis has focused on the development and implementation of a novel protein 
labelling system based on the enzyme FMDV 3C protease and the Native Chemical 
Ligation reaction. By using a combination of chemistry and biology, proof-of-principle 
work was successfully carried out to validate this 3Cpro/NCL labelling strategy. The 
utility of this approach was explored by the development of a protein labelling library, 
allowing fluorescent and affinity tags to be specifically incorporated into a protein. 
Moreover accompanying protocols have been developed to facilitate the use of this 
technique for alternative protein and labels. 
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6.1 The 3Cpro/NCL labelling strategy 
6.1.1 Successful development of methodology  
The 3Cpro/NCL labelling strategy has been successfully developed as a site-specific protein 
labelling technique111. This has utilised the modified cleavage sequence of 3Cpro 91, namely 
PAKQC, to engineer a protein with an N-terminal cysteine residue. This allowed the use of 
the chemical reaction NCL59 to specifically attach a thioester moiety onto the protein. 
A suitable expression system was used to generate a protein with the requisite N-terminal 
cysteine residue (Chapter 2). The model protein, the PH domain from PKB, was expressed 
using the pGEX_3C plasmid as a fusion with GST, linked by the sequence PAKQC. Following 
3Cpro cleavage on glutathione beads and subsequent removal of the protease using its 
His-tag, the C-PH protein was obtained. 
This protein was suitable for labelling via NCL (Chapter 2). A single fluorescein thioester 
derivative was successfully attached to the protein using standard NCL conditions, as 
verified by MALDI-TOF analysis. Moreover it was shown that this labelling process did not 
compromise the biological activity of the protein, as it was still able to act as a probe for the 
lipids PI(3,4,5)P3 and PI(3,4)P2
105. 
6.1.2 Generation of labelling toolbox 
A key advantage of the 3Cpro/NCL labelling strategy is the flexibility built into it via the NCL 
reaction. This will allow the ligation of any group onto the N-terminus of a protein provided 
that it can be derivatised into a thioester59.  The development of a labelling library 
consisting of easily accessibly thioesters will exploit this generic characteristic of this 
approach. 
The generation of thioester labels has been done using a standardised technique74 (Chapter 
4 and 5). Using a NHS-activated ester, a typical derivative of protein labels, and the thiol 
MESNa, a thioester derivative can be obtained using a facile technique within a few hours. A 
simple trial NCL reaction with a cysteine N-terminal peptide can determine suitable 
condition for protein labelling. It is important to be aware of the stability of the thioesters as 
this can affect the success of the labelling reaction, though an increase in the amount of 
label used can overcome this.  
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This method was used to add two new fluorescent labels to the fluorescein thioester: 
PromoFluor 488 and Rhodamine Red (Chapter 4). These labels are green and red 
respectively and allow for choice of colours as well as the option of multicolour imaging 
studies. These labels are also a FRET pair, allowing for their use in fluorescent assays.  
This can just as easily be applied to alternative, non-fluorescent groups as exemplified by 
the biotinylation of the PH domain using the 3Cpro/NCL labelling system (Chapter 5). The 
same, standardised approach was used to develop and label C-PH with a biotin thioester. 
Moreover the NCL technique was taken into a new direction, allowing the site-specific 
labelling of a protein from within a protein mixture. This exciting development will allow the 
facile use of this methodology for protein pull-down studies. 
This nascent labelling library exemplifies the versatility of the 3Cpro/NCL system. A single 
protein, C-PH, has now been tagged with fluorescein (Chapter 2), PromoFluor 488 (Chapter 
4) and Rhodamine Red (chapter 4) for cellular imaging studies, as well as with biotin 
(Chapter 5) for pull-down studies. Moreover the generation of these labels and the ligation 
itself have all been carried out using a standardised set of protocols that can now be applied 
to any desired label.  
6.1.3 Comparison of the 3Cpro/NCL system with existing methods 
The use of 3Cpro compares favourably with existing protease techniques for generating 
N-terminal cysteine proteins (Chapter 3). Processing of a target protein by 3Cpro can be done 
in a suitable time frame, comparable to the gold standard of molecular biology proteases 
TEV71. In fact the yield for the generation of a 3C fusion protein with GST is significantly 
higher then that for TEV. 3Cpro is also likely to be more specific and have less off-site 
secondary proteolysis then with the standard protease Thrombin72. Moreover it should be 
possible to develop a dual labelling system with 3Cpro and TEV due to the high degree of 
orthogonality between the two cleavage sites.  
It also holds up well against the intein mediated method64. On one hand it does require the 
extra protease cleavage and purification steps not needed for inteins. However the indepth 
study of the cleavage site suggests that 3Cpro will not have problems with the identity of the 
P’ residues, whilst these have been known to adversely affect intein cleavage67. 
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In terms of labelling proteins, this technique has all the advantages of using chemical tags; 
namely a wide range of small molecules that can be attached5. However the use of the NCL 
reaction confers an extra benefit, allowing site-specific ligation without any extra protein 
modification required. This was seen by the facile ligation of a single labelling molecule onto 
the PH domain, and emphasised by the specific biotinylation of the protein from within a 
mixture. 
This also means that this approach has a number of advantages over labelling with GFP1, 
which has the drawback of a lack of variety of labels as well as being very bulky in size. 
However GFP does allow access to in vivo labelling that is not possible with this system. It 
should be possible to co-express the GST-PAKQC fusion with 3Cpro, as this has been achieved 
with TEV136, which could be processed in vivo. Also thioester labels have been developed 
that are cell permeable176. However the vast array of proteins and thiols in cell would react 
with it resulting in low-level non-specific background labelling176, as seen with the initial 
biotin protein mixture labelling experiments in Chapter 5. Whereas GFP can be expressed as 
a fusion with a target protein, with no modification or processing required, in a completely 
specific manner5. Therefore whilst the 3Cpro/NCL system is preferable for in vitro, it cannot 
complete with GFP for in vivo labelling. 
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6.2 Use of the 3Cpro/NCL labelling strategy by non chemists 
The aim of this thesis was not only to generate a novel protein labelling system but 
moreover for it to be usable by non chemists. In order for this to happen, a ‘labelling 
toolbox’ has been generated. This contains the pGEX_3C plasmid to clone the target protein 
into, the 3Cpro enzyme to process the enzyme and the thioester labels to attach. The 
protease and labels have been divided up into single use aliquots and suitable storage 
conditions have been detailed.  
There are further developments that can be done to make this system more valuable. The 
first involved the generation of the thioester labels. This is currently achieved by incubating 
an NHS-ester derivative with an excess MESNa thiol74. However the NCL reaction involves 
using the same thiol as a catalyst. Therefore it might be possible to generate the thioester in 
situ and then dialyse it into the correct MESNa concentration for NCL. The specificity of the 
ligation reaction should prevent any by-products of the thioester synthesis, such as the 
carboxylic acid derivative, from reacting with the protein. Investigation and optimisation of 
this could lead to a method for generating the thioesters without the need for HPLC 
purification, making it even more facile and accessible.  
Another area that needs to be worked on to make this system more beneficial is the range 
of thioesters in the labelling library. The three fluorescent molecules should be added to, 
thus allowing the selection of an appropriate label based on excitation and emission 
wavelengths, brightness, efficiency, stability, susceptibility to photobleaching9. Also 
environmentally fluorophores, such as dansyl which has a fluorescent spectrum that varied 
according to the hydrophobicity of the environment177, should be added too. Alternatively 
thioester biomolecules could be synthesised to allow attachment of peptides, sugars or 
lipids onto the N-terminus of a target protein. 
The versatility of this 3Cpro/NCL system lies in the fact that any protein expressed in the 
pGEX_3C plasmid and processed with 3Cprocan be ligated to a suitable thioester for a wide 
array of studies. As such this system has been used by collaborators for their own work. A 
fragment of the cell cycle regulator Cdh1 was labelled with fluorescein using NCL with the 
aim of investigating its binding to the protein CCT175.  Also the key malarial enzyme MTIP 
was expressed in two domains, one N15-labelled and one C13-labelled in order to join these 
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two together via NCL for NMR studies178. In both of these cases the N-terminal cysteinyl 
protein were expressed using this system. 
The 3Cpro/NCL labelling strategy and accompanying toolbox is a useful addition to current 
protein labelling methodologies. It is a facile and generic technique that has been used to 
label several proteins for a number of different experiments.  The resources and protocols 
created by this PhD thesis should enable the use of this technique for a wide array of 
protein studies. 
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Appendix 
 
Characterisation data  
• Sequencing data for plasmids pGEX_3C, pGEX_3C_PH, pGEX_TEV, pGEX_TEV_PH 
• ESI data for thioester labels of carboxyfluorescein, PromoFluor 488, Rhodamine Red 
and biotin 
• Protein sequence for C-PH 
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DNA sequences of the plasmids used in this thesis 
pGEX_3C 
CCAGCAAGTA TATAGCATGG CCTTTGCAGG GCTGGCAAGC CACGTTTGGT GGTGGCGACC 
ATCCTCCAAA ATCGGATCTG GTTCCGCGTG GATCCCCGGC GAAACAGTGT GAATTCCCGG 
GTCGACTCGA GCGGCCGCAT CGTGACTGAC TGACGATCTG CCTCGCGCGT TTCGGTGATG  
 
pGEX_3C_PH 
CCAGCAAGTA TATAGCATGG CCTTTGCAGG GCTGGCAAGC CACGTTTGGT GGTGGCGACC 
ATCCTCCAAA ATCGGATCTG GTTCCGCGTG GATCCCCGGC GAAACAGTGT GAATTCCGTA  
TGAGCGACGT GGCTATTGTG AAGGAGGGTT GGCTGCACAA ACGAGGGGAG TACATCAAGA  
CCTGGCGGCC ACGCTACTTC CTCCTCAAGA ATGATGGCAC CTTCATTGGC TACAAGGAGC  
GGCCGCAGGA TGTGGACCAA CGTGAGGCTC CCCTCAACAA CTTCTCTGTG GCGCAGTGCC  
AGCTGATGAA GACGGAGCGG CCCCGGCCCA ACACCTTCAT CATCCGCTGC CTGCAGTGGA  
CCACTGTCAT CGAACGCACC TTCCATGTGG AGACTCCTGA GGGCGGGAGG AGTGGACAAC  
CGCCATCCAG ACTGTGGCTG ACGGCCTCAA GAAGCAGGAG GAGTGAGGTC GACTCGAGCG  
 
pGEX_TEV 
CCAGCAAGTA TATAGCATGG CCTTTGCAGG GCTGGCAAGC CACGTTTGGT GGTGGCGACC 
ATCCTCCAAA ATCGGATCTG GTTCCGCGTG GATCCGAGAA CCTGTACTTC CAGTGTGAAT 
TCCCGGGTCG ACTCGAGCGG CCGCATCGTG ACTGACTGAC GATCTGCCTC GCGCGTTTCG  
 
pGEX_TEV_PH 
CCAGCAAGTA TATAGCATGG CCTTTGCAGG GCTGGCAAGC CACGTTTGGT GGTGGCGACC 
ATCCTCCAAA ATCGGATCTG GTTCCGCGTG GATCCGAGAA CCTGTACTTC CAGTGTGAAT  
TCCGTATGAG CGACGTGGCT ATTGTGAAGG AGGGTTGGCT GCACAAACGA GGGGAGTACA  
TCAAGACCTG GCGGCCACGC TACTTCCTCC TCAAGAATGA TGGCACCTTC ATTGGCTACA  
AGGAGCGGCC GCAGGATGTG GACCAACGTG AGGCTCCCCT CAACAACTTC TCTGTGGCGC  
AGTGCCAGCT GATGAAGACG GAGCGGCCCC GGCCCAACAC CTTCATCATC CGCTGCCTGC 
AGTGGACCAC TGTCATCGAA CGCACCTTCC ATGTGGAGAC TCCTGAGGGC GGGAGGAGTG  
GACAACCGCC ATCCAGACTG TGGCTGACGG CCTCAAGAAG CAGGAGGAGG AGGTCGACTC  
 
 
Sequencing primer, BamH I, 3C site, TEV Site, EcoR I, PH domain, Sal I,  
 
 
 
  
185 
 
 
pGEX_3C sequencing data 
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pGEX_3C_PH sequencing data 
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pGEX_TEV sequencing data 
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pGEX_TEV_PH sequencing data 
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ESI Data for Thioester Labels 
Carboxyfluorescein Thioester 
 
PromoFluor 488 Thioester 
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Rhodamine Red Thioester  
 
Biotin Thioester  
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Protein Sequence of C-PH 
 
CEFMSDVAIV KEGWLHKRGE YIKTWRPRYF LLKNDGTFI GYKERPQDVD QREAPLNNFSV 
AQCQLMKTER PRPNTFIIRCL QWTTVIERTFH VETPEEREEW TTAIQTVADG LKKQEE 
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